onvo-10q_20200630.htm

0001564590-20-038895.txt : 20200810 0001564590-20-038895.hdr.sgml : 20200810 20200810160040 ACCESSION NUMBER: 0001564590-20-038895 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200810 DATE AS OF CHANGE: 20200810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORGANOVO HOLDINGS, INC. CENTRAL INDEX KEY: 0001497253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 271488943 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35996 FILM NUMBER: 201089221 BUSINESS ADDRESS: STREET 1: 440 STEVENS AVENUE, SUITE 200 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858-224-1000 MAIL ADDRESS: STREET 1: 440 STEVENS AVENUE, SUITE 200 CITY: SOLANA BEACH STATE: CA ZIP: 92075 FORMER COMPANY: FORMER CONFORMED NAME: REAL ESTATE RESTORATION & RENTAL, INC. DATE OF NAME CHANGE: 20100722 10-Q 1 onvo-10q_20200630.htm 10-Q onvo-10q_20200630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-35996

Organovo Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware		27-1488943
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

440 Stevens Ave, Suite 200, Solana Beach, CA 92075		(858) 224-1000
(Address of principal executive offices and zip code)		(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of Each Exchange on which registered
Common Stock, $0.001 par value	ONVO	The Nasdaq Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 1, 2020, a total of 130,618,203 shares of the registrant’s Common Stock, $0.001 par value, were outstanding.

ORGANOVO HOLDINGS, INC.

INDEX

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of June 30, 2020 (Unaudited) and March 31, 2020	3
	Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss for the Three Months Ended June 30, 2020 and 2019	4
	Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended June 30, 2020 and 2019	5
	Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended June 30, 2020 and 2019	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25
Item 4.	Controls and Procedures	26
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44
Item 3.	Defaults Upon Senior Securities	44
Item 4.	Mine Safety Disclosure	44
Item 5.	Other Information	44
Item 6.	Exhibits	45

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Organovo Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands except for share and per share data)

	June 30, 2020			March 31, 2020
	(Unaudited)
Assets
Current Assets
Cash and cash equivalents	$	24,787		$	27,356
Accounts receivable		84			111
Prepaid expenses and other current assets		630			851
Total current assets		25,501			28,318
Other assets, net		120			123
Total assets	$	25,621		$	28,441
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	110		$	720
Accrued expenses		725			1,090
Total current liabilities		835			1,810
Commitments and Contingencies
Stockholders’ Equity
Common stock, $0.001 par value; 200,000,000 shares authorized, 130,618,203 and 130,558,098 shares issued and outstanding at June 30, 2020 and March 31, 2020, respectively		131			131
Additional paid-in capital		306,889			305,965
Accumulated deficit		(282,234	)		(279,465	)
Total stockholders’ equity		24,786			26,631
Total Liabilities and Stockholders’ Equity	$	25,621		$	28,441

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(in thousands except share and per share data)

	Three Months Ended			Three Months Ended
	June 30, 2020			June 30, 2019
Revenues
Products and services	$	—		$	606
Collaborations and licenses		—			10
Grants		—			52
Total Revenues		—			668
Cost of revenues		—			51
Research and development expenses		—			3,823
Selling, general and administrative expenses		2,786			3,315
Total costs and expenses		2,786			7,189
Loss from Operations		(2,786	)		(6,521	)
Other Income (Expense)
Gain on fixed asset disposals		6			1
Interest income		8			197
Other Income		5			—
Total Other Income		19			198
Income Tax Expense		(2	)		—
Net Loss	$	(2,769	)	$	(6,323	)
Net loss per common share—basic and diluted	$	(0.02	)	$	(0.05	)
Weighted average shares used in computing net loss per common share—basic and diluted		130,588,481			126,854,907
Comprehensive Loss:
Net loss	$	(2,769	)	$	(6,323	)
Comprehensive loss	$	(2,769	)	$	(6,323	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

(in thousands)

	Three Months Ended June 30, 2019
					Additional
	Common Stock				Paid-in			Accumulated
	Shares		Amount		Capital			Deficit			Total
Balance at March 31, 2019		124,015	$	124	$	296,929		$	(260,755	)	$	36,298
Issuance of common stock under employee and director stock option, RSU, and purchase plans		177		—		(52	)		—			(52	)
Issuance of common stock from public offering, net		6,087		6		4,990			—			4,996
Stock-based compensation expense		—		—		1,220			—			1,220
Net loss		—		—		—			(6,323	)		(6,323	)
Balance at June 30, 2019 (Unaudited)		130,279	$	130	$	303,087		$	(267,078	)	$	36,139


	Three Months Ended June 30, 2020
					Additional
	Common Stock				Paid-in			Accumulated
	Shares		Amount		Capital			Deficit			Total
Balance at March 31, 2020		130,558	$	131	$	305,965		$	(279,465	)	$	26,631
Issuance of common stock under employee and director stock option, RSU, and purchase plans		60		—		(1	)		—			(1	)
Stock-based compensation		—		—		925			—			925
Net loss		—		—		—			(2,769	)		(2,769	)
Balance at June 30, 2020 (Unaudited)		130,618	$	131	$	306,889		$	(282,234	)	$	24,786

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

	Three Months Ended			Three Months Ended
	June 30, 2020			June 30, 2019
Cash Flows From Operating Activities
Net loss	$	(2,769	)	$	(6,323	)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on disposal of fixed assets		(6	)		(1	)
Depreciation and amortization		4			205
Stock-based compensation		925			1,220
Increase (decrease) in cash resulting from changes in:
Accounts receivable		27			(35	)
Grants receivable		—			(44	)
Inventory		—			(16	)
Prepaid expenses and other assets		224			360
Accounts payable		(610	)		(75	)
Accrued expenses		(365	)		(1,142	)
Deferred revenue		—			7
Operating lease right-of-use assets and liabilities, net		—			(91	)
Net cash used in operating activities		(2,570	)		(5,935	)
Cash Flows From Investing Activities
Proceeds from disposals of fixed assets		2			1
Net cash provided by investing activities		2			1
Cash Flows From Financing Activities
Proceeds from issuance of common stock and exercise of warrants, net		—			4,996
Employee taxes paid related to net share settlement of equity awards		(1	)		(52	)
Net cash provided by (used in) financing activities		(1	)		4,944
Net decrease in cash, cash equivalents, and restricted cash		(2,569	)		(990	)
Cash, cash equivalents, and restricted cash at beginning of period		27,356			36,556
Cash, cash equivalents, and restricted cash at end of period	$	24,787		$	35,566
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	24,787		$	35,487
Restricted cash		—			79
Total cash, cash equivalent and restricted cash	$	24,787		$	35,566
Supplemental Disclosure of Cash Flow Information:
Receivable related to fixed asset sales	$	5		$	—
Assets held for sale	$	1		$	—
Income taxes paid	$	(2	)	$	—

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Note 1. Description of Business

Nature of operations

Organovo Holdings, Inc. (“Organovo Holdings,” “Organovo,” and “the Company”) is an early-stage biotechnology company that has focused on pioneering the development of bioprinted 3D human tissues that emulate key aspects of human biology and disease. Except where specifically noted or the context otherwise requires, references to “Organovo Holdings,” “the Company,” and “Organovo” in these notes to the unaudited condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc. and Opal Merger Sub, Inc.

Historical Operations and Strategic Alternatives Process

Prior to August 2019, the Company has focused its efforts on developing its in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. The Company also explored the development of other potential pipeline in vivo tissue constructs in-house and through collaborations with academic and government researchers. In the past, the Company also explored the development of in vitro tissues, including proof of concept models of diseased tissues, for use in drug discovery and development.

In August 2019, after a rigorous assessment of its in vitro liver therapeutic tissue program, the Company concluded that the variability of biological performance and related duration of potential benefits no longer supported an attractive opportunity due to redevelopment challenges and lengthening timelines to compile sufficient data to support an IND filing. As a result, the Company suspended development of its lead program and all other related in-house pipeline development activities.

The Company’s Board also engaged a financial advisory firm to explore the Company’s available strategic alternatives, including evaluating a range of ways to generate value from its technology platform and intellectual property, its commercial and development capabilities, its listing on the Nasdaq Capital Market, and the Company’s remaining financial assets. These strategic alternatives included possible mergers and business combinations, sales of part or all of our assets, and licensing and partnering arrangements. The Company implemented various restructuring steps to manage its resources and extend its cash runway, including reducing commercial activities related to its liver tissues, except for sales of primary human cells out of inventory, negotiating an exit from its long-term facility lease, selling various assets, and reducing its workforce. Additionally, in November 2019, the Company sold certain inventory and equipment and related proprietary information held by its wholly-owned subsidiary, Samsara Sciences, Inc. (“Samsara”), and as a result of such sale, Samsara ceased its operations.

After conducting a diligent and extensive process of evaluating strategic alternatives and identifying and reviewing potential candidates for a strategic acquisition or other transaction, which included the receipt of more than 27 non-binding indications of interest from interested parties and careful evaluation and consideration of those proposals, and following extensive negotiation with Tarveda, on December 13, 2019, the Company entered into a merger agreement with Tarveda (the “Merger Agreement”). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company’s wholly-owned merger subsidiary would merge (the “Merger”) into Tarveda, with Tarveda surviving the Merger. The Merger Agreement included various conditions to the consummation of the Merger, including approval by the Company’s stockholders at a Special Meeting of Stockholders to be held on April 7, 2020 (the “Special Meeting”).

At the Special Meeting, the Merger was not approved by the Company’s stockholders. As a result, the Company terminated the Merger Agreement with Tarveda. Pursuant to the terms of the Merger Agreement, the Company was obligated to reimburse certain of Tarveda’s merger-related expenses not to exceed $300,000, which was offset by Tarveda’s portion of shared expenses incurred by Organovo in fiscal 2020.

The Cooperation Agreement and Advisory Nominees Proposal

Company’s existing directors, Richard Maroun and David Shapiro, resigned from the Board and all Board committees. The Board also agreed to nominate, recommend, support and solicit proxies for the re-election of Messrs. Murphy and Stern at the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). The Board also agreed to nominate, recommend, support and solicit proxies for an advisory stockholder vote (the “Advisory Nominees Proposal”) at the 2020 Annual Meeting to appoint three individuals, Douglas Jay Cohen, David Gobel and Alison Tjosvold Milhous (collectively, the “Advisory Nominees”), to the Board. Mr. Murphy identified each of the Advisory Nominees. If the final vote tabulation for the Advisory Nominees Proposal receives more votes cast “FOR” than “AGAINST” its approval, the Board has approved the appointment of the Advisory Nominees, to be automatically effective immediately following the final adjournment of the 2020 Annual Meeting. In addition, immediately following the appointment of the Advisory Nominees, each of our existing directors (other than Messrs. Murphy and Stern) will resign from the Board, which will result in Messrs. Murphy and Stern and the Advisory Nominees constituting the full membership of the Board (collectively, the “New Director Slate”).

Proposed Drug Discovery Business

The New Director Slate has advised the Company that if the Advisory Nominees Proposal is approved at the 2020 Annual Meeting, the New Director Slate intends to recommence operations and focus the Company’s efforts on developing highly customized human tissues as living, dynamic models of human biology and disease for use in drug discovery and development. The New Director Slate has advised the Company that it believes the Company’s proprietary technology can be used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, and function. The New Director Slate also believes the Company can utilize its proprietary technology to develop highly customized and dynamic models of human disease, including cell type-specific compartments, prevalent intercellular tight junctions, and microvascular structures. They believe these features can facilitate the Company’s development of complex, multicellular disease models for use in the development of targeted therapeutics for various diseases including, among others, intestine, kidney, skin and breast diseases. Market opportunities may include externally-partnered or internally-directed drug discovery and the clinical development of new molecular entities or repurposed drugs in-licensed from other pharmaceutical companies. The goal of the New Director Slate is for the Company to establish a pipeline of drug candidates in high-value disease areas, aiming to commence human clinical testing for at least one drug candidate within a three to four year timeframe.

If the Advisory Nominees Proposal is approved, the New Director Slate intends to restart the Company’s research operations by hiring a team of R&D professionals with the experience required to develop bioprinted and other 3D tissues for use in drug discovery, to leverage 3D models of disease to discover new drug candidates, and to develop new drug candidates for the initiation of clinical studies.

The New Director Slate has advised the Company that they expect our research and development staff to grow to seven to ten employees. They also expect to maintain or grow a general and administrative staff of three to five employees to support the Company’s operations and reporting requirements as a public company.

If the Advisory Nominees Proposal is approved, the New Director Slate has advised us that the Company expects to lease sufficient office and laboratory space to support its requirements. They expect that the Company will need space in the short term in the 3,000-7,000 sq. ft. range, with mixed office and laboratory space. They expect to lease a new facility in San Diego at prevailing market terms.

COVID-19

The extent to which the coronavirus impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. In particular, the continued coronavirus pandemic could adversely impact the Company’s operations, including among others, the timing and ability to pursue strategic alternatives, given the impact it may have on the manufacturing and supply chain, sales and marketing and clinical trial operations of potential strategic partners, and the ability, if we elect to do so, to advance our research and development activities and pursue development of any of our pipeline products, each of which could have an adverse impact on the Company’s business and financial results.

Note 2. Summary of Significant Accounting Policies

Basis of presentation and principles of consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2020 is derived from the Company’s audited consolidated balance sheet at that date.

The unaudited condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2021 (see “Note 1. Description of Business”).

Liquidity

As of June 30, 2020, the Company had cash and cash equivalents of approximately $24.8 million and an accumulated deficit of approximately $282.2 million. The Company also had negative cash flows from operations of approximately $2.6 million during the three months ended June 30, 2020.

Through June 30, 2020, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the three months ended June 30, 2020, the Company issued no shares of its common stock through its ATM facility.

Throughout the strategic alternatives assessment process, the Company has taken steps to manage its resources and extend its cash runway including selling various assets and reducing its workforce to the minimum level necessary to explore and support these strategic alternatives as well as to support the remainder of the Company’s on-going business activities and assets, including its intellectual property platform and collaborations with research institutions and universities.

The Company believes its cash and cash equivalents on hand will be sufficient to meet its financial obligations for at least the next 12 months of operations. If the Advisory Proposal is approved, this will trigger a “Change of Control” under Organovo’s severance plan, as well as its Directors and Officers (“D&O”) liability insurance policies, requiring the following cash outlays: i) approximately $3.0 million for severance obligations and ii) approximately $2.0 million (or $1.7 million net of returned premium) for a six year D&O tail insurance policy. In addition, to the extent the New Director Slate recommences the Company’s operations and focus its efforts on drug discovery and development, the Company will need to raise additional capital to implement this new business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. If required, the Company may seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Company’s business, operating results, financial condition and ability to continue as a going concern.

Use of estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the unaudited condensed consolidated financial statements include those assumed in the valuation of stock-based compensation expense, the valuation of impairment of long-lived assets, our assessment of contingent liabilities that would require the establishment of a reserve, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions. Though the impact of the COVID-19 pandemic to its business and operating results presents additional uncertainty, the Company continues to use the best information available to inform its critical accounting estimates.

Impairment of long-lived assets

In accordance with ASC 360-10, the Company records an impairment loss on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets (i.e. not able to be recovered). The Company’s pursuit of strategic alternatives requires the reevaluation of the recoverability of the gross carrying value of its long-lived assets. The Company performed an asset impairment analysis on its long-lived asset group, consisting primarily of licensed intangible assets, computer equipment, and software following the completion of various asset sales prior to June 30, 2020, which concluded that the carrying amount is not recoverable. However, the Company’s analysis indicated that carrying amount of the asset group does not exceed its fair value. As such, no impairment loss is required to be recognized. Nonetheless, it is reasonably possible that the impairment analysis may change in the near term resulting in the need to write down those assets to fair value. The Company will continue to monitor assets for impairment.

Revenue recognition

The Company has generated revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations.

The Company recognized revenue under Topic 606, Revenue from Contracts with Customers (“Topic 606”) when (or as) the promised services were transferred to customers in an amount that reflects the consideration to which it expected to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concluded were within the scope of ASC 606, the Company performed the following five steps: (i) identified the contract(s) with a customer; (ii) identified the performance obligation(s) in the contract; (iii) determined the transaction price; (iv) allocated the transaction price to the performance obligation(s) in the contract; and (v) recognized revenue when (or as) the performance obligation(s) were satisfied. At contract inception, the Company assessed the goods or services promised within each contract, assessed whether each promised good or service was distinct and identified those that were performance obligations. The Company recognized as revenue the amount of the transaction price that was allocated to the respective performance obligation when (or as) the performance obligation was satisfied.

Billings to customers or payments received from customers were included in deferred revenue on the consolidated balance sheet until all revenue recognition criteria were met. As of June 30, 2020 and March 31, 2020, the Company had no deferred revenue.

Service revenues

The Company’s service-based business, Organovo, Inc., utilized its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contained multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which were satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer did not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service could be customized for each customer, it was not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilized point-in-time recognition under Topic 606.

For service contracts, the Company allocated the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price was not observable through past transactions, the Company estimated the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts was a fixed consideration.

In connection to the Company’s decision to pursue its strategic alternatives, the Company halted commercial activities related to its liver tissues. The Company is expected to continue to maintain its external research collaborations and its intellectual property portfolio.

Product sales, net

typically upon delivery. Product revenues were recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration did not differ materially from its historical practices. Variable consideration was estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflected the Company’s best estimates of the amount of consideration to which it was entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may have differed from the Company’s estimates. If actual results varied materially from the Company’s estimates, the Company would have adjusted these estimates, which would have affected revenue from product sales and earnings in the period such estimates were adjusted.

The Company provided no right of return to its customers except in cases where a customer obtained authorization from the Company for the return. To date, there have been no product returns.

In March 2020, the Company dissolved Samsara.

Collaborative research, development, and licenses

The Company has entered into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzed whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”).

The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements were distinct performance obligations, whether there were determinable stand-alone prices, and whether any licenses were functional or symbolic. The Company evaluated each performance obligation to determine if it could be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities were considered fixed, while milestone payments were identified as variable consideration which must be evaluated to determine if it was constrained and, therefore, excluded from the transaction price.

The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provided the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company determined that the intellectual property license was not distinct from the continued support promised under the agreement and was therefore a single combined performance obligation. The Company recognized revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation would not be fully satisfied until the end of the contract.

As of September 30, 2019, the Company completed its obligations under the existing agreements with respect to receipts of revenue and does not anticipate recording any further revenue. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements.

Grant revenue

In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company concluded this government grant was not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company concluded this government grant did meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition did not apply, as the Company is a business entity and the grant was with a governmental agency.

Revenues from this grant were based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue was recognized as the Company incurred expenses that were related to the grant. The Company believes this policy was consistent with the overarching premise in Topic 606, to ensure that it recognized revenues to reflect the transfer of promised goods or services to customers in an amount that reflected the consideration to which it expected to be entitled in exchange for those goods or services, even though there was no “exchange” as defined in the ASC. The Company believed the recognition of revenue as costs were incurred and amounts became earned/realizable was analogous to the concept of transfer of control of a service over time under Topic 606.

In connection to the Company’s decision to pursue its strategic alternatives, specific to the NIH NASH grant, all internal research activities have been halted and transferred to the University of California, San Diego, leaving a remaining available balance of approximately $0.5 million that will not be utilized by the Company.

Cost of revenues

The Company reported no cost of revenues for the three months ended June 30, 2020 and approximately $0.1 million in cost of revenues for the three months ended June 30, 2019. Cost of revenues consisted of costs related to manufacturing and delivering product and service revenue.

Net loss per share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three months ended June 30, 2020 or 2019, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive.

Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 12.0 million at June 30, 2020 and 14.6 million at June 30, 2019.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.

Adoption of New Accounting Pronouncements

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. The amendments in this update provide more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from this amendment are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance became effective for the Company on April 1, 2020 and did not have a significant impact on the Company’s unaudited condensed consolidated financial statements.

Note 3. Stockholders’ Equity

Stock-based compensation expense and valuation information

Stock-based awards include stock options and restricted stock units under the 2012 Equity Incentive Plan, as amended (“2012 Plan”) and Inducement Awards, performance-based restricted stock units under an Incentive Award Performance-Based Restricted Stock Unit Agreement, and rights to purchase stock under the 2016 Employee Stock Purchase Plan (“ESPP”). The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense.

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended
	June 30, 2020		June 30, 2019
Research and development	$	—	$	164
General and administrative	$	925	$	1,056
Total	$	925	$	1,220

The total unrecognized compensation cost related to unvested stock option grants as of June 30, 2020 was approximately $2,651,000 and the weighted average period over which these grants are expected to vest is 1.58 years, assuming no change of control.

The total unrecognized compensation cost related to unvested restricted stock units (not including performance-based restricted stock units) as of June 30, 2020 was approximately $702,000, which will be recognized over a weighted average period of 1.48 years, assuming no change of control.

The total unrecognized compensation cost related to unvested performance-based restricted stock units as of June 30, 2020 was approximately $1,038,000, which will be recognized over a weighted average period of 1.19 years, assuming no change of control.

As of June 30, 2020, there are no participants enrolled into the employee stock purchase plan for the current purchase period, beginning March 1, 2020.

The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. The measurement and classification of share-based payments to non-employees is consistent with the measurement and classification of share-based payments to employees. There were no options granted in the three months ended June 30, 2020 and 2019.

The fair value of each restricted stock unit and performance-based restricted stock unit is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant.

The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the Company’s ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:

	Three Months Ended			Three Months Ended
	June 30, 2020*			June 30, 2019
Dividend yield		—			—
Volatility		0.00	%		43.69	%
Risk-free interest rate		0.00	%	2.52
Expected term	0 months			6 months
Grant date fair value	$	-		$	0.29

*There are no participants in the ESPP for the current purchase period (beginning March 1, 2020).

The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The expected life is the 6-month purchase period.

Preferred stock

The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock.

Common stock

On June 25, 2019, the Company received a notice letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum closing bid price of $1 per share, as set forth in Nasdaq Listing Rule 5450(a)(1). On December 26, 2019, the Company obtained an additional compliance period of 180 calendar days by electing to transfer to The Nasdaq Capital Market. On March 26, 2020, the Company obtained shareholder approval to effect a reverse stock split in a range from 20:1 to 40:1, which remains subject to the approval of the Company’s board of directors, in order to meet the minimum closing bid price per share requirement under the Nasdaq Listing Rules. On April 17, 2020 the Company received an additional notice letter from Nasdaq indicating that based on extraordinary market conditions, Nasdaq has determined to toll the compliance periods for bid price and market value of publicly held shares requirements (collectively, the “Price-based Requirements”) through June 30, 2020. Accordingly, since the Company had 66 calendar days remaining in its compliance period as of April 16, 2020, the Company will, upon reinstatement of the Price-based Requirements, still have 66 calendar days from July 1, 2020, or until September 4, 2020, to regain compliance. The Company can regain compliance, either during the suspension or during the compliance period resuming after the suspension, by evidencing compliance with the Price-based Requirements for a minimum of 10 consecutive trading days. The Company intends to comply with the Price-based Requirements by effecting the Reverse Stock Split. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or maintain compliance with the other listing requirements necessary to maintain the listing of its common stock on The Nasdaq Capital Market. The Company’s failure to regain compliance during this second compliance period could result in delisting.

The Company has an effective shelf registration statement on Form S-3 (File No. 333-222929) and the related prospectus previously declared effective by the Securities and Exchange Commission (the “SEC”) on February 22, 2018 (the “2018 Shelf”), that expires on February 22, 2021, which registered $100,000,000 of common stock, preferred stock, warrants and units, or any combination of the foregoing.

On March 16, 2018, the Company entered into a Sales Agreement (“2018 Sales Agreement”) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an “Agent” and together, the “Agents”) and filed a prospectus supplement to the 2018 Shelf, pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in at-the-market sales transactions having an aggregate offering price of up to $50,000,000 (the “Shares”). Any shares offered and sold will be issued pursuant to the Company’s 2018 Shelf.

During the three months ended June 30, 2020 and 2019, the Company issued 0 and 6,087,382 shares of common stock, respectively, for net proceeds of $0 and $5.0 million in at-the-market offerings under the 2018 Sales Agreement.

As of June 30, 2020, the Company has sold an aggregate of 17,719,185 shares of common stock in at-the-market offerings under the 2018 Sales Agreement, with gross proceeds of approximately $18.7 million. Based on these sales, the Company cannot raise more than an aggregate of $81.3 million in future offerings under the 2018 Shelf, including the $31.3 million remaining available for future issuance through its at-the-market program under the 2018 Sales Agreement.

Restricted stock units

The following table summarizes the Company’s restricted stock units (not including performance-based restricted stock units) activity from March 31, 2020 through June 30, 2020:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2020		480,256		$	1.95
Granted		—		$	—
Vested		(61,626	)	$	2.57
Cancelled / forfeited		—		$	—
Unvested at June 30, 2020		418,630		$	1.85

Performance-based restricted stock units

On April 24, 2017, the Company issued a Performance-Based Restricted Stock Unit Award for 208,822 shares of common stock (the “PBRSU”) to its newly hired Chief Executive Officer. The PBRSU was issued outside of the 2012 Plan, in the Inducement Award Agreement, as an “inducement award” within the meaning of Nasdaq Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 23, 2017, the Board of Directors formally approved the vesting criteria for the PBRSU. The vesting of the PBRSU is divided into five separate tranches each with independent vesting criteria. The first four tranches had performance criteria related to annual revenue goals with measurement at the end of fiscal year 2018 (20 percent), fiscal year 2019 (20 percent), fiscal year 2020 (20 percent), and fiscal year 2021 (20 percent). The fifth tranche had a performance metric related to a path to profitability goal measured as Negative Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) achievable at any point between the grant date and the end of fiscal year 2020 (20 percent). The number of units that ultimately vest for each tranche will range from 0 percent to 120 percent of the target amount, not to exceed 208,822 in aggregate. On December 12, 2018, the Board of Directors formally approved an amendment to the vesting criteria for the PBRSUs. As of December 12, 2018, 100 percent of the Negative Adjusted EBITDA tranche, or 41,764 shares had vested and 8,352 units had been forfeited. Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones. As of June 30, 2020, no tranches are expected to vest unless there is a change in control.

Based on the amended PBRSU vesting terms, a Type III modification, the modified grant date fair value of the PBRSUs is $165,000 of which one-third is being recognized over the expected service period of each tranche ending on April 23, 2023. The Company began recording stock-based compensation expense for the initial performance tranches after the August 23, 2017 grant date when the initial financial performance goals were established and approved and has modified its recording of compensation expense in accordance with the amended performance tranches beginning on December 12, 2018.

On July 2, 2019, the Company issued Performance-Based Restricted Stock Unit Awards (the “PBRSU Retention Awards”) for an aggregate of 6,027,899 shares of common stock to its management team. The PBRSUs were issued pursuant to the 2012 Plan. The PBRSU Retention Awards will vest in full upon the earlier of the Company’s engagement in a pre-IND meeting with the FDA, twenty-four months from the grant date, or a change in control. As of June 30, 2020, all PBRSUs are expected to vest twenty-four months from the grant date.

The following table summarizes the Company’s performance-based restricted stock unit activity from March 31, 2020 through June 30, 2020:

	Number of Shares		Weighted Average Price
Unvested at March 31, 2020		3,952,927	$	0.51
Granted		—	$	—
Vested		—	$	—
Cancelled / forfeited		—	$	—
Unvested at June 30, 2020		3,952,927	$	0.51

Stock options

The following table summarizes the Company’s stock option activity from March 31, 2020 to June 30, 2020:

	Options Outstanding		Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2020		7,638,076	$	2.08	$	37,440
Options granted		—	$	—	$	—
Options cancelled / forfeited		—	$	—	$	—
Options exercised		—	$	—	$	—
Outstanding at June 30, 2020		7,638,076	$	2.08	$	79,237
Vested and Exercisable at June 30, 2020		4,593,119	$	2.48	$	3,396

The weighted average remaining contractual term of options exercisable and outstanding at June 30, 2020 was approximately 7.13 years.

Employee Stock Purchase Plan

In June 2016, our Board of Directors adopted, and in August 2016 stockholders subsequently approved, the 2016 Employee Stock Purchase Plan (“ESPP”). The Company reserved 1,500,000 shares of common stock for issuance thereunder. The ESPP permits employees after five months of service to purchase common stock through payroll deductions, limited to 15 percent of each employee’s compensation up to $25,000 per employee per year or 10,000 shares per employee per six-month purchase period. Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering period commenced in September 2016. At June 30, 2020, there were 1,188,718 shares available for purchase under the ESPP.

Common stock reserved for future issuance

Common stock reserved for future issuance consisted of the following at June 30, 2020:

Common stock options outstanding and reserved under the 2012 Plan			5,549,864
Common stock reserved under the 2012 Plan			14,158,654
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,188,718
Restricted stock units outstanding under the 2012 Plan			418,630
Performance-based restricted stock units outstanding under the 2012 Plan			3,794,221
Common stock options outstanding and reserved under the Incentive Award Agreement			2,088,212
Performance-based restricted stock units outstanding under the Incentive Award Agreement			158,706
Total at June 30, 2020			27,357,005

Note 4. Collaborative Research, Development, and License Agreements

In December 2016, the Company signed a collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen® Bioprinter at the university for the purpose of developing a kidney organoid for potential therapeutic applications. The Company received up-front payments in January and March 2017, which has been recorded as deferred revenue. Revenue of $0 and $10,000 was recorded under this agreement for the three months ended June 30, 2020 and 2019, respectively. The Company completed its obligations under this agreement and does not anticipate recording any further revenue.

Note 5. Commitments and Contingencies

Legal matters

In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business.

On January 30, 2020, the Company received a demand letter (the “Letter”) from a purported stockholder alleging that the disclosures in the Form S-4 filed with the SEC on December 23, 2019 violated federal securities laws by failing to disclose certain allegedly material information. The Letter demands, among other things, that the Company make corrective disclosures and reserves the right to pursue legal action. The Company believes the assertions in the Letter are without merit and now moot.

On March 4, 2020, the Company received a letter from the SEC regarding an inquiry into certain of the Company’s prior disclosures and related operations. The Company is cooperating with the SEC in response to a subpoena.

The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability.

The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures. During the period presented, the Company has not recorded any accrual for loss contingencies associated with any claims or legal proceedings; determined that an unfavorable outcome is probable or reasonably possible; or determined that the amount or range of any possible loss is reasonably estimable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected.

Note 6. Leases

Operating Leases

In October 2019, the Company entered into an agreement to rent office space at 440 Stevens Avenue, Suite 200, Solana Beach, California 92075. This agreement is a month-to-month contract and can be terminated at-will by either party at any time. As such, the Company has concluded that this agreement does not contain a lease and will be expensed as incurred. Monthly rental payments are approximately $4,000 per month.

The Company recorded operating lease expense for its former facilities on 6275 Nancy Ridge Drive, San Diego, California 92121 and its copy machines on a straight-line basis over the life of the leases, which were terminated in the third quarter of fiscal 2019. For the three months ended June 30, 2020 and 2019, the Company recorded operating lease expense of approximately $0 and $262,000, respectively. In addition, the Company recorded rent expense for the office space of approximately $12,000 and $0 for the three months ended June 30, 2020 and 2019, respectively. Variable lease costs associated with the Company’s leases, such as payments for additional monthly fees to cover the Company’s share of certain facility expenses (common area maintenance, or CAM) are expensed as incurred. Variable lease expense was approximately $0 and $107,000 for the three months ended June 30, 2020 and 2019, respectively. Short-term lease cost for the three months ended June 30, 2020 and 2019 was approximately $0 and $15,000, respectively. The short-term lease was terminated in the second quarter of fiscal 2020.

Note 7. Concentrations

Credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. Because it was in the early commercial stage, the Company’s revenues to date have been derived from a relatively small number of customers and collaborators. However, the Company has not historically experienced any accounts receivable write-downs and management does not believe significant credit risk exists as of June 30, 2020.

Note 8. Related Parties

From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business and on terms and conditions it believes are as fair as those it offers and receives from independent third parties. These agreements are ratified by the Company’s Board of Directors or a committee thereof pursuant to its related party transaction policy.

During fiscal 2020, the Company provided services to Viscient Biosciences (“Viscient”), an entity for which Keith Murphy, the Company’s director, as of July 15, 2020, and former Chief Executive Officer and President, serves as the Chief Executive Officer and President. In addition to the services provided by Organovo, Viscient has purchased primary human cell-based products from its former subsidiary, Samsara. There was approximately $84,000 of accounts receivable outstanding as of June 30, 2020 and $60,000 of accounts receivable outstanding as of June 30, 2019. The Company and Viscient have agreed on a payment plan under which Viscient has made a payment of approximately $28,000 on or before June 17, 2020 and will make a payment of approximately $28,000 on or before July 24, 2020; $19,000 on or before August 23, 2020; $19,000 on or before September 22, 2020, and $19,000 on or before October 22, 2020. Through the date of filing, Viscient has made payments in aggregate of $84,000. Further, in July 2020, we entered into a Cooperation Agreement with Mr. Murphy. See “Note 1. Description of Business” and “Note 10. Subsequent Events” for more information.

Note 9. Restructuring

In August 2019, after a rigorous assessment of the Company’s lead liver therapeutic tissue program following completion of various preclinical studies, the Company’s Board of Directors (the “Board”) concluded that the variability of biological performance and related duration of potential benefits presented development challenges and lengthy redevelopment timelines that no longer supported an attractive opportunity for the Company and its stockholders. Furthermore, the Board deemed the stage of development of the Company’s other therapeutic pipeline assets, including stem cell based tissue programs, to be too premature to potentially reach IND filing status within an acceptable investment horizon and with the Company’s available resources. As a result, the Company suspended all development of its lead program and all other related pipeline development activity and engaged a financial advisory firm to explore its strategic alternatives, including evaluating a range of ways to generate value from the Company’s technology platform and intellectual property, its commercial and development capabilities, its listing on the Nasdaq Stock Market, and its remaining financial assets. Under the restructuring plan, the Company terminated the employment of 52 employees, or 90 percent of its workforce and recorded a restructuring charge during the year ended March 31, 2020 of approximately $2.7 million, related to employee severance and benefits costs, of which approximately $1.7 million was paid out during the fiscal second quarter, approximately $0.9 million was paid out during the fiscal third quarter, approximately $0.1 million was paid out during the fiscal fourth quarter, and less than $0.1 million was paid out during the first quarter of fiscal 2021.

No restructuring charges were recorded during the three months ended June 30, 2020 and 2019.

The following table summarizes the activity and balances of the restructuring reserve (in thousands):

	Severance for Involuntary Employee Terminations
Balance at March 31, 2020	$	21
Reserve established		—
Increase to reserve		—
Utilization of reserve:
Payments		(21	)
Balance at June 30, 2020	$	—

Note 10. Subsequent Events

On July 14, 2020, we entered into a Cooperation Agreement with Mr. Murphy. Pursuant to the Cooperation Agreement, the Board appointed Messrs. Murphy and Stern to the six member Board as Class III directors, with terms expiring at the Company’s 2020 Annual Meeting and two of the Company’s existing directors, Richard Maroun and David Shapiro, resigned from the Board and from each Board committee on which they serve, effective immediately. The Board also agreed to nominate, recommend, support and solicit proxies for the re-election of Messrs. Murphy and Stern at the 2020 Annual Meeting. The Board also agreed to nominate, recommend, support and solicit proxies for an advisory stockholder vote (the “Advisory Nominees Proposal”) at the 2020 Annual Meeting to appoint three individuals, Douglas Jay Cohen, David Gobel and Alison Tjosvold Milhous (collectively, the “Advisory Nominees”), to the Board. If the final vote tabulation for the Advisory Nominees Proposal receives more votes cast “FOR” than “AGAINST” its approval, our Board has approved the appointment of the Advisory Nominees, to be automatically effective immediately following the final adjournment of the 2020 Annual Meeting. In addition, immediately following the appointment of the Advisory Nominees, each of our existing directors (other than Messrs. Murphy and Stern) will resign from the Board, which will result in Messrs. Murphy and Stern and the Advisory Nominees constituting the full membership of the Board (collectively, the “New Director Slate”) and will trigger a “Change of Control” under Organovo’s severance plan, as well as its Directors and Officers (“D&O”) liability insurance policies, requiring the following cash outlays: i) approximately $3.0 million for severance obligations and ii) approximately $2.0 million (or $1.7 million net of returned premium) for a six year D&O tail insurance policy. Please see “Note 1. Business Description” for a discussion of the new business plan the New Director Slate intends for the Company to pursue if they are appointed to the Board following the final adjournment of the 2020 Annual Meeting.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management’s discussion and analysis of financial condition and results of operations should be read in conjunction with our historical consolidated financial statements and the related notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2020. This discussion and analysis contains forward-looking statements, such as statements related to our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions such as “will,” “may,” “could,” “should,” or similar expressions, identify certain of these forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks and uncertainties, including those described in this Quarterly Report on Form 10-Q, as well as the risk factors disclosed in our Annual Report on the Form 10-K for the fiscal year ended March 31, 2020, filed with the Securities and Exchange Commission on May 28, 2020, that could cause our actual results or events to differ materially from those expressed or implied by such forward-looking statements. Except to the limited extent required by applicable law, the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report.

Basis of Presentation

The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the Securities and Exchange Commission (the “SEC”) instructions to Quarterly Reports on Form 10-Q. Accordingly, the unaudited condensed consolidated financial statements presented elsewhere in this Form 10-Q and discussed below are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (“GAAP”) to be included in a full set of financial statements. The audited financial statements for the year ended March 31, 2020, filed with the SEC on Form 10-K on May 28, 2020 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Overview

We are an early-stage biotechnology company that has focused on pioneering the development of bioprinted 3D human tissues that emulate key aspects of human biology and disease.

Historical Operations and Strategic Alternatives Process

Prior to August 2019, we have focused our efforts on developing our in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. We also explored the development of other potential pipeline in vivo tissue constructs in-house and through collaborations with academic and government researchers. In the past, we also explored the development of in vitro tissues, including proof of concept models of diseased tissues, for use in drug discovery and development.

In August 2019, after a rigorous assessment of our in vitro liver therapeutic tissue program, we concluded that the variability of biological performance and related duration of potential benefits no longer supported an attractive opportunity due to redevelopment challenges and lengthening timelines to compile sufficient data to support an IND filing. As a result, we suspended development of our lead program and all other related in-house pipeline development activities.

Our Board also engaged a financial advisory firm to explore our available strategic alternatives, including evaluating a range of ways to generate value from our technology platform and intellectual property, our commercial and development capabilities, our listing on the Nasdaq Capital Market, and our remaining financial assets. These strategic alternatives included possible mergers and business combinations, sales of part or all of our assets, and licensing and partnering arrangements. We implemented various restructuring steps to manage our resources and extend our cash runway, including reducing commercial activities related to our liver tissues, except for sales of primary human cells out of inventory, negotiating an exit from our long-term facility lease, selling various assets, and reducing our workforce. Additionally, in November 2019, we sold certain inventory and equipment and related proprietary information held by our wholly-owned subsidiary, Samsara Sciences, Inc. (“Samsara”), and as a result of such sale, Samsara ceased its operations.

Tarveda, on December 13, 2019, we entered into a merger agreement with Tarveda (the “Merger Agreement”). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, our wholly-owned merger subsidiary would merge (the “Merger”) into Tarveda, with Tarveda surviving the Merger. The Merger Agreement included various conditions to the consummation of the Merger, including approval by our stockholders at a Special Meeting of Stockholders scheduled for April 7, 2020 (the “Special Meeting”).

At the Special Meeting, the Merger was not approved by our stockholders. As a result, we terminated the Merger Agreement with Tarveda. Pursuant to the terms of the Merger Agreement, we were obligated to reimburse certain of Tarveda’s merger-related expenses not to exceed $300,000, which was offset by Tarveda’s portion of shared expenses incurred by Organovo in fiscal 2020.

The Cooperation Agreement and Advisory Nominees Proposal

Following the Special Meeting and the termination of the Merger Agreement, our Board continued to solicit stockholder feedback regarding the Company’s strategic alternatives and how to maximize stockholder value. In response to feedback from our largest stockholder regarding its desire for the Board to consider opportunities in the 3D bioprinting field and suggestion that the Board should speak with Keith Murphy, the Company’s founder, stockholder and former Chief Executive Officer and Chairman, for potential business ideas, our Board initiated discussions with Mr. Murphy. Based on these discussions, we entered into a Cooperation Agreement with Mr. Murphy on July 14, 2020 (the “Cooperation Agreement”). Under the terms of the Cooperation Agreement, the Board appointed Mr. Murphy and Adam K. Stern to the Board as Class III directors, and two of the Company’s existing directors, Richard Maroun and David Shapiro, resigned from the Board and the committees thereof. The Board also agreed to nominate, recommend, support and solicit proxies for the re-election of Messrs. Murphy and Stern at the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). The Board also agreed to nominate, recommend, support and solicit proxies for an advisory stockholder vote (the “Advisory Nominees Proposal”) at the 2020 Annual Meeting to appoint three individuals, Douglas Jay Cohen, David Gobel and Alison Tjosvold Milhous (collectively, the “Advisory Nominees”), to the Board. Mr. Murphy identified each of the Advisory Nominees. If the final vote tabulation for the Advisory Nominees Proposal receives more votes cast “FOR” than “AGAINST” its approval, the Board has approved the appointment of the Advisory Nominees, to be automatically effective immediately following the final adjournment of the 2020 Annual Meeting. In addition, immediately following the appointment of the Advisory Nominees, each of our existing directors (other than Messrs. Murphy and Stern) will resign from the Board, which will result in Messrs. Murphy and Stern and the Advisory Nominees constituting the full membership of the Board (collectively, the “New Director Slate”).

Proposed Drug Discovery Business

The New Director Slate has advised us that if the Advisory Nominees Proposal is approved at the 2020 Annual Meeting, the New Director Slate intends to recommence operations and focus our future efforts on developing highly customized human tissues as living, dynamic models of human biology and disease for use in drug discovery and development. The New Director Slate has advised us that it believes our proprietary technology can be used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, and function. The New Director Slate also believes we can utilize our proprietary technology to develop highly customized and dynamic models of human disease, including cell type-specific compartments, prevalent intercellular tight junctions, and microvascular structures. They believe these features can facilitate the development of complex, multicellular disease models for use in the development of targeted therapeutics for various diseases including, among others, intestine, kidney, skin and breast diseases. Market opportunities may include externally-partnered or internally-directed drug discovery and the clinical development of new molecular entities or repurposed drugs in-licensed from other pharmaceutical companies. The goal of the New Director Slate is to establish a pipeline of drug candidates in high-value disease areas, aiming to commence human clinical testing for at least one drug candidate within a three to four year timeframe.

The New Director Slate advised us that it believes we have a significant opportunity to change the classic model of drug discovery using 3D bioprinted human tissues and other 3D models (sometimes known as “organoids” or “organs on a chip”). They have advised that the Company’s new paradigm will involve augmenting available animal disease models, or replacing animal disease models altogether, in the discovery process with more relevant disease models utilizing 3D bioprinted human tissues developed by the Company. They believe our 3D bioprinted human tissues may enable us to study the treatment of human disease by replicating key aspects of human biology in areas where this is currently a challenge with existing models. Rather than offering contract research services (as we have done in the past), they believe we should focus on identifying and developing our own drug candidates, including from unique compounds or repurposed drugs in-licensed from other pharmaceutical companies. After identifying a drug candidate, they may have us out-license the drug candidate or they may elect to have us develop the drug candidate internally. In addition to drug discovery, they believe we should continue to evaluate opportunities to monetize our intellectual property and technologies along the way as a means to generate funds to support our primary business. They also believe that we should continue to identify and work with partners and collaborators, including leading academic research sites, to develop new enabling applications which can support its discovery and development mission.

If the Advisory Nominees Proposal is approved, the New Director Slate intends to restart our research and development operations by hiring a team of R&D professionals with the experience required to develop bioprinted and other 3D tissues for use in drug discovery, to leverage 3D models of disease to discover new drug candidates, and to develop new drug candidates for the initiation of clinical studies.

The New Director Slate has advised us that they expect our research and development staff to grow to seven to ten employees. They also expect to maintain or grow a general and administrative staff of three to five employees to support our operations and reporting requirements as a public company.

If the Advisory Nominees Proposal is approved, the New Director Slate has advised us that they expect to lease sufficient office and laboratory space to support our requirements. They expect that we will need space in the short term in the 3,000-7,000 sq. ft. range, with mixed office and laboratory space. They expect to lease a new facility in San Diego at prevailing market terms.

In the event the Advisory Nominees Proposal is not approved by our stockholders, we may pursue one of the following courses of action, which include but are not limited to the following actions:

•

Pursue another strategic transaction similar to the Merger. We may resume our process of evaluating other candidate companies interested in pursuing a strategic transaction and, if a candidate is identified, focus our attention on negotiating and completing such strategic transaction with such candidate.

•

Continue to operate and expand our business. We could elect to continue to operate and expand our business and pursue licensing or partnering transactions or utilize our intellectual property and platform technology to pursue the redevelopment of our liver tissues or the development of therapeutic tissues currently being studied by our collaborators. Due to the early development stage of our, and our collaborators’, potential therapeutic tissues, any such redevelopment or development efforts would require a significant amount of time and financial resources, and would be subject to all the risk and uncertainties involved in the development of novel, early stage therapeutic products, research tools, and drug screening technologies. There is no assurance that we could raise sufficient capital to support these efforts, that our development efforts would be successful commercially in the case of research applications or that we could successfully obtain any required regulatory approvals required to market any therapeutic product we pursued. We would also need to increase qualified scientific, sales and marketing, and administrative staffing, lease a suitable facility and make other expenditures necessary to support these efforts.

•

Dissolve and liquidate our assets. Our Board may determine that it is in the best interests of the Company and our stockholders to dissolve and liquidate our assets, subject to approval by our stockholders. In that event, we would be required to pay all of our debts and contractual obligations and to set aside certain reserves for potential future claims. If we dissolve and liquidate our assets, there can be no assurance as to the amount or timing of available cash that will remain for distribution to our stockholders after paying our debts and other obligations and setting aside funds for our contingent liabilities.

COVID-19

The extent to which the coronavirus impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. In particular, the continued COVID-19 pandemic could adversely impact our operations, including among others, the timing and ability to pursue strategic alternatives, given the impact it may have on the manufacturing and supply chain, sales and marketing and clinical trial operations of potential strategic partners and the ability, if we elect to do so, to advance our research and development activities and pursue development of any of our pipeline products each of which could have an adverse impact on our business and our financial results. However, our employees and consultants have been working remotely prior to the COVID-19 pandemic and we currently believe our operations have not otherwise been negatively impacted by the pandemic.

Critical Accounting Policies, Estimates, and Judgments

Our financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to stock-based compensation expense, the valuation of impairment of long-lived assets, and the valuation allowance on deferred tax assets. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. Besides the estimates identified above that are considered critical, we make many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed critical, affect reported amounts of assets, liabilities, revenues and expenses, as well as disclosures of contingent assets and liabilities. These estimates and judgments are also based on historical experience and other factors that are believed to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known, even for estimates and judgments that are not deemed critical.

There have been no significant changes to our critical accounting policies since March 31, 2020. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements, refer to Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Note 1. Description of Business and Summary of Significant Accounting Policies” in the Notes to Consolidated Financial Statements contained in our Annual Report on Form 10-K for the year ended March 31, 2020, filed with the SEC on May 28, 2020.

Results of Operations

Comparison of the three months ended June 30, 2020 and 2019

The following table summarizes our results of operations for the three months ended June 30, 2020 and 2019 (in thousands, except %):

	Three months ended
	June 30,				Increase (decrease)
	2020		2019		$			%
Revenues	$	-	$	668	$	(668	)		(100	%)
Cost of revenues	$	-	$	51	$	(51	)		(100	%)
Research and development	$	-	$	3,823	$	(3,823	)		(100	%)
Selling, general and administrative	$	2,786	$	3,315	$	(529	)		(16	%)
Other income	$	19	$	198	$	(179	)		(90	%)

Revenues

We had no revenue for the three months ended June 30, 2020 compared to $0.7 million of revenue for the three months ended June 30, 2019, due to a cessation of revenue generating activities following our decision to restructure operations to preserve capital as we pursue various strategic alternatives.

Costs and Expenses

Cost of Revenues

Cost of product and service revenues, which reflects expenses related to manufacturing our products and delivering services was zero for the three months ended June 30, 2020, compared to approximately $0.1 million for the three months ended June 30, 2019. The decrease was due to the cessation of revenue generating activities following our decision to restructure operations to preserve capital as we pursue various strategic alternatives.

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended June 30, 2020 and 2019 (in thousands, except %):

	Three months ended					Three months ended					Increase (decrease)
	June 30, 2020		% of total			June 30, 2019		% of total			$			%
Research and development	$	-		0	%	$	3,528		92	%	$	(3,528	)		(100	%)
Non-cash stock-based compensation		-		0	%		164		4	%		(164	)		(100	%)
Depreciation and amortization		-		0	%		131		4	%		(131	)		(100	%)
Total research and development expenses	$	-		0	%	$	3,823		100	%	$	(3,823	)		(100	%)

Research and development expenses were zero, a decrease of $3.8 million, or 100%, from the prior year period as we eliminated all research and development activities following our decision to pursue our strategic alternatives during the second quarter of fiscal 2020. This action caused a $1.7 million reduction of personnel related costs, a $0.8 million reduction in lab supply costs, a $0.8 million reduction in facilities costs, and a $0.5 million reduction in all other costs. The Company’s average full-time research and development staff decreased from an average of forty-one full-time employees for the three months ended June 30, 2019 to an average of zero full-time employees for the three months ended June 30, 2020. Going forward, based on the outcome of the Advisory Proposal vote and strategic decisions that the Board may make, the Company may elect to pursue renewed research and development activities with an associated increase in expenses.

Selling, General and Administrative Expenses

The following table summarizes our selling, general and administrative expenses for the three months ended June 30, 2020 and 2019 (in thousands, except %):

	Three months ended					Three months ended					Increase (decrease)
	June 30, 2020		% of total			June 30, 2019		% of total			$			%
Selling, general and administrative	$	1,857		67	%	$	2,185		66	%	$	(328	)		(15	%)
Non-cash stock-based compensation		925		33	%		1,056		32	%		(131	)		(12	%)
Depreciation and amortization		4		0	%		74		2	%		(70	)		(95	%)
Total selling, general and administrative expenses	$	2,786		100	%	$	3,315		100	%	$	(529	)		(16	%)

For the three months ended June 30, 2020, selling, general and administrative expenses were approximately $2.8 million, a decrease of $0.5 million, or 16%, over the prior year period as we restructured our operations to preserve capital as we explore strategic alternatives. These actions caused a $0.9 million decrease in personnel costs and a $0.1 million decrease in all other costs, which were offset by a $0.3 million increase in corporate costs and a $0.2 million increase in allocated facilities costs. Our average selling, general and administrative headcount was six full-time employees for the three months ended June 30, 2020 compared to twenty-one full-time employees in the prior year period.

Other Income (Expense)

Other income was less than $0.1 million for the three months ended June 30, 2020 as compared to $0.2 million for the three months ended June 30, 2019, due to a decrease in interest income caused by lower average yields and investment balances.

Financial Condition, Liquidity and Capital Resources

Until our recent decision to explore strategic alternatives, we had primarily devoted our efforts to developing and commercializing a platform technology to produce and study living tissues that emulate key aspects of human biology and disease, raising capital and building infrastructure. Following the decision to explore strategic alternatives, we have taken steps to manage our resources and extend our cash runway, including reducing all commercial and research and development laboratory activities, except for sales of primary human cells out of inventory, negotiating an exit from our long-term facility lease, selling lab equipment and inventory, and reducing our workforce to the minimum level necessary to explore and support these strategic alternatives and maintain our core intellectual property, licenses and collaborations with research institutions and universities.

As of June 30, 2020, we had cash and cash equivalents of approximately $24.8 million and an accumulated deficit of $282.2 million. We also had negative cash flow from operations of $2.6 million during the three months ended June 30, 2020. At March 31, 2020, we had cash and cash equivalents of approximately $27.4 million and an accumulated deficit of $279.5 million.

At June 30, 2020, we had total current assets of approximately $25.5 million and current liabilities of approximately $0.8 million, resulting in working capital of $24.7 million. At March 31, 2020, we had total current assets of approximately $28.3 million and current liabilities of approximately $1.8 million, resulting in working capital of $26.5 million.

The following table summarizes the primary sources and uses of cash for the three months ended June 30, 2020 and 2019 (in thousands):

	Three months ended
	June 30,
	2020			2019
Net cash (used in) provided by:
Operating activities	$	(2,570	)	$	(5,935	)
Investing activities		2			1
Financing activities		(1	)		4,944
Net decrease in cash, cash equivalents, and restricted cash	$	(2,569	)	$	(990	)

Operating activities

Net cash used in operating activities for the three months ended June 30, 2020 was approximately $2.6 million as compared to $5.9 million used in operating activities for the three months ended June 30, 2019. This $3.4 million decrease in operating cash usage can be attributed primarily to a $3.1 million improvement in the net loss less depreciation and amortization and stock-based compensation, resulting from the Company’s restructuring and reduction of headcount and a $0.3 million reduction in the change in working capital between the two periods.

Investing activities

Net cash provided by investing activities was less than $0.1 million for the three months ended June 30, 2020 and 2019.

Financing activities

Net cash used by financing activities was less than $0.1 million during the three months ended June 30, 2020 compared to net cash provided by financing activities of approximately $4.9 million during the three months ended June 30, 2019. Financing in the prior year period was driven by the sale of common stock through at-the-market (“ATM”) offerings.

Operations funding requirements

Through June 30, 2020, we have financed our operations primarily through the sale of common stock in public offerings, the private placement of equity securities, from revenue derived from products and research-based services, grants, and collaborative research agreements, and from the sale of convertible notes.

The Company believes its cash and cash equivalents on hand will be sufficient to meet its financial obligations for at least the next 12 months of operations If the Advisory Proposal is approved, and the New Director Slate recommences the Company’s operations and focuses its efforts on drug discovery and development, the Company will need to raise additional capital to implement this new business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises.

Based on our use of the 2018 Shelf through June 30, 2020, we cannot raise more than $81.3 million in future offerings under the 2018 Shelf, including through our at-the-market program.

Having insufficient funds may require us to relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. We cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Company’s business, operating results, financial condition and ability to continue as a going concern.

As of June 30, 2020, we had 130,618,203 total issued and outstanding shares of common stock.

In addition, our 2008 Equity Incentive Plan provided for the issuance of up to 1,521,584 shares of common stock upon the exercise of outstanding stock options, of which 896,256 shares were issued. The 2008 Equity Incentive Plan terminated on July 1, 2018. The 2012 Equity Incentive Plan, as amended, provides for the issuance of up to 28,553,986 shares of our common stock, of which 14,158,654 shares remain available for issuance as of June 30, 2020, to executive officers, directors, advisory board members, employees and consultants. Additionally, 1,500,000 shares of common stock have been reserved for issuance under the 2016 ESPP, of which 1,188,718 shares remain available for future issuance as of June 30, 2020. Lastly, 2,246,918 shares of common stock have been reserved for issuances under Inducement Award Agreements. In aggregate, issued and outstanding common stock, shares underlying outstanding warrants, and shares issuable under outstanding equity awards or reserved for future issuance under the 2008 and 2012 Equity Incentive Plans, the Inducement Award Agreements, and the 2016 ESPP total 157,975,208 shares of common stock as of June 30, 2020.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements, including unrecorded derivative instruments that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We have certain warrants and options outstanding but we do not expect to receive sufficient proceeds from the exercise of these instruments unless and until the underlying securities are registered, and/or all restrictions on trading, if any, are removed, and in either case the trading price of our common stock is significantly greater than the applicable exercise prices of the options and warrants.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies under Item 305(e).

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the quarterly period covered by this report were designed and operating effectively.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and our Chief Financial Officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 5 of the Notes to the Unaudited Condensed Consolidated Financial Statements within this Form 10-Q for a discussion of our legal proceedings and contingencies.

ITEM 1A. RISK FACTORS

Investment in our common stock involves a substantial degree of risk and should be regarded as speculative. As a result, the purchase of our common stock should be considered only by persons who can reasonably afford to lose their entire investment. Before you elect to purchase our common stock, you should carefully consider the risk and uncertainties described below in addition to the other information incorporated herein by reference. Additional risks and uncertainties of which we are unaware or which we currently believe are immaterial could also materially adversely affect our business, financial condition or results of operations. If any of the risks or uncertainties discussed in this Annual Report occur, our business, prospects, liquidity, financial condition and results of operations could be materially and adversely affected, in which case the trading price of our common stock could decline, and you could lose all or part of your investment.

Risks Related to COVID-19

We face risks related to health epidemics, including the recent COVID-19 pandemic, which could have a material adverse effect on our business and results of operations.

In December 2019 a respiratory illness caused by a novel strain of coronavirus, SARS-CoV-2, causing the Coronavirus Disease 2019, also known as COVID-19 or coronavirus emerged. While initially the outbreak was largely concentrated in China it has spread globally. Global health concerns relating to the COVID-19 pandemic have been weighing on the macroeconomic environment, and the pandemic has significantly increased economic volatility and uncertainty. The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. The extent to which the coronavirus impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. The continued COVID-19 pandemic could adversely impact our operations, including among others, the timing and ability to pursue strategic alternatives, given the impact it may have on the manufacturing and supply chain, sales and marketing and clinical trial operations of potential strategic partners, and the ability, if we elect to do so, to advance our research and development activities and pursue development of any of our pipeline products, each of which could have an adverse impact on our business and our financial results.

In addition, the stock market has been unusually volatile during the COVID-19 pandemic and such volatility may continue. Our stock price has also experienced volatility during this time, including occasional significant increases and decreases, and such increases and decreases may repeat or continue for the foreseeable future.

There are no comparable recent events which may provide guidance as to the effect of the COVID-19 pandemic, and, as a result, the ultimate impact of the pandemic, or any similar health epidemic that may occur in the future, is highly uncertain and subject to change. We do not yet know the full extent of COVID-19’s impact on our business, our operations, or the global economy as a whole. However, the effects may have a material adverse impact on our future results of operations.

Risks Related to the Proposed Go Forward Business

If the Advisory Nominees Proposal is approved at the 2020 Annual Meeting, the New Director Slate has advised us that it intends for the Company to recommence operations and focus our efforts on utilizing our 3D bioprinting technology to develop human tissues and disease models for drug discovery and development. In this case, the Company will be recommencing its operations as an early-stage company with an unproven business strategy, and may never achieve profitability.

If the Advisory Nominees Proposal is approved at the Annual Meeting, the New Director Slate has advised us that it intends for the Company to recommence operations and focus its efforts on utilizing its 3D bioprinting technology to develop human tissues and disease models for drug discovery and development. In this case, the Company will be recommencing its operations as an early-stage company with an unproven business strategy, and may never achieve profitability. Our success will depend upon the viability of our platform technology and any disease models we develop, as well as on our ability to determine which drug candidates we should pursue. Our success will also depend on our ability to select an appropriate development strategy for any drug candidates we identify, including internal development or partnering or licensing arrangements with pharmaceutical companies. We may never achieve profitability, or even if we achieve profitability, we may not be able to maintain or increase our profitability.

The New Director Slate has advised us that they expect that the Company will incur substantial additional operating losses over the next several years as our research and development activities increase. The amount of future losses and when, if ever, we will achieve profitability are uncertain. Our ability to generate revenue and achieve profitability will depend on, among other things:

•

successfully developing human tissues and disease models for drug discovery and development that enable us to identify drug candidates;

•

successfully outsource certain portions of our development efforts;

•

entering into partnering or licensing arrangements with pharmaceutical companies to further develop and conduct clinical trials for any drug candidates we identify;

•

obtaining any necessary regulatory approval for any drug candidates we identify; and

•

raising sufficient funds to finance our activities and long-term business plan.

We might not succeed at any of these undertakings. If we are unsuccessful at one or more of these undertakings, our business, prospects, and results of operations will be materially adversely affected.

Using our platform technology to develop human tissues and disease models for drug discovery and development is new and unproven.

Utilizing our 3D bioprinting platform technology to develop human tissues and disease models for drug discovery and development will involve new and unproven technologies, disease models and approaches, each of which is subject to the risk associated with new and evolving technologies. To date, we have not identified or developed any drug candidates utilizing the business model recommended by the New Director Slate. Our future success will depend on our ability to utilize our 3D bioprinting platform to develop human tissues and disease models that will enable us to identify and develop viable drug candidates. We may experience unforeseen technical complications, unrecognized defects and limitations in our technology or our ability to develop disease models or identify viable drug candidates. These complications could materially delay or substantially increase the anticipated costs and time to identify and develop viable drug candidates, which would have a material adverse effect on our business and financial condition and our ability to continue operations.

We will face intense competition in our drug discovery efforts.

The biotechnology industry is subject to intense competition and rapid and significant technological change. There are many potential competitors for the disease indications we may pursue, including major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. Many of these competitors have significantly greater financial and technical resources, experience and expertise in the following areas than we have, including:

•

research and technology development;

•

development of or access to disease models;

•

identification and development of drug candidates;

•

regulatory processes and approvals; and

•

identifying and entering into agreements with potential collaborators.

Principal competitive factors in our industry include: the quality, scientific and technical support, management and the execution of drug development and regulatory approval strategies; skill and experience of employees, including the ability to recruit and retain skilled, experienced employees; intellectual property portfolio; range of capabilities, including drug identification, development and regulatory approval; and the availability of substantial capital resources to fund these activities.

In order to effectively compete, we may need to make substantial investments in our research and technology development, drug candidate identification and development, testing and regulatory approval and licensing and business development activities. There is no assurance that we will be successful in discovering effective drug candidates using our 3D bioprinted tissues or disease models. Our technologies and drug development plans also may be rendered obsolete or noncompetitive as a result of technologies, products and services introduced by competitors. Any of these risks may prevent us from building a successful drug discovery business or entering into a strategic partnership or collaboration related to, any drug candidates we identify on favorable terms, or at all.

If we purse drug development through 3D bioprinted tissues and disease models, we will require access to a constant, steady, reliable supply of human cells to support our development activities.

If we pursue drug development through 3D bioprinted tissues and disease models, we will require access to a constant, steady, reliable supply of human cells to support our development activities. We typically purchased certain qualified human cells from selected third-party suppliers based on quality assurance, cost effectiveness, and regulatory requirements. We formed our wholly-owned subsidiary, Samsara, to eventually serve as a key source of the primary human cells we utilized in our business and we recently dissolved Samsara in connection with pursuing the proposed Merger with Tarveda, which was not successful. If we recommence our development operation, we will need to identify one or more sources of qualified human cells and there can be no guarantee that we would be able to access the quantity and quality of raw materials needed at a cost-effective price. In this event, any failure to obtain a reliable supply of sufficient human cells or a supply at cost effective prices would harm our business and our results of operations and could cause us to be unable to obtain a sufficient supply of human cells to support our drug development efforts.

The business plan proposed by the New Director Slate will be adversely impacted if we are unable to successfully attract, hire and integrate key additional employees or contractors.

Our future success depends in part on our ability to successfully attract and then retain key additional executive officers and other key employees and contractors to support our proposed drug discovery plans. Recruiting and retaining qualified scientific and clinical personnel is critical to our success. Competition to hire qualified personnel in our industry is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. If we are unable to attract and retain high quality personnel, our ability to pursue our drug discovery business will be limited, and our business, prospects, financial condition and results of operations may be adversely affected.

The business plan proposed by the New Director Slate will be adversely impacted if we are unable to secure adequate laboratory facilities and equipment.

In connection with our strategic alternatives process and restructuring beginning in August 2019, we exited our lease agreement for our prior company headquarters (which included laboratory space) and sold most of our lab equipment (with the exception of our bioprinters). In order to proceed with our proposed business plan, we will need to secure adequate lab space and equipment. If we are unable to secure such space and equipment at all, or on commercially reasonable terms, our business opportunity would be adversely impacted.

We may require substantial additional funding to pursue the business plan proposed by the New Director Slate. Raising additional capital would cause dilution to our existing stockholders and may restrict our operations or require us to relinquish rights to our technologies or to a drug candidate.

We currently do not have any committed external source of funds and do not expect to generate any meaningful revenue in the foreseeable future. The New Director Slate has advised us that they believe that our existing cash, cash equivalents and marketable securities and interest thereon will be sufficient to fund our projected operating requirements under the proposed business plan for at least 12 months. They have based these estimates on assumptions that may prove to be wrong, and the Company may use its available capital resources sooner than it currently expects if the operating plans change. If the New Director Slate elects to change the proposed business plan and decide that the Company should pursue further research and development activities, the Company will require substantial additional funding to operate its proposed business, including expanding its facilities and hiring additional qualified personnel, and would expect to finance these cash needs through a combination of equity offerings, debt financings, government or other third-party funding and licensing or collaboration arrangements.

Further, additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to curtail or cease our operations. Raising additional funding through debt or equity financing is likely to be difficult or unavailable altogether given the early stage of our technology and any drug candidates we identify. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline further and existing stockholders may not agree with our financing plans or the terms of such financings.

Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results.

Before obtaining marketing approval from regulatory authorities for the sale of any drug candidates we identify, any such drug candidates must undergo extensive clinical trials to demonstrate the safety and efficacy of the drug candidates in humans. Human clinical testing is expensive and can take many years to complete, and we cannot be certain that any clinical trials will be conducted as planned or completed on schedule, if at all. The New Director Slate has advised us that they may elect to have the Company complete this testing, or some portion thereof, internally or enter into a partnering or development agreement with a pharmaceutical company to complete these trials. Our inability, or the inability of any third party with whom we enter into a partnering or development agreement, to successfully complete preclinical and clinical development could result in additional costs to us and negatively impact our ability to generate revenues or receive development or milestone payments. Our future success is dependent on our ability, or the ability of any pharmaceutical company with who we enter into a partnering or development agreement, to successfully develop, obtain regulatory approval for, and then successfully commercialize any drug candidates we identify.

Any drug candidates we identify will require additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in applicable jurisdictions, achieving and maintaining commercial-scale supply, building of a commercial organization, substantial investment and significant marketing efforts. We are not permitted to market or promote any of our drug candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our drug candidates.

We, or any third party with whom we enter into a partnering or development agreement, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to earn development or milestone payments or for any drug candidates to obtain regulatory approval, including:

•

we, or any third party with whom we enter into a partnering or development agreement, may experience delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

•

we, or any third party with whom we enter into a partnering or development agreement, may fail to obtain sufficient enrollment in clinical trials or participants may fail to complete clinical trials;

•

clinical trials of our drug candidates may produce negative or inconclusive results, and we, or any pharmaceutical company with who we enter into a partnering or development agreement, may decide, or regulators may require, additional clinical trials;

•

we, or any third party with whom we enter into a partnering or development agreement, may decide, or regulators or institutional review boards may require the suspension or termination of clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;

•

regulators or institutional review boards may require additional or unanticipated clinical trials to obtain approval or any drug candidates may be subject to additional post-marketing testing requirements to maintain regulatory approval;

•

regulators may revise the requirements for approving any drug candidates, or such requirements may not be as anticipated;

•

the cost of clinical trials for any drug candidates may be greater than anticipated;

•

the supply or quality of any drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate or may be delayed;

•

regulatory authorities may suspend or withdraw their approval of a product or impose restrictions on its distribution; and

•

we may experience delays due to the recent COVID-19 pandemic, including with respect to the receipt of drug candidates or other materials, submission of NDAs, filing of INDs and starting any clinical trials for other indications or programs.

If we, or any third party with whom we enter into a partnering or development agreement, experience delays in the completion of, or termination of, any clinical trial of any drug candidates that we develop, or are unable to achieve clinical endpoints due to unforeseen events, such as the COVID-19 pandemic, the commercial prospects of our drug candidates will be harmed, and our ability to develop milestones, development fees or product revenues from any of these drug candidates will be delayed.

The New Director Slate has advised us that they expect that the Company will rely upon third-party contractors and service providers for the execution of critical aspects of any future development programs. Failure of these collaborators to provide services of a suitable quality and within acceptable timeframes may cause the delay or failure of any future development programs.

The New Director Slate has advised us that they expect that the Company will outsource certain functions, tests and services to contract research organizations (“CROs”), medical institutions and collaborators as well as outsourcing manufacturing to collaborators and/or contract manufacturers, and we rely on third parties for quality assurance, clinical monitoring, clinical data management and regulatory expertise. They may elect in the future to engage a CRO to run all aspects of a clinical trial on our behalf. There is no assurance that such individuals or organizations will be able to provide the functions, tests, biologic supply or services as agreed upon or in a quality fashion and we could suffer significant delays in the development of our drug candidates or development programs.

In some cases, there may be only one or few providers of such services, including clinical data management or manufacturing services. In addition, the cost of such services could be significantly increased over time. We may rely on third parties and collaborators to enroll qualified patients and conduct, supervise and monitor our clinical trials. Our reliance on these third parties and collaborators for clinical development activities reduces our control over these activities. Our reliance on these parties, however, does not relieve us of our regulatory responsibilities, including ensuring that our clinical trials are conducted in accordance with GCP regulations and the investigational plan and protocols contained in the regulatory agency applications. In addition, these third parties may not complete activities on schedule or may not manufacture under cGMP conditions. Preclinical or clinical studies may not be performed or completed in accordance with GLP regulatory requirements or our trial design. If these third parties or collaborators do not successfully carry out their contractual duties or meet expected deadlines, obtaining regulatory approval for manufacturing and commercialization of our drug candidates may be delayed or prevented. We may rely substantially on third-party data managers for our clinical trial data. There is no assurance that these third parties will not make errors in the design, management or retention of our data or data systems. There is no assurance these third parties will pass FDA or regulatory audits, which could delay or prohibit regulatory approval.

In addition, we will exercise limited control over our third-party partners and vendors, which makes us vulnerable to any errors, interruptions or delays in their operations. If these third parties experience any service disruptions, financial distress or other business disruption, or difficulties meeting our requirements or standards, it could make it difficult for us to operate some aspects of our business.

The near and long-term viability of the drug discovery and development efforts proposed by the New Director Slate will depend on the Company’s ability to successfully establish strategic relationships.

The near and long-term viability of the drug discovery and development efforts proposed by the New Director Slate will depend in part on the Company’s ability to successfully establish new strategic partnering, collaboration and licensing arrangements with biotechnology companies, pharmaceutical companies, universities, hospitals, insurance companies and or government agencies. Establishing strategic relationships is difficult and time-consuming. Potential partners and collaborators may not enter into relationships with us based upon their assessment of our technology or drug candidates or our financial, regulatory or intellectual property position. If we fail to establish a sufficient number of strategic relationships on acceptable terms, we may not be able to develop and obtain regulatory approval for our drug candidates or generate sufficient revenue to fund further research and development efforts. Even if we establish new strategic relationships, these relationships may never result in the successful development or regulatory approval for any drug candidates we identify for a number of reasons both within and outside of our control.

Risks Related to our Historical Business

The development of new biopharmaceutical products involves a lengthy and complex process.

We previously focused the majority of our resources on the development of our liver tissue candidate. In addition to our liver tissue candidate, we conducted initial research and development activities on several other tissue candidates. Each of our therapeutic tissue candidates were in the early stages of research and development and would have required substantial financial resources, development, preclinical testing, clinical trials, manufacturing scale-up and regulatory approval prior to being ready for sale. If we decide to renew our focus on developing our liver tissue candidate and expend funds for such development, this process could take many years of effort without any assurance of ultimate success. Product development efforts with respect to a tissue candidate could fail for many reasons, including:

•

the failure of the tissue candidate in preclinical or clinical studies, including failing to demonstrate sufficient durability and functionality to support further development activities;

•

the inability to satisfy the regulatory requirements to successfully submit an IND with the FDA;

•

adverse patient reactions to the tissue candidate or indications of other safety concerns;

•

insufficient clinical trial data to support the effectiveness or superiority of the tissue candidate;

•

inability to manufacture sufficient quantities of the tissue candidate for development, clinical, or commercialization activities in a timely and cost-efficient manner;

•

failure to obtain, or delays in obtaining, the required regulatory approvals for the tissue candidate, the facilities or the process used to manufacture the tissue candidate;

•

changes in the regulatory environment, including pricing and reimbursement, that make development of a new product or of an existing product for a new indication no longer attractive;

•

the failure to obtain or maintain satisfactory drug reimbursement rates by governmental or third-party payers; and

•

the development of a competitive product or therapy.

The 3D bioprinted tissue candidates that we were developing represent new therapeutic approaches that could be subject to heightened regulatory scrutiny, delays in clinical development and/or delays in achieving the regulatory approvals required for commercialization.

Our liver tissue candidate represented a new approach to treating liver disease, inborn errors of metabolism, and other diseases. Similarly, our other early stage therapeutic tissue candidates represented new therapeutic approaches in their respective disease areas. However, we were unable to achieve satisfactory results with the liver tissue candidate which we were developing. As a result, the development of these therapeutic tissue candidates would be subject to a number of challenges, including:

•

obtaining regulatory approval from the FDA and other regulatory authorities, which have limited experience with regulating the development and commercialization of 3D bioprinted human tissues developing and deploying consistent and reliable processes for manufacturing 3D bioprinted tissues for implantation into patients;

•

utilizing these tissue candidates in combination with other therapies, which may increase the risk of adverse side effects;

•

developing processes for the safe administration of these tissues, including long-term follow-up for all patients who receive these tissue candidates;

•

sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and process these tissue candidates that are free from viruses and other pathogens that may increase the risk of adverse side effects;

•

developing a manufacturing process and distribution network that can provide a stable supply with a cost of goods that allows for an attractive return on investment;

•

qualifying, engaging, and training clinical trial investigators and institutions who will be able to implement the institutionally-approved protocols, recruit and treat patients, and generate data in accordance with targeted goals and timelines; and

•

establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party payors and government authorities.

The regulatory approval process for novel tissue candidates, such as our therapeutic tissue candidates, can be more expensive and take longer than for other, better known or extensively studied product candidates.

Further, the manufacturing processes we would be required to use in connection with our therapeutic tissue candidates may not yield a sufficient supply of satisfactory products that are safe, effective, scalable, or profitable.

Moreover, actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to subscribe to the novel treatment options.

Physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Physicians may not be willing to undergo training to adopt novel therapies, may decide the therapy is too complex to adopt without appropriate training and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of a new therapy do not or will not outweigh its costs.

We have not yet tested any bioprinted therapeutic tissue candidates in clinical trials. Results in early preclinical studies may not be indicative of results obtained in later preclinical studies. Similarly, results from early clinical trials may not be indicative of results obtained in later clinical trials.

Our tissue candidates involve novel technologies and have never been evaluated in clinical trials. It is unknown how translatable the preclinical animal models used in our preclinical studies are to humans. If we elect to resume the development of our therapeutic tissues, we would be required to demonstrate through adequate and well-controlled clinical trials that our tissue candidates are safe and effective, with a favorable risk-benefit profile, for use in their target indications before we could have sought regulatory approvals for their commercial sale. Initial positive results we have observed for our tissue candidates in preclinical animal models may not be predictive of results from our later preclinical trial results, nor of results from future clinical trials in humans. For example, in May 2019, we announced that data generated from a larger group of animal studies differed from our earlier pilot studies and put into question the durability and functionality of our liver tissue candidate. In August 2019, we announced our decision to stop pursuing the development of our liver tissue candidate following our completion of additional studies that did not resolve the durability and functionality issues we had identified. We also announced that as a result of these adverse study results, our board of directors determined that it is in the best interests of our stockholders to explore our available strategic alternatives, rather than to continue to pursue our therapeutic liver tissue and other early stage development projects.

Our experience manufacturing therapeutic tissues is limited. We believe that manufacturing issues, including technical or quality issues or issues, contributed to the viability and functionality issues with our liver tissue candidate, and our ultimate decision to stop the development of this tissue. There is no assurance that we can solve these and any future manufacturing issues.

Before initiating a clinical trial or commercializing any of our tissue candidates, we would have been required to demonstrate to the FDA that the chemistry, manufacturing and controls for our tissue products meet applicable requirements. Because no bioprinted tissue product has been approved in the United States, there is no manufacturing facility that has demonstrated the ability to comply with FDA requirements, and therefore the timeframe and requirements for demonstrating compliance to the FDA’s satisfaction is uncertain.

Bioprinted tissue manufacturing is an emerging industry. To our knowledge, there are no contract manufacturing organizations with experience in manufacturing bioprinted tissue products under GMP conditions. We have conducted all of our manufacturing internally.

We conducted all of our research in research facilities and we were in the process of implementing applicable FDA manufacturing requirements. However, we have limited experience as a company in developing a manufacturing facility that meets all applicable GMP requirements, and we may never have been successful in developing our own manufacturing facility.

Manufacturing our therapeutic tissue candidates is complicated and presents novel technical challenges. We believe that manufacturing issues, including technical or quality issues, contributed to the viability and functionality issues with our liver tissue candidate, and our ultimate decision to stop the development of this tissue. If we elect to resume the development of our therapeutic tissues, we may encounter problems achieving adequate quantities and quality of clinical-grade materials to conduct our clinical trials, or to meet FDA, European Medicines Agency or other applicable standards or specifications with consistent and acceptable production yields and costs.

We have not scaled up the manufacturing process for our therapeutic liver tissue beyond the scale used for research and nonclinical studies. The time and efforts required for us to develop and validate our manufacturing process to support clinical use would potentially delay our ability to develop this program in accordance with our expected timelines.

In order to manufacture and supply any of our tissue candidates on a commercial scale in the future, we would be required to bolster our quality control and quality assurance capabilities, including by augmenting our manufacturing processes and adding personnel. We may encounter problems hiring and retaining the experienced specialist scientific and manufacturing personnel needed to operate our manufacturing process, which could result in additional delays in our production or difficulties in maintaining compliance with applicable regulatory requirements. Further, if we engage in scale-up manufacturing of any approved product, we may encounter unexpected issues relating to the manufacturing processes, donor variability, or the quality, purity or stability of the product, and we may be required to refine or alter our manufacturing processes to address these issues. Resolving these issues could result in significant additional delays and result in significantly increased costs.

Further, any unresolved problems in our manufacturing process could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our ability to successfully enter into a strategic partnership or collaboration related to, or otherwise license or sell the assets or intellectual property associated with, our in vivo therapeutic tissues and manufacturing technologies on favorable terms, or at all.

We obtained our clinical grade livers from a single source, and if we elect to resume the development of our therapeutic liver tissue, we will need to reestablish a commercial source for our clinical grade livers or isolated cells to support our clinical trials and/or commercialization.

Our liver tissue candidate was manufactured using human primary liver cells from non-transplantable livers we receive from the International Institute for the Advancement of Medicine. We relied upon this single source to obtain the clinical grade non-transplantable livers that served as the starting materials for manufacturing the liver cells we used in our therapeutic liver tissue. The availability and quality of clinical grade livers may be sporadic and unpredictable. As a result, if we elect to renew our focus on development of our therapeutics tissues, we will need to reestablish a commercial source for our clinical grade livers or isolated cells to supply our clinical program or meet commercial demand, and our development plans may be delayed or stalled, which would significantly harm our business. In addition, in order to preserve resources, we discontinued our ability to isolate liver cells from donated organs by restructuring our operations and dissolving our Samsara subsidiary. In order to recommence isolating liver cells from donated organs, we would need to reestablish the access to cell isolation capabilities either through an external collaboration or internally, which could require significant time and financial resources.

Our liver tissue candidate included primary cells from two donors. If the FDA did not authorize us to include cells from more than one donor, our development timeline would be delayed.

Our NovoTissues Liver product was manufactured using cells from a liver donor and cells from an umbilical cord donor. Under 21 CFR §1271, cells from more than one donor cannot be combined in the manufacturing process absent a waiver from the FDA. We applied to the FDA for a waiver authorizing us to include cells from two donors in manufacturing our therapeutic liver tissue for clinical trials. As a result, even if we elected to resume the development of our therapeutic liver tissues, we would be required to redesign our therapeutic liver tissue unless we received a waiver from the FDA. This decision by the FDA could result in additional development costs and a delay in our development timeline, in which case our business would be materially harmed.

If we elect to resume the development of our therapeutic tissues, we may not enjoy the market exclusivity benefits of any orphan drug designation.

Under the Orphan Drug Act, the first product with an orphan drug designation receives market exclusivity, which prohibits the FDA from approving the “same” drug for the same indication. The FDA has stated that drugs can be the “same” even when they are not identical, but has not provided guidance with respect to how it will determine “sameness” in the context of 3D bioprinted tissues. If we elected to continue to pursue the development of our therapeutic tissues, it could be possible that another bioprinted therapeutic tissue product could be approved for the treatment of a disease one of our orphan products is intended to treat before our product is approved, which means that we would not obtain orphan drug exclusivity and could also potentially be blocked from approval until the first product’s orphan drug exclusivity for a product expires or until we demonstrated, if we could, that our product is superior. Further, if we obtained orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care.

If we elect to resume the development of our therapeutic tissues, a competitor may achieve regulatory approval before we do or develop therapies that are more advanced or effective than ours, which would harm our business and financial condition, and our ability to successfully market or commercialize any tissue candidates.

The biotechnology and pharmaceutical industries, including the fields of gene therapies, cellular therapies, and engineered tissue products, are characterized by rapid technological progress, competition, and a strong emphasis on intellectual property. We are aware of several companies focused on developing gene therapies and cellular therapies for use in treating end stage liver disease and/or inborn errors of metabolism. If we elect to resume the development of our therapeutic tissues, we may face competition from large or specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies, and public and private research institutions.

Some of our potential competitors, alone or with their strategic partners, have greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in these industries may result in even greater concentration of resources among a smaller number of competitors. If we elect to resume the development of our therapeutic tissues, these competitors may obtain FDA or other regulatory approval for their products more rapidly than us, which could result in our competitors establishing a strong market position before we would be able to enter the market, if ever. Further, new or advanced technologies may render our tissue candidates uneconomical or obsolete. Our competitors could also develop products that are safer, more effective, have fewer or less side effects, or are more convenient or less expensive than any tissue candidates that we elected to develop.

If we elect to resume the development of our in vitro tissues business, such business would depend on new and unproven technology and approaches, and we may be unable to establish it as a profitable, standalone business.

Our in vitro products and services involve new and unproven models and approaches. We began offering our first commercial product (and related research services), our ExVive™ Human Liver Tissue, on a limited basis in April 2014 and more broadly in November 2014. We began offering our second product (and related research services), our ExVive™ Human Kidney Tissue, for predictive preclinical testing of drug compounds in September 2016. In May 2019, we announced plans to conduct additional preclinical studies necessary to optimize our manufacturing processes and complete additional preclinical studies that would generate consistent scientific data regarding the prolonged functionality and therapeutic benefits of our in vivo liver tissues. After a rigorous assessment of our liver therapeutic tissue program following completion of these additional studies, we concluded that the variability of biological performance and related duration of potential benefits presented development challenges and lengthy timelines that no longer supported an attractive opportunity. As a result, we suspended development of our lead program. We also suspended development of all other related pipeline development activity.

Our commercial products reflected a novel approach to preclinical testing of drug compounds and disease modeling, and even if we elect to resume the development of our products there is no assurance that they would perform as expected or as would be required by our customers. The commercial acceptance of, and the results of our efforts to increase customer awareness and demand for, our drug discovery and biological research tools, products and services, did not result in our development of a profitable, standalone business. In addition, we experienced that some of our customers continued to require unique features, cell sourcing, validation data, or greater degrees of reproducibility than we were able to achieve to date, in order to utilize our commercial products in their drug discovery, biological research or development programs. Even if we or our customers are successful in our respective efforts, we or our customers may not be able to discover or develop commercially viable therapeutics or other products therefrom. Based on these and other risks, there is no assurance that, if we elect to resume the development of our in vitro tissues business, that we would be successful in our efforts to advance the programs and commercialize our products.

The successful commercialization of our in vitro products and services is subject to a variety of risks.

If we elect to pursue the commercialization of our in vitro products and services, any such efforts would be subject to risks and uncertainties, including:

•

failing to develop products or services that are effective, reproducible, and competitive;

•

failing to demonstrate the commercial and technical viability of any products or services that we successfully develop, failing to meet customer expectations or requirements or otherwise failing to achieve market acceptance of such products or services;

•

failing to be cost effective and timely;

•

being unable to implement features or functionality required by customers;

•

being difficult or impossible to manufacture on a large scale;

•

being unable to establish and maintain supply and manufacturing relationships with reliable third parties;

•

being unable to obtain a sufficient supply of human cells for our products, services and research and development activities on a timely basis and at acceptable quality levels and costs;

•

failing to develop our products and services before the successful marketing of similar products and services by competitors;

•

being unable to hire and retain qualified personnel; and

•

infringing the proprietary rights of third parties or competing with superior products marketed by third parties.

If we elect to resume the development and commercialization of our in vitro products, any of these or any other risks and uncertainties could occur, our efforts to commercialize our in vitro products and services may be unsuccessful, which would harm our business and results of operations. Further, these risks may prevent us from successfully entering into a strategic partnership or collaboration related to, or otherwise license or sell the assets or intellectual property associated with, our in vivo therapeutic liver tissue on favorable terms, or at all. If we fail to do so, any strategic transaction we consummate may offer limited value for our business and proprietary technology and may not enhance stockholder value.

If we elect to resume the development and commercialization of our in vitro products, we would face intense competition which could result in reduced acceptance and demand for our in vitro products and services.

The biotechnology industry is subject to intense competition and rapid and significant technological change. There are many potential competitors for our in vitro products and services, including major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. Many of these competitors have significantly greater financial and technical resources, experience and expertise in the following areas than we have, including:

•

research and technology development;

•

product identification and development;

•

regulatory processes and approvals;

•

production and manufacturing;

•

securing government contracts and grants to support their research and development efforts;

•

sales and marketing of products, services and technologies; and

•

identifying and entering into agreements with potential collaborators.

Principal competitive factors in our industry include: the quality, scientific and technical support, price and breadth of technology and services; management and the execution of product development and commercialization strategies; skill and experience of employees, including the ability to recruit and retain skilled, experienced employees; intellectual property portfolio; range of capabilities, including product identification, development, regulatory approval, manufacturing and marketing; and the availability of substantial capital resources to fund these activities.

In order to effectively compete, we would need to make substantial investments in our research and technology development, product identification and development, testing and regulatory approval, manufacturing, customer awareness activities, publications of our technology and results in scientific publications and sales and marketing activities. If we elected to do so, there is no assurance that we would be successful in commercializing and gaining significant market share for any products or services we offer in part through use of our technology. Our technologies, products and services also may be rendered obsolete or noncompetitive as a result of products and services introduced by competitors. Any of these risks may prevent us from successfully building a successful in vitro business or entering into a strategic partnership or collaboration related to, or otherwise license or sell the assets or intellectual property associated with, our in vitro business on favorable terms, or at all. If we fail to do so, any strategic transaction we consummate may offer limited value for our business and proprietary technology and may not enhance stockholder value.

If we elect to resume the development and commercialization of our in vitro products, we would require access to a constant, steady, reliable supply of human cells to successfully develop and commercialize our in vitro products and services.

If we elect to resume the development and commercialization of our in vitro products, we would require a reliable supply of qualified human cells for our commercial products and services and for our research and product development activities. We typically purchased certain qualified human cells from selected third-party suppliers based on quality assurance, cost effectiveness, and regulatory requirements. We formed our wholly-owned subsidiary, Samsara, to eventually serve as a key source of the primary human cells we utilized in our business and we recently dissolved Samsara in connection with pursuing the proposed Merger with Tarveda, which was not successful. We have relied on a combination of third-party suppliers and Samsara to meet our demand for human cells for our in vitro business. We worked closely with Samsara and our third-party suppliers to assure adequate supply while maintaining high quality and reliability. Following any resumption of the development and commercialization of our in vitro products and services, if demand for our products and services were to grow significantly, we would most likely need to identify additional sources of qualified human cells and there can be no guarantee that we would be able to access the quantity and quality of raw materials needed at a cost-effective price. In this event, any failure to obtain a reliable supply of sufficient human cells or a supply at cost effective prices would harm our business and our results of operations and could cause us to be unable to comply with the associated contractual obligations we would owe to our customers and collaboration partners.

Risks Related to Government Regulation

Violation of government regulations or quality programs could harm demand for our products or services, and the evolving nature of government regulations could have an adverse impact on our business.

To the extent that our products are used in the manufacturing or testing processes for customers drug and medical device products, such end-products or services may be regulated by the FDA under Quality System Regulations (“QSR”) or the Centers for Medicare & Medicaid Services under Clinical Laboratory Improvement Amendments of 1988 (“CLIA’88”) regulations. The customer is ultimately responsible for QSR, CLIA’88 and other compliance requirements for their products. Failure to comply with these requirements could result in lost sales of our products and regulatory delays or objections and potential product liability claims. In

addition, customers may require that services be conducted pursuant to the requirements of Good Laboratory Practice (“GLP”) in order to provide suitable data for their INDs and other regulatory filings. No regulatory review of data from our platform technology has yet been conducted and there is no guarantee that our technology will be acceptable under GLP, or that compliance with GLP requirements could be achieved on the timetable required by customers. As a result, the violation of government regulations or failure to comply with quality requirements could harm demand for these products or services, and the evolving nature of government regulations could have an adverse impact on our ability to commercialize our products or services or sell the assets or intellectual property associated with these products and services on favorable terms, or at all. If we fail to do so, any strategic transaction we consummate may offer limited value for our existing business and proprietary technology and may not enhance stockholder value.

In the past, we have used hazardous chemicals, biological materials and infectious agents in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.

Our product manufacturing, research and development, and testing activities have involved the controlled use of hazardous materials, including chemicals, biological materials and infectious disease agents. We cannot eliminate the risks of accidental contamination or the accidental spread or discharge of these materials, or any resulting injury from such an event. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed our insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. We were also subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, and the experimental use of animals. Our operations may have required that environmental permits and approvals be issued by applicable government agencies. If we failed to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance.

Risks Related to Our Capital Requirements, Finances and Operations

Our board of directors may decide to pursue a dissolution and liquidation of the Company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.

If the Advisory Proposal is not approved at the 2020 Annual Meeting, our board of directors may decide to pursue a dissolution and liquidation of the Company, which would also require stockholder approval. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations, and the costs that would be incurred to effect such liquidation or dissolution. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution and liquidation of the Company, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provisions for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our remaining cash assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation of the Company. If a dissolution and liquidation were pursued, our board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of our liquidation, dissolution or winding up.

We may be unable to continue as a going concern in the future.

We have had recurring losses from operations since inception and will likely not generate meaningful revenue for the foreseeable future. We believe that our existing cash, cash equivalents and marketable securities and interest thereon will be sufficient to fund our projected operating requirements under our current operating plan. However, if our operating plans change and our projected operating requirements increase, we may be unable to continue as a going concern. In this event, the perception that we may not be able to continue as a going concern may have an adverse impact on our business due to concerns about our ability to meet our future contractual obligations or pursue additional strategic transactions. Further, if we are unable to continue as a going concern, we may have to liquidate our assets, and the values we receive for our assets in liquidation and dissolution could be significantly lower than the values reflected in our financial statements and an investor could lose all or part of its investment in our equity.

If we were to resume our research and development activities and pursue development of any of our pipeline products, we would require substantial additional funding. Raising additional capital would cause dilution to our existing stockholders and may restrict our operations or require us to relinquish rights to our technologies or to a product candidate.

We currently do not have any committed external source of funds and do not expect to generate any meaningful revenue in the foreseeable future. We believe that our existing cash, cash equivalents and marketable securities and interest thereon will be sufficient to fund our projected operating requirements under our current operating plan. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect if our operating plans change. If

our current operating plans change and we decide to pursue further research and development activities, we will require substantial additional funding to operate our business, including to expand our facilities and hire additional qualified personnel, and would expect to finance these cash needs through a combination of equity offerings, debt financings, government or other third-party funding and licensing or collaboration arrangements.

To the extent that we raise additional capital through the sale of equity or convertible debt, the ownership interests of our stockholders will be diluted. In addition, the terms of any equity or convertible debt we agree to issue may include liquidation or other preferences that adversely affect the rights of our stockholders. Convertible debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, and declaring dividends, and may impose limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.

Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to curtail or cease our operations.

Given our failure to obtain stockholder approval for the proposed Merger with Tarveda, raising additional funding through debt or equity financing will be difficult or not successful at all, would be dilutive and may cause the market price of our common stock to decline further. Raising additional funding through debt or equity financing is likely to be difficult or unavailable altogether given the early stage of our therapeutic candidates. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline further and existing stockholders may not agree with our financing plans or the terms of such financings.

We have a history of operating losses and expect to incur significant additional operating losses.

We have generated operating losses each year since we began operations, including $2.8 million and $6.5 million for the three months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, we had incurred cumulative operating losses of $232.7 million and cumulative net losses totaling $282.3 million. We expect to incur substantial additional operating losses over the next several years. To achieve profitability, we must either generate sufficient revenue through our in vitro tissues business to offset the costs of operating our business, or we must successfully develop and obtain regulatory approval for one or more of our therapeutic candidates and effectively market and sell any products we develop. Even if we are successful in commercializing a therapeutic product that receives regulatory approval, we may not be able to realize revenues at a level that would allow us to achieve or sustain profitability. We may never generate significant revenue, and even if we do generate significant revenue, we may never achieve profitability.

Our quarterly operating results may vary, which could negatively affect the market price of our common stock.

Our results of operations in any quarter may vary from quarter to quarter and are influenced by such factors as expenses related to:

•

evaluating and implementing strategic alternatives, technology licensing opportunities, potential collaborations, and other strategic transactions;

•

responding to the SEC inquiry;

•

responding to shareholder demand letters; and

•

changes in costs related to the COVID-19 pandemic or the general global economy.

We believe that operating results for any particular quarter are not necessarily a meaningful indication of future results. Nonetheless, fluctuations in our quarterly operating results could negatively affect the market price of our common stock.

Our business could be adversely impacted if we are unable to retain our executive officers and other key personnel.

Our future success will depend to a significant degree upon the continued contributions of our key personnel, especially our executive officers. We do not currently have long-term employment agreements with our executive officers or our other key personnel, and there is no guarantee that our executive officers or key personnel will remain employed with us. Moreover, we have not obtained key man life insurance that would provide us with proceeds in the event of the death, disability or incapacity of any of our executive officers or other key personnel. Further, the process of attracting and retaining suitable replacements for any executive officers and other key personnel we lose in the future would result in transition costs and would divert the attention of other members of our senior management from our existing operations. Additionally, such a loss could be negatively perceived in the capital markets. The election of the New Director Slate would represent a change of control, whereby the officers will likely leave the company and need to be replaced.

We may be subject to security breaches or other cybersecurity incidents that could compromise our information and expose us to liability.

We routinely collect and store sensitive data (such as intellectual property, proprietary business information and personally identifiable information) for the Company, its employees and its suppliers and customers. We make significant efforts to maintain the security and integrity of our computer systems and networks and to protect this information. However, like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee error, malfeasance or other disruption. Any such breach could result in unauthorized access to (or disclosure of) sensitive, proprietary or confidential information of ours, our employees or our suppliers or customers, and/or loss or damage to our data. Any such unauthorized access, disclosure, or loss of information could cause competitive harm, result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and/or cause reputational harm.

Risks Related to Our Common Stock and Liquidity Risks

We could fail to maintain the listing of our common stock on The Nasdaq Capital Market, which could seriously harm the liquidity of our stock and our ability to raise capital or complete a strategic transaction.

The Nasdaq Stock Market LLC (“Nasdaq”) has established continued listing requirements, including a requirement to maintain a minimum closing bid price of at least $1 per share. If a company trades for 30 consecutive business days below such minimum closing bid price, it will receive a deficiency notice from Nasdaq. Assuming it is in compliance with the other continued listing requirements, Nasdaq would provide such company a period of 180 calendar days in which to regain compliance by maintaining a closing bid price at least $1 per share for a minimum of ten consecutive business days.

On June 25, 2019, we received a notice letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of our common stock for the last 30 consecutive business days, we no longer met the requirement to maintain a minimum closing bid price of $1 per share, as set forth in Nasdaq Listing Rule 5450(a)(1). On December 26, 2019, we obtained an additional compliance period of 180 calendar days by electing to transfer to The Nasdaq Capital Market to take advantage of the additional compliance period offered on that market. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market. On March 26, 2020, we obtained shareholder approval to effect a reverse stock split in a range from 20:1 to 40:1, which is subject to the approval of our board of directors (such final ratio, as determined by our board of directors, the “Reverse Stock Split Ratio” such reverse stock split, the “Reverse Stock Split”). On April 17, 2020 we received an additional notice letter from Nasdaq indicating that based on extraordinary market conditions, Nasdaq has determined to toll the compliance periods for bid price and market value of publicly held shares requirements (collectively, the “Price-based Requirements”) through June 30, 2020. Accordingly, since we had 66 calendar days remaining in, the compliance period as of April 16, 2020, we will, upon reinstatement of the Price-based Requirements, still have 66 calendar days from July 1, 2020, or until September 4, 2020, to regain compliance. We can regain compliance, either during the suspension or during the compliance period resuming after the suspension, by evidencing compliance with the Price-based Requirements for a minimum of 10 consecutive trading days. We intend to comply with the Price-based Requirements by effecting the Reverse Stock Split. However, there can be no assurance that we will be able to regain compliance with the minimum bid price requirement or maintain compliance with the other listing requirements necessary for us to maintain the listing of our common stock on The Nasdaq Capital Market. If we are unable to cure the deficiency or regain compliance, our common stock will be delisted from The Nasdaq Capital Market and begin trading on the OTC bulletin board.

A delisting from The Nasdaq Capital Market and commencement of trading on the OTC bulletin board would likely result in a reduction in some or all of the following, each of which could have a material adverse effect on stockholders:

•

the liquidity of our common stock;

•

the market price of our common stock (and the accompanying valuation of our Company);

•

our ability to obtain financing or complete a strategic transaction;

•

the number of institutional and other investors that will consider investing in shares of our common stock;

•

the number of market markers or broker-dealers for our common stock; and

•

the availability of information concerning the trading prices and volume of shares of our common stock.

The Reverse Stock Split that we intend to effect may not increase our stock price over the long-term.

The principal purpose of the Reverse Stock Split is to increase the per share market price of our common stock. It cannot be assured, however, that the Reverse Stock Split will accomplish the objective of increasing the per share market price of our common stock for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of our common stock will proportionally increase the market price of our common stock, it cannot be assured that the Reverse Stock Split will increase the

market price of our common stock by a multiple of the Reverse Stock Split Ratio, as determined by our board of directors, or result in any permanent or sustained increase in the market price of our common stock, which is dependent upon many factors, including our business and financial performance, general market conditions and prospects for future success. Therefore, while price of our common stock might meet the continued listing requirements for The Nasdaq Capital Market initially, it cannot be assured that it will continue to do so.

The Reverse Stock Split may decrease the liquidity of our common stock.

Although our board of directors believes that the anticipated increase in the market price of our common stock could encourage interest in our common stock and possibly promote greater liquidity for our stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the Reverse Stock Split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for our common stock.

The Reverse Stock Split may lead to a decrease in our overall market capitalization.

Should the market price of our common stock decline after the Reverse Stock Split, the percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the Reverse Stock Split. A reverse stock split may be viewed negatively by the market and, consequently, can lead to a decrease in our market capitalization. If the per share market price does not increase in proportion to the Reverse Stock Split ratio, then the value of our Company, as measured by its stock capitalization, will be reduced. In some cases, the per share stock price of companies that have effected reverse stock splits subsequently declined back to pre-reverse split levels, and accordingly, it cannot be assured that the total market value of our common stock will remain the same after the Reverse Stock Split is effected, or that the Reverse Stock Split will not have an adverse effect on the stock price of our common stock due to the reduced number of shares outstanding after the Reverse Stock Split.

Our two largest shareholders have significant influence over key decision making as a result of their concentrated ownership of the voting power of our outstanding capital stock.

Our two largest shareholders, ARK Investment Management LLC (“ARK”) and Nikko Asset Management Americas, Inc. (“Nikko”), collectively own approximately 30% of our outstanding stock and, as demonstrated by the unsuccessful proposed Merger with Tarveda, are able to exercise sufficient voting rights to control the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation, sale of all or substantially all of our assets, or liquidation or dissolution. This concentrated position could delay, defer, or prevent a change of control, merger, consolidation, or sale of all or substantially all of our assets, or liquidation or dissolution that a substantial portion of our other stockholders support, or conversely this significant influence could potentially result in the consummation of such a transaction or liquidation that a substantial portion of our other stockholders do not support. This significant influence could also discourage a potential investor from acquiring our common stock or a potential counterparty from entering into negotiations about a potential strategic transaction and might harm the trading price of our common stock. As stockholders, even with significant influence, ARK and Nikko are entitled to vote their shares in their own interests, which may not always be in the interests of our stockholders generally.

We have a limited trading history and there is no assurance that an active market in our common stock will continue at present levels or increase in the future.

There is limited trading history in our common stock, and although our common stock is now traded on The Nasdaq Capital Market, there is no assurance that an active market in our common stock will continue at present levels or increase in the future. As a result, an investor may find it difficult to dispose of our common stock on the timeline and at the volumes they desire. This factor limits the liquidity of our common stock and may have a material adverse effect on the market price of our common stock and on our ability to raise additional capital.

Compliance with the reporting requirements of federal securities laws can be expensive.

We are a public reporting company in the United States, and accordingly, subject to the information and reporting requirements of the Exchange Act and other federal securities laws, including the compliance obligations of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”). The costs of complying with the reporting requirements of the federal securities laws, including preparing and filing annual and quarterly reports and other information with the SEC and furnishing audited reports to stockholders, can be substantial.

If we fail to comply with the rules of Section 404 of the Sarbanes-Oxley Act related to accounting controls and procedures, or, if we discover material weaknesses and deficiencies in our internal control and accounting procedures, we may be subject to sanctions by regulatory authorities and our stock price could decline.

Section 404 of the Sarbanes-Oxley Act (the “Section 404”) requires that we evaluate and determine the effectiveness of our internal control over financial reporting. We believe our system and process evaluation and testing comply with the management certification requirements of Section 404. We cannot be certain, however, that we will be able to satisfy the requirements in Section 404 in all future periods. If we are not able to continue to meet the requirements of Section 404 in a timely manner or with adequate compliance, we may be subject to sanctions or investigation by regulatory authorities, such as the SEC or Nasdaq. Any such action could adversely affect our financial results or investors’ confidence in us and could cause our stock price to fall. Moreover, if we are not able to comply with the requirements of Section 404 in a timely manner, or if we identify deficiencies in our internal controls that are deemed to be material weaknesses, we may be required to incur significant additional financial and management resources to achieve compliance.

The price of our common stock may continue to be volatile, which could lead to losses by investors and costly securities litigation.

The trading price of our common stock is likely to be highly volatile and could fluctuate in response to factors such as:

•

announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

•

continued macroeconomic conditions related to the COVID-19 pandemic;

•

any announcement regarding the strategic transaction process;

•

reduced government funding for research and development activities;

•

actual or anticipated variations in our operating results;

•

adoption of new accounting standards affecting our industry;

•

additions or departures of key personnel;

•

sales of our common stock or other securities in the open market;

•

degree of coverage of securities analysts and reports and recommendations issued by securities analysts regarding our business;

•

volume fluctuations in the trading of our common stock; and

•

other events or factors, many of which are beyond our control.

The stock market is subject to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been initiated against such a company. Litigation initiated against us, whether or not successful, could result in substantial costs and diversion of our management’s attention and resources, which could harm our business and financial condition.

Investors may experience dilution of their ownership interests because of the future issuance of additional shares of our capital stock.

We are authorized to issue 200,000,000 shares of common stock and 25,000,000 shares of preferred stock. As of June 30, 2020, there were an aggregate of 157,975,208 shares of our common stock issued and outstanding and available for issuance on a fully diluted basis and no shares of preferred stock outstanding. That total for our common stock includes 27,357,005 shares of our common stock that may be issued upon the exercise of outstanding stock options or is available for issuance under our equity incentive plans, and 1,188,718 shares of common stock that may be issued through our Employee Stock Purchase Plan (“ESPP”).

In the future, we may issue additional authorized but previously unissued equity securities to raise funds to support our continued operations and to implement our business plan. We may also issue additional shares of our capital stock or other securities that are convertible into or exercisable for our capital stock in connection with hiring or retaining employees, future acquisitions, or for other business purposes. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders may result. In addition, the future issuance of any such additional shares of capital stock may create downward pressure on the trading price of our common stock. There can be no assurance that we will not be required to issue additional shares, warrants or other convertible securities in the future in conjunction with any capital raising efforts, including at a price (or exercise prices) below the price at which shares of our common stock is currently traded on The Nasdaq Capital Market. Moreover, depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.

We do not intend to pay dividends for the foreseeable future.

We have paid no dividends on our common stock to date and it is not anticipated that any dividends will be paid to holders of our common stock in the foreseeable future. While our future dividend policy will be based on the operating results and capital needs of our business, it is currently anticipated that any earnings will be retained to finance our future expansion and for the implementation of our business plan. As an investor, you should take note of the fact that a lack of a dividend can further affect the market value of our stock and could significantly affect the value of any investment.

Anti-takeover provisions in our organizational documents and Delaware law may discourage or prevent a change of control, even if an acquisition would be beneficial to our stockholders, which could affect our stock price adversely and prevent attempts by our stockholders to replace or remove our current management.

Our certificate of incorporation and bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions:

•

authorize the issuance of preferred stock which can be created and issued by our board of directors without prior stockholder approval, with rights senior to those of the common stock;

•

provide for a classified board of directors, with each director serving a staggered three-year term;

•

prohibit our stockholders from filling board vacancies, calling special stockholder meetings, or taking action by written consent; and

•

require advance written notice of stockholder proposals and director nominations.

In addition, we are subject to the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our certificate of incorporation, bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delaying or impeding a merger, tender offer, or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.

Risks Related to Our Intellectual Property

If we are not able to adequately protect our proprietary rights, our business could be harmed.

Our success will depend to a significant extent on our ability to obtain patents and maintain adequate protection for our technologies, intellectual property and products and service offerings in the United States and other countries. If we do not protect our intellectual property adequately, competitors may be able to use our technologies and gain a competitive advantage.

To protect our products and technologies, we and our collaborators and licensors must prosecute and maintain existing patents, obtain new patents and pursue other intellectual property protection. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technologies or from developing competing products and technologies. Moreover, the patent positions of many biotechnology and pharmaceutical companies are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, we cannot guarantee that:

•

any patent applications filed by us will issue as patents;

•

third parties will not challenge our proprietary rights, and if challenged that a court or an administrative board of a patent office will hold that our patents are valid and enforceable;

•

third parties will not independently develop similar or alternative technologies or duplicate any of our technologies by inventing around our claims;

•

any patents issued to us will cover our technology and products as ultimately developed;

•

we will develop additional proprietary technologies that are patentable;

•

the patents of others will not have an adverse effect on our business; or

•

as issued patents expire, we will not lose some competitive advantage.

We may not be able to protect our intellectual property rights throughout the world.

Certain foreign jurisdictions have an absolute requirement of novelty that renders any public disclosure of an invention immediately fatal to patentability in such jurisdictions. Therefore, there is a risk that we may not be able to protect some of our intellectual property in the United States or abroad due to disclosures, which we may not be aware of, by our collaborators or licensors. Some foreign jurisdictions prohibit certain types of patent claims, such as “method-of-treatment/use-type” claims; thus, the scope of protection available to us in such jurisdictions is limited.

Moreover, filing, prosecuting and defending patents on all of our potential products and technologies throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not sought or obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our future products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.

We may be involved in lawsuits or other proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.

Competitors may infringe our patents or the patents of our collaborators or licensors. Or, our licensors may breach or otherwise prematurely terminate the provisions of our license agreements with them. To counter infringement or unauthorized use, we may be required to file infringement claims or lawsuits, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our collaborators or licensors is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Additionally, our licensors may retain certain rights to use technologies licensed by us for research purposes. Patent disputes can take years to resolve, can be very costly and can result in loss of rights, injunctions and substantial penalties. Moreover, patent disputes and related proceedings can distract management’s attention and interfere with running the business.

Furthermore, because of the potential for substantial discovery in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments which could harm our business.

As more companies file patents relating to bioprinters and bioprinted tissues, it is possible that patent claims relating to bioprinters or bioprinted human tissue may be asserted against us, and any such assertions could harm our business. Moreover, we may face claims from non-practicing entities, which have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. Any such claims, with or without merit, could be time-consuming to defend, result in costly litigation and diversion of resources, cause product shipment or delays or require us to enter into royalty or license agreements. These licenses may not be available on acceptable terms, or at all. Even if we are successful in defending such claims, infringement and other intellectual property litigation can be expensive and time-consuming to litigate and divert management’s attention from our core business. Any of these events could harm our business significantly.

Our current and future research, development and commercialization activities also must satisfy the obligations under our license agreements. Any disputes arising under our license agreements could be costly and distract our management from the conduct of our business. Moreover, premature termination of a license agreement could have an adverse impact on our business.

In addition to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the United States Patent and Trademark Office (“PTO”) to determine the priority of invention. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party.

Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our patents or those of our collaborators or licensors in the PTO. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology.

We depend on license agreements with University of Missouri, Clemson, and UniQuest for rights to use certain patents, pending applications, and know how. Failure to comply with obligations under these agreements and any related or other termination of these agreements could materially harm our business and prevent us from developing or commercializing new product candidates.

We are party to license agreements with University of Missouri, Clemson, and UniQuest PC under which we were granted exclusive rights to patents and patent applications that are important to our business and to our ability to develop and commercialize our NovoGen Bioprinters and 3D tissue products fabricated using our NovoGen Bioprinters. Our rights to use these patents and patent applications and employ the inventions claimed in these licensed patents are subject to the continuation of and our compliance with the terms of our license agreements. If we were to breach the terms of these license agreements and the agreements were terminated as a result, our ability to continue to develop and commercialize our NovoGen Bioprinters and 3D tissue products and to operate our business could be adversely impacted.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following exhibit index shows those exhibits filed with this report and those incorporated herein by reference:

Exhibit No.		Description

2.1		Agreement and Plan of Merger and Reorganization, dated as of December 13, 2019, by and among Organovo Holdings, Inc., Opal Merger Sub, Inc. and Tarveda Therapeutics, Inc. (incorporated by reference from Exhibit 2.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on December 16, 2019).

2.2		First Amendment to Merger Agreement, dated as of January 26, 2020, by and among Organovo Holdings, Inc., Opal Merger Sub, Inc. and Tarveda Therapeutics, Inc. (incorporated by reference from Exhibit 2.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on January 29, 2020).

2.3		Form of Support Agreement, by and between Organovo, Tarveda and certain directors, officers and stockholders of Tarveda (incorporated by reference from Exhibit 2.2 to the Company’s Current Report on Form 8-K, as filed with the SEC on December 16, 2019).

2.4		Form of Support Agreement, by and between Tarveda, Organovo and certain directors and officers of Organovo (incorporated by reference from Exhibit 2.3 to the Company’s Current Report on Form 8-K, as filed with the SEC on December 16, 2019).

2.5		Form of Lock-Up Agreement, by and among Tarveda, Organovo and certain directors and officers of Tarveda and Organovo (incorporated by reference from Exhibit 2.4 to the Company’s Current Report on Form 8-K, as filed with the SEC on December 16, 2019).

2.6		Cooperation Agreement, dated July 14, 2020, between the Company and Keith Murphy. (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 15, 2020).

2.7		Form of Release Agreement by Keith Murphy in favor of the Company’s directors and officers (incorporated by reference from Exhibit 10.2 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 15, 2020).

2.8		Form of Separation and Mutual Release Agreement with the Company’s directors (incorporated by reference from Exhibit 10.3 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 15, 2020).

2.9		Form of Separation Agreement and Release with the Company’s officers (incorporated by reference from Exhibit 10.4 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 15, 2020).

3.1		Certificate of Incorporation of Organovo Holdings, Inc. (Delaware) (incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on February 3, 2012).

3.2		Certificate of Amendment of Certificate of Incorporation of Organovo Holdings, Inc. (incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 27, 2018).

3.3		Bylaws of Organovo Holdings, Inc. (Delaware) (incorporated by reference from Exhibit 3.2 to the Company’s Current Report on Form 8-K, as filed with the SEC on February 3, 2012).

3.4		Amendment to Organovo Holdings Bylaws, dated October 10, 2019 (incorporated by reference from Exhibit 99.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on October 11, 2019).

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1		Certification pursuant to 18 U.S.C. Section 1350.*

101	Interactive Data File*

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ORGANOVO HOLDINGS, INC.

Date: August 10, 2020	By:	/s/ Taylor Crouch
	Name:	Taylor Crouch
	Title:	Chief Executive Officer and President (Principal Executive Officer)


Date: August 10, 2020	By:	/s/ Craig Kussman
	Name:	Craig Kussman
	Title:	Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 onvo-ex311_6.htm EX-31.1 onvo-ex311_6.htm

Exhibit 31.1

CERTIFICATION

I, Taylor Crouch, Chief Executive Officer and President of Organovo Holdings, Inc. (the “Registrant”), certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Registrant;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting

Dated: August 10, 2020

/s/ Taylor Crouch

Taylor Crouch

Chief Executive Officer and President

(Principal Executive Officer)

EX-31.2 3 onvo-ex312_7.htm EX-31.2 onvo-ex312_7.htm

Exhibit 31.2

CERTIFICATION

I, Craig Kussman, Chief Financial Officer of Organovo Holdings, Inc. (the “Registrant”), certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Registrant;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting

Dated: August 10, 2020

/s/ Craig Kussman

Craig Kussman

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 onvo-ex321_8.htm EX-32.1 onvo-ex321_8.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Organovo Holdings, Inc. (the “Company”) for the period ended June 30, 2020, as filed with the Securities and Exchange Commission (the “Report”), I, Taylor Crouch, Chief Executive Officer and President and I, Craig Kussman, Chief Financial Officer of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 10, 2020

/s/ Taylor Crouch

Taylor Crouch

Chief Executive Officer and President

(Principal Executive Officer)

/s/ Craig Kussman

Craig Kussman

Chief Financial Officer

(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to Organovo Holdings, Inc. and will be retained by Organovo Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission, and is not to be incorporated by reference into any filing of Organovo Holdings, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 onvo-20200630.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares onvo:sqft onvo:Participant xbrli:pure onvo:Tranche onvo:Employee 0001497253 2020-04-01 2020-06-30 0001497253 2020-08-01 0001497253 2020-06-30 0001497253 2020-03-31 0001497253 onvo:ProductsAndServicesMember 2020-04-01 2020-06-30 0001497253 onvo:ProductsAndServicesMember 2019-04-01 2019-06-30 0001497253 us-gaap:LicenseAndServiceMember 2020-04-01 2020-06-30 0001497253 us-gaap:LicenseAndServiceMember 2019-04-01 2019-06-30 0001497253 us-gaap:GrantMember 2020-04-01 2020-06-30 0001497253 us-gaap:GrantMember 2019-04-01 2019-06-30 0001497253 2019-04-01 2019-06-30 0001497253 us-gaap:CommonStockMember 2019-03-31 0001497253 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001497253 us-gaap:RetainedEarningsMember 2019-03-31 0001497253 2019-03-31 0001497253 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001497253 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001497253 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001497253 us-gaap:CommonStockMember 2019-06-30 0001497253 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001497253 us-gaap:RetainedEarningsMember 2019-06-30 0001497253 2019-06-30 0001497253 us-gaap:CommonStockMember 2020-03-31 0001497253 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001497253 us-gaap:RetainedEarningsMember 2020-03-31 0001497253 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001497253 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001497253 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001497253 us-gaap:CommonStockMember 2020-06-30 0001497253 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001497253 us-gaap:RetainedEarningsMember 2020-06-30 0001497253 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001497253 onvo:PerformanceBasedRestrictedStockUnitsMember 2020-04-01 2020-06-30 0001497253 srt:MaximumMember 2020-04-01 2020-06-30 0001497253 srt:MinimumMember 2020-04-01 2020-06-30 0001497253 onvo:AtTheMarketFacilityMember 2020-06-30 0001497253 onvo:DirectorsAndOfficersMember 2020-04-01 2020-06-30 0001497253 onvo:DirectorsAndOfficersMember srt:MaximumMember 2020-04-01 2020-06-30 0001497253 onvo:DirectorsAndOfficersMember srt:MinimumMember 2020-04-01 2020-06-30 0001497253 us-gaap:ProductMember 2020-04-01 2020-06-30 0001497253 onvo:NationalInstituteOfHealthResearchGrantTwoMember 2017-07-01 2017-07-31 0001497253 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001497253 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001497253 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001497253 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001497253 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001497253 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0001497253 onvo:PerformanceBasedRestrictedStockUnitsMember 2020-06-30 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember 2020-04-01 2020-06-30 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember 2019-04-01 2019-06-30 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember 2020-06-30 0001497253 srt:MinimumMember 2019-06-25 2019-06-25 0001497253 onvo:TwoThousandEighteenSalesAgreementMember 2020-04-01 2020-06-30 0001497253 us-gaap:IPOMember 2020-09-30 0001497253 onvo:AtTheMarketFacilityMember onvo:TwoThousandEighteenSalesAgreementMember srt:MaximumMember 2018-03-16 0001497253 onvo:TwoThousandEighteenSalesAgreementMember onvo:AtTheMarketFacilityMember 2020-04-01 2020-06-30 0001497253 onvo:TwoThousandEighteenSalesAgreementMember onvo:AtTheMarketFacilityMember 2019-04-01 2019-06-30 0001497253 onvo:TwoThousandEighteenSalesAgreementMember 2020-06-30 0001497253 onvo:TwoThousandEighteenSalesAgreementMember 2019-04-01 2019-12-31 0001497253 onvo:TwoThousandEighteenSalesAgreementMember srt:MaximumMember 2020-06-30 0001497253 onvo:TwoThousandEighteenSalesAgreementMember onvo:AtTheMarketFacilityMember 2020-06-30 0001497253 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember srt:ChiefExecutiveOfficerMember 2017-04-24 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFourMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFourMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFourMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember srt:MinimumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember srt:MaximumMember 2017-08-22 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember srt:MaximumMember 2017-08-23 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember 2018-12-11 2018-12-12 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember 2018-12-11 2018-12-12 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember 2020-06-30 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember onvo:ShareBasedCompensationAwardTrancheFiveMember 2020-04-01 2020-06-30 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember 2020-06-30 0001497253 srt:ManagementMember onvo:PerformanceBasedRestrictedStockUnitsRetentionAwardsMember 2019-07-02 0001497253 srt:ManagementMember onvo:PerformanceBasedRestrictedStockUnitsRetentionAwardsMember 2019-07-02 2019-07-02 0001497253 onvo:PerformanceBasedRestrictedStockUnitsMember 2020-03-31 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember us-gaap:EmployeeStockOptionMember 2020-06-30 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember 2020-06-30 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember us-gaap:EmployeeStockOptionMember 2020-06-30 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember onvo:PerformanceBasedRestrictedStockUnitsMember 2020-06-30 0001497253 onvo:InducementAwardAgreementMember us-gaap:EmployeeStockOptionMember 2020-06-30 0001497253 onvo:InducementAwardAgreementMember onvo:PerformanceBasedRestrictedStockUnitsMember 2020-06-30 0001497253 onvo:DecemberTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2020-04-01 2020-06-30 0001497253 onvo:DecemberTwoThousandSixteenNonExclusiveResearchAffiliationCollaborativeMember us-gaap:LicenseAndServiceMember 2019-04-01 2019-06-30 0001497253 2019-10-01 2019-10-31 0001497253 onvo:ViscientBiosciencesMember 2020-06-30 0001497253 onvo:ViscientBiosciencesMember 2019-06-30 0001497253 onvo:ViscientBiosciencesMember onvo:PaymentOnOrBeforeJuneSeventeenTwoThousandAndTwentyMember 2020-06-30 0001497253 onvo:ViscientBiosciencesMember onvo:PaymentOnOrBeforeJulyTwentyFourTwoThousandAndTwentyMember 2020-06-30 0001497253 onvo:ViscientBiosciencesMember onvo:PaymentOnOrBeforeAugustTwentyThreeTwoThousandAndTwentyMember 2020-06-30 0001497253 onvo:ViscientBiosciencesMember onvo:PaymentOnOrBeforeSeptemberTwentyTwoTwoThousandAndTwentyMember 2020-06-30 0001497253 onvo:ViscientBiosciencesMember onvo:PaymentOnOrBeforeOctoberTwentyTwoTwoThousandAndTwentyMember 2020-06-30 0001497253 onvo:ViscientBiosciencesMember us-gaap:SubsequentEventMember 2020-07-01 2020-08-10 0001497253 2019-04-01 2020-03-31 0001497253 onvo:EmployeeSeveranceAndBenefitsCostsMember 2019-04-01 2020-03-31 0001497253 onvo:EmployeeSeveranceAndBenefitsCostsMember 2020-01-01 2020-03-31 0001497253 onvo:EmployeeSeveranceAndBenefitsCostsMember 2019-10-01 2019-12-31 0001497253 onvo:EmployeeSeveranceAndBenefitsCostsMember 2019-07-01 2019-09-30 0001497253 onvo:EmployeeSeveranceAndBenefitsCostsMember srt:MaximumMember 2020-04-01 2020-06-30 0001497253 us-gaap:EmployeeSeveranceMember 2020-03-31 0001497253 us-gaap:EmployeeSeveranceMember 2020-04-01 2020-06-30 0001497253 us-gaap:EmployeeSeveranceMember 2020-06-30 0001497253 onvo:DirectorsAndOfficersMember us-gaap:SubsequentEventMember 2020-07-14 2020-07-14 0001497253 onvo:DirectorsAndOfficersMember us-gaap:SubsequentEventMember srt:MaximumMember 2020-07-14 2020-07-14 0001497253 onvo:DirectorsAndOfficersMember us-gaap:SubsequentEventMember srt:MinimumMember 2020-07-14 2020-07-14 10-Q false 2020-06-30 2021 Q1 ONVO ORGANOVO HOLDINGS, INC. 0001497253 --03-31 Non-accelerated Filer false true false 130618203 001-35996 Yes 27-1488943 440 Stevens Ave Suite 200 Solana Beach CA 92075 858 224-1000 Yes Common Stock, $0.001 par value NASDAQ DE true false

24787000

27356000

84000

111000

630000

851000

25501000

28318000

120000

123000

25621000

28441000

110000

720000

725000

1090000

835000

1810000

131000

306889000

305965000

-282234000

-279465000

24786000

26631000

25621000

28441000

0.001

200000000

130618203

130558098

130618203

130558098

606000

10000

52000

668000

51000

3823000

2786000

3315000

2786000

7189000

-2786000

-6521000

6000

1000

8000

197000

5000

19000

198000

2000

-2769000

-6323000

-0.02

-0.05

130588481

126854907

-2769000

-6323000

124015000

124000

296929000

-260755000

36298000

177000 0 -52000 0 -52000 6087000 6000 4990000 0 4996000

1220000

-6323000

130279000

130000

303087000

-267078000

36139000

130558000

131000

305965000

-279465000

26631000

60000 0 -1000 0 -1000

925000

-2769000

130618000

131000

306889000

-282234000

24786000

6000

1000

4000

205000

925000

1220000

-27000

35000

0 44000

16000

-224000

-360000

-610000

-75000

-365000

-1142000

7000

0 91000

-2570000

-5935000

2000

1000

2000

1000

0 4996000

1000

52000

-1000

4944000

-2569000

-990000

27356000

36556000

24787000

35566000

35487000

79000

5000 0 1000 0

2000

Note 1. Description of Business Nature of operations Organovo Holdings, Inc. (“Organovo Holdings,” “Organovo,” and “the Company”) is an early-stage biotechnology company that has focused on pioneering the development of bioprinted 3D human tissues that emulate key aspects of human biology and disease. Except where specifically noted or the context otherwise requires, references to “Organovo Holdings,” “the Company,” and “Organovo” in these notes to the unaudited condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc. and Opal Merger Sub, Inc. Historical Operations and Strategic Alternatives Process Prior to August 2019, the Company has focused its efforts on developing its in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. The Company also explored the development of other potential pipeline in vivo tissue constructs in-house and through collaborations with academic and government researchers. In the past, the Company also explored the development of in vitro tissues, including proof of concept models of diseased tissues, for use in drug discovery and development. In August 2019, after a rigorous assessment of its in vitro liver therapeutic tissue program, the Company concluded that the variability of biological performance and related duration of potential benefits no longer supported an attractive opportunity due to redevelopment challenges and lengthening timelines to compile sufficient data to support an IND filing. As a result, the Company suspended development of its lead program and all other related in-house pipeline development activities. The Company’s Board also engaged a financial advisory firm to explore the Company’s available strategic alternatives, including evaluating a range of ways to generate value from its technology platform and intellectual property, its commercial and development capabilities, its listing on the Nasdaq Capital Market, and the Company’s remaining financial assets. These strategic alternatives included possible mergers and business combinations, sales of part or all of our assets, and licensing and partnering arrangements. The Company implemented various restructuring steps to manage its resources and extend its cash runway, including reducing commercial activities related to its liver tissues, except for sales of primary human cells out of inventory, negotiating an exit from its long-term facility lease, selling various assets, and reducing its workforce. Additionally, in November 2019, the Company sold certain inventory and equipment and related proprietary information held by its wholly-owned subsidiary, Samsara Sciences, Inc. (“Samsara”), and as a result of such sale, Samsara ceased its operations. After conducting a diligent and extensive process of evaluating strategic alternatives and identifying and reviewing potential candidates for a strategic acquisition or other transaction, which included the receipt of more than 27 non-binding indications of interest from interested parties and careful evaluation and consideration of those proposals, and following extensive negotiation with Tarveda, on December 13, 2019, the Company entered into a merger agreement with Tarveda (the “Merger Agreement”). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company’s wholly-owned merger subsidiary would merge (the “Merger”) into Tarveda, with Tarveda surviving the Merger. The Merger Agreement included various conditions to the consummation of the Merger, including approval by the Company’s stockholders at a Special Meeting of Stockholders to be held on April 7, 2020 (the “Special Meeting”). At the Special Meeting, the Merger was not approved by the Company’s stockholders. As a result, the Company terminated the Merger Agreement with Tarveda. Pursuant to the terms of the Merger Agreement, the Company was obligated to reimburse certain of Tarveda’s merger-related expenses not to exceed $300,000, which was offset by Tarveda’s portion of shared expenses incurred by Organovo in fiscal 2020. The Cooperation Agreement and Advisory Nominees Proposal Following the Special Meeting and the termination of the Merger Agreement, the Company’s Board continued to solicit stockholder feedback regarding the Company’s strategic alternatives and how to maximize stockholder value. In response to feedback from its largest stockholder regarding its desire for the Board to consider opportunities in the 3D bioprinting field and suggestion that the Board should speak with Keith Murphy, the Company’s founder, stockholder and former Chief Executive Officer and Chairman, for potential business ideas, the Company’s Board initiated discussions with Mr. Murphy. Based on these discussions, the Company entered into a Cooperation Agreement with Mr. Murphy on July 14, 2020 (the “Cooperation Agreement”). Under the terms of the Cooperation Agreement, the Board appointed Mr. Murphy and Adam K. Stern to the Board as Class III directors, and two of the Company’s existing directors, Richard Maroun and David Shapiro, resigned from the Board and all Board committees. The Board also agreed to nominate, recommend, support and solicit proxies for the re-election of Messrs. Murphy and Stern at the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). The Board also agreed to nominate, recommend, support and solicit proxies for an advisory stockholder vote (the “Advisory Nominees Proposal”) at the 2020 Annual Meeting to appoint three individuals, Douglas Jay Cohen, David Gobel and Alison Tjosvold Milhous (collectively, the “Advisory Nominees”), to the Board. Mr. Murphy identified each of the Advisory Nominees. If the final vote tabulation for the Advisory Nominees Proposal receives more votes cast “FOR” than “AGAINST” its approval, the Board has approved the appointment of the Advisory Nominees, to be automatically effective immediately following the final adjournment of the 2020 Annual Meeting. In addition, immediately following the appointment of the Advisory Nominees, each of our existing directors (other than Messrs. Murphy and Stern) will resign from the Board, which will result in Messrs. Murphy and Stern and the Advisory Nominees constituting the full membership of the Board (collectively, the “New Director Slate”). Proposed Drug Discovery Business The New Director Slate has advised the Company that if the Advisory Nominees Proposal is approved at the 2020 Annual Meeting, the New Director Slate intends to recommence operations and focus the Company’s efforts on developing highly customized human tissues as living, dynamic models of human biology and disease for use in drug discovery and development. The New Director Slate has advised the Company that it believes the Company’s proprietary technology can be used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, and function. The New Director Slate also believes the Company can utilize its proprietary technology to develop highly customized and dynamic models of human disease, including cell type-specific compartments, prevalent intercellular tight junctions, and microvascular structures. They believe these features can facilitate the Company’s development of complex, multicellular disease models for use in the development of targeted therapeutics for various diseases including, among others, intestine, kidney, skin and breast diseases. Market opportunities may include externally-partnered or internally-directed drug discovery and the clinical development of new molecular entities or repurposed drugs in-licensed from other pharmaceutical companies. The goal of the New Director Slate is for the Company to establish a pipeline of drug candidates in high-value disease areas, aiming to commence human clinical testing for at least one drug candidate within a three to four year timeframe. If the Advisory Nominees Proposal is approved, the New Director Slate intends to restart the Company’s research operations by hiring a team of R&D professionals with the experience required to develop bioprinted and other 3D tissues for use in drug discovery, to leverage 3D models of disease to discover new drug candidates, and to develop new drug candidates for the initiation of clinical studies. The New Director Slate has advised the Company that they expect our research and development staff to grow to seven to ten employees. They also expect to maintain or grow a general and administrative staff of three to five employees to support the Company’s operations and reporting requirements as a public company. If the Advisory Nominees Proposal is approved, the New Director Slate has advised us that the Company expects to lease sufficient office and laboratory space to support its requirements. They expect that the Company will need space in the short term in the 3,000-7,000 sq. ft. range, with mixed office and laboratory space. They expect to lease a new facility in San Diego at prevailing market terms. COVID-19 <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019 a respiratory illness caused by a novel strain of coronavirus, SARS-CoV-2, causing the Coronavirus Disease 2019, also known as COVID-19 or coronavirus emerged. While initially the outbreak was largely concentrated in China it has spread globally. Global health concerns relating to the COVID-19 pandemic have been weighing on the macroeconomic environment, and the pandemic has significantly increased economic volatility and uncertainty. The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which the coronavirus impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. In particular, the continued coronavirus pandemic could adversely impact the Company’s operations, including among others, the timing and ability to pursue strategic alternatives, given the impact it may have on the manufacturing and supply chain, sales and marketing and clinical trial operations of potential strategic partners, and the ability, if we elect to do so, to advance our research and development activities and pursue development of any of our pipeline products, each of which could have an adverse impact on the Company’s business and financial results.

Note 2. Summary of Significant Accounting Policies Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2020 is derived from the Company’s audited consolidated balance sheet at that date. The unaudited condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2021 (see “Note 1. Description of Business”). Liquidity As of June 30, 2020, the Company had cash and cash equivalents of approximately $24.8 million and an accumulated deficit of approximately $282.2 million. The Company also had negative cash flows from operations of approximately $2.6 million during the three months ended June 30, 2020. Through June 30, 2020, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the three months ended June 30, 2020, the Company issued no shares of its common stock through its ATM facility. Throughout the strategic alternatives assessment process, the Company has taken steps to manage its resources and extend its cash runway including selling various assets and reducing its workforce to the minimum level necessary to explore and support these strategic alternatives as well as to support the remainder of the Company’s on-going business activities and assets, including its intellectual property platform and collaborations with research institutions and universities. The Company believes its cash and cash equivalents on hand will be sufficient to meet its financial obligations for at least the next 12 months of operations. If the Advisory Proposal is approved, this will trigger a “Change of Control” under Organovo’s severance plan, as well as its Directors and Officers (“D&O”) liability insurance policies, requiring the following cash outlays: i) approximately $3.0 million for severance obligations and ii) approximately $2.0 million (or $1.7 million net of returned premium) for a six year D&O tail insurance policy. In addition, to the extent the New Director Slate recommences the Company’s operations and focus its efforts on drug discovery and development, the Company will need to raise additional capital to implement this new business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. If required, the Company may seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Company’s business, operating results, financial condition and ability to continue as a going concern. Use of estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the unaudited condensed consolidated financial statements include those assumed in the valuation of stock-based compensation expense, the valuation of impairment of long-lived assets, our assessment of contingent liabilities that would require the establishment of a reserve, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions. Though the impact of the COVID-19 pandemic to its business and operating results presents additional uncertainty, the Company continues to use the best information available to inform its critical accounting estimates. Impairment of long-lived assets In accordance with ASC 360-10, the Company records an impairment loss on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets (i.e. not able to be recovered). The Company’s pursuit of strategic alternatives requires the reevaluation of the recoverability of the gross carrying value of its long-lived assets. The Company performed an asset impairment analysis on its long-lived asset group, consisting primarily of licensed intangible assets, computer equipment, and software following the completion of various asset sales prior to June 30, 2020, which concluded that the carrying amount is not recoverable. However, the Company’s analysis indicated that carrying amount of the asset group does not exceed its fair value. As such, no impairment loss is required to be recognized. Nonetheless, it is reasonably possible that the impairment analysis may change in the near term resulting in the need to write down those assets to fair value. The Company will continue to monitor assets for impairment. Revenue recognition The Company has generated revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. The Company recognized revenue under Topic 606, Revenue from Contracts with Customers (“Topic 606”) when (or as) the promised services were transferred to customers in an amount that reflects the consideration to which it expected to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concluded were within the scope of ASC 606, the Company performed the following five steps: (i) identified the contract(s) with a customer; (ii) identified the performance obligation(s) in the contract; (iii) determined the transaction price; (iv) allocated the transaction price to the performance obligation(s) in the contract; and (v) recognized revenue when (or as) the performance obligation(s) were satisfied. At contract inception, the Company assessed the goods or services promised within each contract, assessed whether each promised good or service was distinct and identified those that were performance obligations. The Company recognized as revenue the amount of the transaction price that was allocated to the respective performance obligation when (or as) the performance obligation was satisfied. Billings to customers or payments received from customers were included in deferred revenue on the consolidated balance sheet until all revenue recognition criteria were met. As of June 30, 2020 and March 31, 2020, the Company had no deferred revenue. Service revenues The Company’s service-based business, Organovo, Inc., utilized its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contained multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which were satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer did not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service could be customized for each customer, it was not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilized point-in-time recognition under Topic 606. For service contracts, the Company allocated the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price was not observable through past transactions, the Company estimated the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts was a fixed consideration. In connection to the Company’s decision to pursue its strategic alternatives, the Company halted commercial activities related to its liver tissues. The Company is expected to continue to maintain its external research collaborations and its intellectual property portfolio. Product sales, net The Company’s former product-based business, Samsara Sciences, Inc., produced high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognized product revenue when the performance obligation was satisfied, which was at the point in time the customer obtained control of the Company’s product, typically upon delivery. Product revenues were recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration did not differ materially from its historical practices. Variable consideration was estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflected the Company’s best estimates of the amount of consideration to which it was entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may have differed from the Company’s estimates. If actual results varied materially from the Company’s estimates, the Company would have adjusted these estimates, which would have affected revenue from product sales and earnings in the period such estimates were adjusted. The Company provided no right of return to its customers except in cases where a customer obtained authorization from the Company for the return. To date, there have been no product returns. In March 2020, the Company dissolved Samsara. Collaborative research, development, and licenses The Company has entered into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzed whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”). The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements were distinct performance obligations, whether there were determinable stand-alone prices, and whether any licenses were functional or symbolic. The Company evaluated each performance obligation to determine if it could be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities were considered fixed, while milestone payments were identified as variable consideration which must be evaluated to determine if it was constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provided the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company determined that the intellectual property license was not distinct from the continued support promised under the agreement and was therefore a single combined performance obligation. The Company recognized revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation would not be fully satisfied until the end of the contract. As of September 30, 2019, the Company completed its obligations under the existing agreements with respect to receipts of revenue and does not anticipate recording any further revenue. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements. Grant revenue In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company concluded this government grant was not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company concluded this government grant did meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition did not apply, as the Company is a business entity and the grant was with a governmental agency. Revenues from this grant were based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue was recognized as the Company incurred expenses that were related to the grant. The Company believes this policy was consistent with the overarching premise in Topic 606, to ensure that it recognized revenues to reflect the transfer of promised goods or services to customers in an amount that reflected the consideration to which it expected to be entitled in exchange for those goods or services, even though there was no “exchange” as defined in the ASC. The Company believed the recognition of revenue as costs were incurred and amounts became earned/realizable was analogous to the concept of transfer of control of a service over time under Topic 606. In connection to the Company’s decision to pursue its strategic alternatives, specific to the NIH NASH grant, all internal research activities have been halted and transferred to the University of California, San Diego, leaving a remaining available balance of approximately $0.5 million that will not be utilized by the Company. Cost of revenues The Company reported no cost of revenues for the three months ended June 30, 2020 and approximately $0.1 million in cost of revenues for the three months ended June 30, 2019. Cost of revenues consisted of costs related to manufacturing and delivering product and service revenue.   Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three months ended June 30, 2020 or 2019, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 12.0 million at June 30, 2020 and 14.6 million at June 30, 2019. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. Adoption of New Accounting Pronouncements In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. The amendments in this update provide more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from this amendment are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance became effective for the Company on April 1, 2020 and did not have a significant impact on the Company’s unaudited condensed consolidated financial statements.

Note 3. Stockholders’ Equity Stock-based compensation expense and valuation information Stock-based awards include stock options and restricted stock units under the 2012 Equity Incentive Plan, as amended (“2012 Plan”) and Inducement Awards, performance-based restricted stock units under an Incentive Award Performance-Based Restricted Stock Unit Agreement, and rights to purchase stock under the 2016 Employee Stock Purchase Plan (“ESPP”). The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense. Stock-based compensation expense for all stock-based awards consists of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,220</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> The total unrecognized compensation cost related to unvested stock option grants as of June 30, 2020 was approximately $2,651,000 and the weighted average period over which these grants are expected to vest is 1.58 years, assuming no change of control. The total unrecognized compensation cost related to unvested restricted stock units (not including performance-based restricted stock units) as of June 30, 2020 was approximately $702,000, which will be recognized over a weighted average period of 1.48 years, assuming no change of control. The total unrecognized compensation cost related to unvested performance-based restricted stock units as of June 30, 2020 was approximately $1,038,000, which will be recognized over a weighted average period of 1.19 years, assuming no change of control. As of June 30, 2020, there are no participants enrolled into the employee stock purchase plan for the current purchase period, beginning March 1, 2020. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. The measurement and classification of share-based payments to non-employees is consistent with the measurement and classification of share-based payments to employees. There were no options granted in the three months ended June 30, 2020 and 2019.   The fair value of each restricted stock unit and performance-based restricted stock unit is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant. The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the Company’s ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020*</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.69</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.52</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   *There are no participants in the ESPP for the current purchase period (beginning March 1, 2020).   The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The expected life is the 6-month purchase period. Preferred stock The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock. Common stock On June 25, 2019, the Company received a notice letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum closing bid price of $1 per share, as set forth in Nasdaq Listing Rule 5450(a)(1). On December 26, 2019, the Company obtained an additional compliance period of 180 calendar days by electing to transfer to The Nasdaq Capital Market. On March 26, 2020, the Company obtained shareholder approval to effect a reverse stock split in a range from 20:1 to 40:1, which remains subject to the approval of the Company’s board of directors, in order to meet the minimum closing bid price per share requirement under the Nasdaq Listing Rules. On April 17, 2020 the Company received an additional notice letter from Nasdaq indicating that based on extraordinary market conditions, Nasdaq has determined to toll the compliance periods for bid price and market value of publicly held shares requirements (collectively, the “Price-based Requirements”) through June 30, 2020. Accordingly, since the Company had 66 calendar days remaining in its compliance period as of April 16, 2020, the Company will, upon reinstatement of the Price-based Requirements, still have 66 calendar days from July 1, 2020, or until September 4, 2020, to regain compliance. The Company can regain compliance, either during the suspension or during the compliance period resuming after the suspension, by evidencing compliance with the Price-based Requirements for a minimum of 10 consecutive trading days. The Company intends to comply with the Price-based Requirements by effecting the Reverse Stock Split. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or maintain compliance with the other listing requirements necessary to maintain the listing of its common stock on The Nasdaq Capital Market. The Company’s failure to regain compliance during this second compliance period could result in delisting. The Company has an effective shelf registration statement on Form S-3 (File No. 333-222929) and the related prospectus previously declared effective by the Securities and Exchange Commission (the “SEC”) on February 22, 2018 (the “2018 Shelf”), that expires on February 22, 2021, which registered $100,000,000 of common stock, preferred stock, warrants and units, or any combination of the foregoing. On March 16, 2018, the Company entered into a Sales Agreement (“2018 Sales Agreement”) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an “Agent” and together, the “Agents”) and filed a prospectus supplement to the 2018 Shelf, pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in at-the-market sales transactions having an aggregate offering price of up to $50,000,000 (the “Shares”). Any shares offered and sold will be issued pursuant to the Company’s 2018 Shelf. During the three months ended June 30, 2020 and 2019, the Company issued 0 and 6,087,382 shares of common stock, respectively, for net proceeds of $0 and $5.0 million in at-the-market offerings under the 2018 Sales Agreement.   As of June 30, 2020, the Company has sold an aggregate of 17,719,185 shares of common stock in at-the-market offerings under the 2018 Sales Agreement, with gross proceeds of approximately $18.7 million. Based on these sales, the Company cannot raise more than an aggregate of $81.3 million in future offerings under the 2018 Shelf, including the $31.3 million remaining available for future issuance through its at-the-market program under the 2018 Sales Agreement. Restricted stock units The following table summarizes the Company’s restricted stock units (not including performance-based restricted stock units) activity from March 31, 2020 through June 30, 2020:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480,256</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,626</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled / forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at June 30, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418,630</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   Performance-based restricted stock units On April 24, 2017, the Company issued a Performance-Based Restricted Stock Unit Award for 208,822 shares of common stock (the “PBRSU”) to its newly hired Chief Executive Officer. The PBRSU was issued outside of the 2012 Plan, in the Inducement Award Agreement, as an “inducement award” within the meaning of Nasdaq Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 23, 2017, the Board of Directors formally approved the vesting criteria for the PBRSU. The vesting of the PBRSU is divided into five separate tranches each with independent vesting criteria. The first four tranches had performance criteria related to annual revenue goals with measurement at the end of fiscal year 2018 (20 percent), fiscal year 2019 (20 percent), fiscal year 2020 (20 percent), and fiscal year 2021 (20 percent). The fifth tranche had a performance metric related to a path to profitability goal measured as Negative Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) achievable at any point between the grant date and the end of fiscal year 2020 (20 percent). The number of units that ultimately vest for each tranche will range from 0 percent to 120 percent of the target amount, not to exceed 208,822 in aggregate. On December 12, 2018, the Board of Directors formally approved an amendment to the vesting criteria for the PBRSUs. As of December 12, 2018, 100 percent of the Negative Adjusted EBITDA tranche, or 41,764 shares had vested and 8,352 units had been forfeited. Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones. As of June 30, 2020, no tranches are expected to vest unless there is a change in control. Based on the amended PBRSU vesting terms, a Type III modification, the modified grant date fair value of the PBRSUs is $165,000 of which one-third is being recognized over the expected service period of each tranche ending on April 23, 2023. The Company began recording stock-based compensation expense for the initial performance tranches after the August 23, 2017 grant date when the initial financial performance goals were established and approved and has modified its recording of compensation expense in accordance with the amended performance tranches beginning on December 12, 2018. On July 2, 2019, the Company issued Performance-Based Restricted Stock Unit Awards (the “PBRSU Retention Awards”) for an aggregate of 6,027,899 shares of common stock to its management team. The PBRSUs were issued pursuant to the 2012 Plan. The PBRSU Retention Awards will vest in full upon the earlier of the Company’s engagement in a pre-IND meeting with the FDA, twenty-four months from the grant date, or a change in control. As of June 30, 2020, all PBRSUs are expected to vest twenty-four months from the grant date. </div> The following table summarizes the Company’s performance-based restricted stock unit activity from March 31, 2020 through June 30, 2020:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,952,927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.51</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled / forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at June 30, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,952,927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.51</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Stock options The following table summarizes the Company’s stock option activity from March 31, 2020 to June 30, 2020:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,638,076</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,440</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled / forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June 30, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,638,076</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,237</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and Exercisable at June 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,593,119</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.48</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,396</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The weighted average remaining contractual term of options exercisable and outstanding at June 30, 2020 was approximately 7.13 years. Employee Stock Purchase Plan In June 2016, our Board of Directors adopted, and in August 2016 stockholders subsequently approved, the 2016 Employee Stock Purchase Plan (“ESPP”). The Company reserved 1,500,000 shares of common stock for issuance thereunder. The ESPP permits employees after five months of service to purchase common stock through payroll deductions, limited to 15 percent of each employee’s compensation up to $25,000 per employee per year or 10,000 shares per employee per six-month purchase period. Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering period commenced in September 2016. At June 30, 2020, there were 1,188,718 shares available for purchase under the ESPP.  Common stock reserved for future issuance Common stock reserved for future issuance consisted of the following at June 30, 2020:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,549,864</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,158,654</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2016 Employee Stock Purchase Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,188,718</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the 2012 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418,630</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based restricted stock units outstanding under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,794,221</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the Incentive <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Award Agreement</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,088,212</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based restricted stock units outstanding under the Incentive Award <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Agreement</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,706</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total at June 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,357,005</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Note 4. Collaborative Research, Development, and License Agreements In December 2016, the Company signed a collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen® Bioprinter at the university for the purpose of developing a kidney organoid for potential therapeutic applications. The Company received up-front payments in January and March 2017, which has been recorded as deferred revenue. Revenue of $0 and $10,000 was recorded under this agreement for the three months ended June 30, 2020 and 2019, respectively. The Company completed its obligations under this agreement and does not anticipate recording any further revenue.

Note 7. Concentrations Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. Because it was in the early commercial stage, the Company’s revenues to date have been derived from a relatively small number of customers and collaborators. However, the Company has not historically experienced any accounts receivable write-downs and management does not believe significant credit risk exists as of June 30, 2020.

Note 8. Related Parties From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business and on terms and conditions it believes are as fair as those it offers and receives from independent third parties. These agreements are ratified by the Company’s Board of Directors or a committee thereof pursuant to its related party transaction policy. During fiscal 2020, the Company provided services to Viscient Biosciences (“Viscient”), an entity for which Keith Murphy, the Company’s director, as of July 15, 2020, and former Chief Executive Officer and President, serves as the Chief Executive Officer and President. In addition to the services provided by Organovo, Viscient has purchased primary human cell-based products from its former subsidiary, Samsara. There was approximately $84,000 of accounts receivable outstanding as of June 30, 2020 and $60,000 of accounts receivable outstanding as of June 30, 2019. The Company and Viscient have agreed on a payment plan under which Viscient has made a payment of approximately $28,000 on or before June 17, 2020 and will make a payment of approximately $28,000 on or before July 24, 2020; $19,000 on or before August 23, 2020; $19,000 on or before September 22, 2020, and $19,000 on or before October 22, 2020. Through the date of filing, Viscient has made payments in aggregate of $84,000. Further, in July 2020, we entered into a Cooperation Agreement with Mr. Murphy. See “Note 1. Description of Business” and “Note 10. Subsequent Events” for more information.

Note 10. Subsequent Events On July 14, 2020, we entered into a Cooperation Agreement with Mr. Murphy. Pursuant to the Cooperation Agreement, the Board appointed Messrs. Murphy and Stern to the six member Board as Class III directors, with terms expiring at the Company’s 2020 Annual Meeting and two of the Company’s existing directors, Richard Maroun and David Shapiro, resigned from the Board and from each Board committee on which they serve, effective immediately. The Board also agreed to nominate, recommend, support and solicit proxies for the re-election of Messrs. Murphy and Stern at the 2020 Annual Meeting. The Board also agreed to nominate, recommend, support and solicit proxies for an advisory stockholder vote (the “Advisory Nominees Proposal”) at the 2020 Annual Meeting to appoint three individuals, Douglas Jay Cohen, David Gobel and Alison Tjosvold Milhous (collectively, the “Advisory Nominees”), to the Board. If the final vote tabulation for the Advisory Nominees Proposal receives more votes cast “FOR” than “AGAINST” its approval, our Board has approved the appointment of the Advisory Nominees, to be automatically effective immediately following the final adjournment of the 2020 Annual Meeting. In addition, immediately following the appointment of the Advisory Nominees, each of our existing directors (other than Messrs. Murphy and Stern) will resign from the Board, which will result in Messrs. Murphy and Stern and the Advisory Nominees constituting the full membership of the Board (collectively, the “New Director Slate”) and will trigger a “Change of Control” under Organovo’s severance plan, as well as its Directors and Officers (“D&O”) liability insurance policies, requiring the following cash outlays: i) approximately $3.0 million for severance obligations and ii) approximately $2.0 million (or $1.7 million net of returned premium) for a six year D&O tail insurance policy. Please see “Note 1. Business Description” for a discussion of the new business plan the New Director Slate intends for the Company to pursue if they are appointed to the Board following the final adjournment of the 2020 Annual Meeting.

Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2020 is derived from the Company’s audited consolidated balance sheet at that date. The unaudited condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2021 (see “Note 1. Description of Business”). Liquidity As of June 30, 2020, the Company had cash and cash equivalents of approximately $24.8 million and an accumulated deficit of approximately $282.2 million. The Company also had negative cash flows from operations of approximately $2.6 million during the three months ended June 30, 2020. Through June 30, 2020, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the three months ended June 30, 2020, the Company issued no shares of its common stock through its ATM facility. Throughout the strategic alternatives assessment process, the Company has taken steps to manage its resources and extend its cash runway including selling various assets and reducing its workforce to the minimum level necessary to explore and support these strategic alternatives as well as to support the remainder of the Company’s on-going business activities and assets, including its intellectual property platform and collaborations with research institutions and universities. The Company believes its cash and cash equivalents on hand will be sufficient to meet its financial obligations for at least the next 12 months of operations. If the Advisory Proposal is approved, this will trigger a “Change of Control” under Organovo’s severance plan, as well as its Directors and Officers (“D&O”) liability insurance policies, requiring the following cash outlays: i) approximately $3.0 million for severance obligations and ii) approximately $2.0 million (or $1.7 million net of returned premium) for a six year D&O tail insurance policy. In addition, to the extent the New Director Slate recommences the Company’s operations and focus its efforts on drug discovery and development, the Company will need to raise additional capital to implement this new business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. If required, the Company may seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Company’s business, operating results, financial condition and ability to continue as a going concern.

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the unaudited condensed consolidated financial statements include those assumed in the valuation of stock-based compensation expense, the valuation of impairment of long-lived assets, our assessment of contingent liabilities that would require the establishment of a reserve, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions. Though the impact of the COVID-19 pandemic to its business and operating results presents additional uncertainty, the Company continues to use the best information available to inform its critical accounting estimates.

Revenue recognition The Company has generated revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. The Company recognized revenue under Topic 606, Revenue from Contracts with Customers (“Topic 606”) when (or as) the promised services were transferred to customers in an amount that reflects the consideration to which it expected to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concluded were within the scope of ASC 606, the Company performed the following five steps: (i) identified the contract(s) with a customer; (ii) identified the performance obligation(s) in the contract; (iii) determined the transaction price; (iv) allocated the transaction price to the performance obligation(s) in the contract; and (v) recognized revenue when (or as) the performance obligation(s) were satisfied. At contract inception, the Company assessed the goods or services promised within each contract, assessed whether each promised good or service was distinct and identified those that were performance obligations. The Company recognized as revenue the amount of the transaction price that was allocated to the respective performance obligation when (or as) the performance obligation was satisfied. Billings to customers or payments received from customers were included in deferred revenue on the consolidated balance sheet until all revenue recognition criteria were met. As of June 30, 2020 and March 31, 2020, the Company had no deferred revenue. Service revenues The Company’s service-based business, Organovo, Inc., utilized its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contained multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which were satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer did not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service could be customized for each customer, it was not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilized point-in-time recognition under Topic 606. For service contracts, the Company allocated the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price was not observable through past transactions, the Company estimated the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts was a fixed consideration. In connection to the Company’s decision to pursue its strategic alternatives, the Company halted commercial activities related to its liver tissues. The Company is expected to continue to maintain its external research collaborations and its intellectual property portfolio. Product sales, net The Company’s former product-based business, Samsara Sciences, Inc., produced high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognized product revenue when the performance obligation was satisfied, which was at the point in time the customer obtained control of the Company’s product, typically upon delivery. Product revenues were recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration did not differ materially from its historical practices. Variable consideration was estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflected the Company’s best estimates of the amount of consideration to which it was entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may have differed from the Company’s estimates. If actual results varied materially from the Company’s estimates, the Company would have adjusted these estimates, which would have affected revenue from product sales and earnings in the period such estimates were adjusted. The Company provided no right of return to its customers except in cases where a customer obtained authorization from the Company for the return. To date, there have been no product returns. In March 2020, the Company dissolved Samsara. Collaborative research, development, and licenses The Company has entered into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzed whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”). The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements were distinct performance obligations, whether there were determinable stand-alone prices, and whether any licenses were functional or symbolic. The Company evaluated each performance obligation to determine if it could be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities were considered fixed, while milestone payments were identified as variable consideration which must be evaluated to determine if it was constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provided the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company determined that the intellectual property license was not distinct from the continued support promised under the agreement and was therefore a single combined performance obligation. The Company recognized revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation would not be fully satisfied until the end of the contract. As of September 30, 2019, the Company completed its obligations under the existing agreements with respect to receipts of revenue and does not anticipate recording any further revenue. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements. Grant revenue In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company concluded this government grant was not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company concluded this government grant did meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition did not apply, as the Company is a business entity and the grant was with a governmental agency. Revenues from this grant were based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue was recognized as the Company incurred expenses that were related to the grant. The Company believes this policy was consistent with the overarching premise in Topic 606, to ensure that it recognized revenues to reflect the transfer of promised goods or services to customers in an amount that reflected the consideration to which it expected to be entitled in exchange for those goods or services, even though there was no “exchange” as defined in the ASC. The Company believed the recognition of revenue as costs were incurred and amounts became earned/realizable was analogous to the concept of transfer of control of a service over time under Topic 606. In connection to the Company’s decision to pursue its strategic alternatives, specific to the NIH NASH grant, all internal research activities have been halted and transferred to the University of California, San Diego, leaving a remaining available balance of approximately $0.5 million that will not be utilized by the Company.

Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three months ended June 30, 2020 or 2019, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 12.0 million at June 30, 2020 and 14.6 million at June 30, 2019.

Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. Adoption of New Accounting Pronouncements In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. The amendments in this update provide more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from this amendment are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance became effective for the Company on April 1, 2020 and did not have a significant impact on the Company’s unaudited condensed consolidated financial statements.

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,220</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020*</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.69</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.52</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> *There are no participants in the ESPP for the current purchase period (beginning March 1, 2020).

The following table summarizes the Company’s performance-based restricted stock unit activity from March 31, 2020 through June 30, 2020:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,952,927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.51</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled / forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at June 30, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,952,927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.51</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes the Company’s stock option activity from March 31, 2020 to June 30, 2020:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,638,076</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,440</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled / forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June 30, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,638,076</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,237</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and Exercisable at June 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,593,119</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.48</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,396</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Common stock reserved for future issuance consisted of the following at June 30, 2020:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,549,864</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,158,654</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2016 Employee Stock Purchase Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,188,718</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the 2012 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418,630</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based restricted stock units outstanding under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,794,221</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the Incentive <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Award Agreement</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,088,212</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based restricted stock units outstanding under the Incentive Award <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Agreement</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,706</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total at June 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,357,005</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes the activity and balances of the restructuring reserve (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Severance for Involuntary <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employee Terminations</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve established</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase to reserve</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of reserve:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

300000

3000 7000

3000000

2000000 1700000

0 1657000 P3Y 500000

100000

12000000

14600000

164000

925000

1056000

2651000

P1Y6M29D

702000

1038000

P1Y5M23D

P1Y2M8D

0.00

0.0000

0.4369

0.0000

0.0252

P0D

P6M

0.29

25000000

1000000

20:1 to 40:1

20000000

40000000

2021-02-22 100000000 50000000

6087382

5000000

17719185

18700000

81300000 31300000

480256

61626

418630

1.95

2.57

1.85

208822

0.20

2018

0.20

2019

0.20

2020

0.20

2021

0.20

2020

0.00

1.20

0.00

1.20

0.00

1.20

0.00

1.20

0.00

1.20

208822

1.00

41764

8352

158706

Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones.

0 165000

6027899

P24M

3952927

0.51

7638076

4593119

2.08

2.48

37440

79237

3396

P7Y1M17D

1500000

0.15

25000

10000

0.85

P6M 2016-09

Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period.

1188718

5549864

14158654

1188718

418630

3794221

2088212

158706

27357005

10000

4000

262000

12000

107000

15000

84000

60000

28000

19000

84000

0.90

2700000

100000

900000

1700000

100000

21000

3000000

2000000 1700000 There are no participants in the ESPP for the current purchase period (beginning March 1, 2020). EX-101.SCH 6 onvo-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Unaudited Condensed Consolidated Statements of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Description of Business link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Collaborative Research, Development, and License Agreements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Concentrations link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Related Parties link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Restructuring link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Restructuring (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Description of Business - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Stockholders' Equity - Preferred Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Stockholders' Equity - Common Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stockholders' Equity - Summary of Company's Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Collaborative Research, Development, and License Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Leases - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Related Parties - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Restructuring - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Restructuring - Summary of Activity and Balances of Restructuring Reserve (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 onvo-20200630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 onvo-20200630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 onvo-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Shell Company Entity Shell Company Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Current Reporting Status Entity Current Reporting Status Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current Assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Other assets, net Other Assets Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current Liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Total current liabilities Liabilities Current Commitments and Contingencies Commitments And Contingencies Stockholders’ Equity Stockholders Equity [Abstract] Common stock, $0.001 par value; 200,000,000 shares authorized, 130,618,203 and 130,558,098 shares issued and outstanding at June 30, 2020 and March 31, 2020, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Products and services. Products and Services [Member] Products And Services [Member] Collaborations and Licenses [Member] License And Service [Member] Grants [Member] Grant [Member] Statement [Line Items] Statement [Line Items] Revenues Disaggregation Of Revenue [Abstract] Total Revenues Revenue From Contract With Customer Excluding Assessed Tax Cost of revenues Cost Of Goods And Services Sold Research and development expenses Research And Development Expense Selling, general and administrative expenses Selling General And Administrative Expense Total costs and expenses Costs And Expenses Loss from Operations Operating Income Loss Other Income (Expense) Nonoperating Income Expense [Abstract] Gain on fixed asset disposals Gain Loss On Disposition Of Assets Interest income Investment Income Interest Other Income Other Nonoperating Income Total Other Income Nonoperating Income Expense Income Tax Expense Income Tax Expense Benefit Net Loss Net Income Loss Net loss per common share—basic and diluted Earnings Per Share Basic And Diluted Weighted average shares used in computing net loss per common share—basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Comprehensive Loss: Comprehensive Income Net Of Tax [Abstract] Net loss Comprehensive loss Comprehensive Income Net Of Tax Stock issued during period shares under employee and director stock option RSU and purchase plans. Stock issued during period value under employee and director stock option RSU and purchase plans. Stock issued during period shares public offering. Stock issued during period value public offering. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Beginning balance Stockholders Equity Including Portion Attributable To Noncontrolling Interest Beginning balance, Shares Shares Outstanding Issuance of common stock under employee and director stock option, RSU, and purchase plans Stock Issued During Period Value Under Employee And Director Stock Option R S U And Purchase Plans Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares Stock Issued During Period Shares Under Employee And Director Stock Option R S U And Purchase Plans Issuance of common stock from public offering, net Stock Issued During Period Value Public Offering Issuance of common stock from public offering, Shares Stock Issued During Period Shares Public Offering Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Net loss Profit Loss Ending balance Ending balance, Shares Increase decrease in grants receivable. Increase decrease in operating lease right of use asset and liabilities net. Proceeds from issuance of common stock and warrants. Receivable related to fixed asset sales. Assets held for sale. Statement Of Cash Flows [Abstract] Cash Flows From Operating Activities Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Gain on disposal of fixed assets Gain Loss On Sale Of Property Plant Equipment Depreciation and amortization Depreciation Depletion And Amortization Stock-based compensation Allocated Share Based Compensation Expense Increase (decrease) in cash resulting from changes in: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Grants receivable Increase Decrease In Grants Receivable Inventory Increase Decrease In Inventories Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Operating lease right-of-use assets and liabilities, net Increase Decrease In Operating Lease Right Of Use Asset And Liabilities Net Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash Flows From Investing Activities Net Cash Provided By Used In Investing Activities [Abstract] Proceeds from disposals of fixed assets Proceeds From Sale Of Productive Assets Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Cash Flows From Financing Activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock and exercise of warrants, net Proceeds From Issuance Of Common Stock And Warrants Employee taxes paid related to net share settlement of equity awards Payments Related To Tax Withholding For Share Based Compensation Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities Net decrease in cash, cash equivalents, and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents, and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents, and restricted cash at end of period Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract] Cash and cash equivalents Restricted cash Restricted Cash Noncurrent Supplemental Disclosure of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Receivable related to fixed asset sales Receivable Related To Fixed Asset Sales Assets held for sale Assets Held For Sale Income taxes paid Income Taxes Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] Description of Business Nature Of Operations Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Equity [Abstract] Stockholders' Equity Shareholders Equity And Share Based Payments [Text Block] Collaborative Research, Development, and License Agreements Collaborative Arrangement Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Leases [Abstract] Leases Leases Of Lessee Disclosure [Text Block] Risks And Uncertainties [Abstract] Concentrations Concentration Risk Disclosure [Text Block] Related Party Transactions [Abstract] Related Parties Related Party Transactions Disclosure [Text Block] Restructuring And Related Activities [Abstract] Restructuring Restructuring And Related Activities Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of presentation and principles of consolidation. Basis of presentation and principles of consolidation Basis Of Presentation And Principles Of Consolidation Policy [Text Block] Liquidity policy. Liquidity Liquidity Policy [Text Block] Use of estimates Use Of Estimates Impairment of long-lived assets Impairment Or Disposal Of Long Lived Assets Policy [Text Block] Revenue recognition Revenue From Contract With Customer Policy [Text Block] Cost of revenues Cost Of Sales Policy [Text Block] Net loss per share Earnings Per Share Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted stock units (RSUs) [Member] Restricted Stock Units R S U [Member] Performance based restricted stock units. Performance-Based Restricted Stock Units [Member] Performance Based Restricted Stock Units [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Schedule of Stock-based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Fair Value of Employee Stock Purchase Plan Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block] Summary of Company's Restricted Stock Units Activity and Performance Based Restricted Stock Units Activity Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Common stock capital shares reserved for future issuance. Common Stock Reserved for Future Issuance Common Stock Capital Shares Reserved For Future Issuance Table [Text Block] Summary of Activity and Balances of Restructuring Reserve Schedule Of Restructuring Reserve By Type Of Cost [Text Block] Description of business. Description of business. Description Of Business [Table] Description Of Business [Table] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Description Of Business [Line Items] Description Of Business [Line Items] Reimbursement of merger-related expenses Payments For Merger Related Costs Space required for office and laboratory. Space required for office and laboratory Space Required For Office And Laboratory Summary of significant accounting policies. Schedule of summary of significant accounting policy. Schedule Of Summary Of Significant Accounting Policy [Table] Schedule Of Summary Of Significant Accounting Policy [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] At-the-market facility. At-The-Market Facility [Member] At The Market Facility [Member] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Directors and Officers. Directors and Officers [Member] Directors And Officers [Member] Product [Member] Product [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] National Institute of Health research grant two. NIH Research Grants Two [Member] National Institute Of Health Research Grant Two [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Cash and cash equivalents Cash flow from operations Issuance of common stock Insurance premium refunded net. Severance obligations Severance Costs1 Net of returned insurance premium Insurance Premium Refunded Net Impairment of long-lived assets Impairment Of Long Lived Assets Held For Use Deferred revenue Contract With Customer Liability Current Contract with customer liability sales returns. EX-101.PRE 10 onvo-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	ONVO
Entity Registrant Name	ORGANOVO HOLDINGS, INC.
Entity Central Index Key	0001497253
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		130,618,203
Entity File Number	001-35996
Entity Current Reporting Status	Yes
Entity Tax Identification Number	27-1488943
Entity Address, Address Line One	440 Stevens Ave
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Solana Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92075
City Area Code	858
Local Phone Number	224-1000
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Mar. 31, 2020
Current Assets
Cash and cash equivalents	$ 24,787	$ 27,356
Accounts receivable	84	111
Prepaid expenses and other current assets	630	851
Total current assets	25,501	28,318
Other assets, net	120	123
Total assets	25,621	28,441
Current Liabilities
Accounts payable	110	720
Accrued expenses	725	1,090
Total current liabilities	835	1,810
Commitments and Contingencies	0	0
Stockholders’ Equity
Common stock, $0.001 par value; 200,000,000 shares authorized, 130,618,203 and 130,558,098 shares issued and outstanding at June 30, 2020 and March 31, 2020, respectively	131	131
Additional paid-in capital	306,889	305,965
Accumulated deficit	(282,234)	(279,465)
Total stockholders’ equity	24,786	26,631
Total Liabilities and Stockholders’ Equity	$ 25,621	$ 28,441

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Mar. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	130,618,203	130,558,098
Common stock, shares outstanding	130,618,203	130,558,098

XML 14 R4.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Revenues
Total Revenues	$ 0	$ 668
Cost of revenues	0	51
Research and development expenses	0	3,823
Selling, general and administrative expenses	2,786	3,315
Total costs and expenses	2,786	7,189
Loss from Operations	(2,786)	(6,521)
Other Income (Expense)
Gain on fixed asset disposals	6	1
Interest income	8	197
Other Income	5	0
Total Other Income	19	198
Income Tax Expense	(2)	0
Net Loss	$ (2,769)	$ (6,323)
Net loss per common share—basic and diluted	$ (0.02)	$ (0.05)
Weighted average shares used in computing net loss per common share—basic and diluted	130,588,481	126,854,907
Comprehensive Loss:
Net loss	$ (2,769)	$ (6,323)
Comprehensive loss	(2,769)	(6,323)
Products and Services [Member]
Revenues
Total Revenues	0	606
Collaborations and Licenses [Member]
Revenues
Total Revenues	0	10
Grants [Member]
Revenues
Total Revenues	$ 0	$ 52

XML 15 R5.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Mar. 31, 2019	$ 36,298	$ 124	$ 296,929	$ (260,755)
Beginning balance, Shares at Mar. 31, 2019		124,015
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(52)	$ 0	(52)	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		177
Issuance of common stock from public offering, net	4,996	$ 6	4,990	0
Issuance of common stock from public offering, Shares		6,087
Stock-based compensation expense	1,220	$ 0	1,220	0
Net loss	(6,323)	0	0	(6,323)
Ending balance at Jun. 30, 2019	36,139	$ 130	303,087	(267,078)
Ending balance, Shares at Jun. 30, 2019		130,279
Beginning balance at Mar. 31, 2020	26,631	$ 131	305,965	(279,465)
Beginning balance, Shares at Mar. 31, 2020		130,558
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(1)	$ 0	(1)	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		60
Stock-based compensation expense	925	$ 0	925	0
Net loss	(2,769)	0	0	(2,769)
Ending balance at Jun. 30, 2020	$ 24,786	$ 131	$ 306,889	$ (282,234)
Ending balance, Shares at Jun. 30, 2020		130,618

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows From Operating Activities
Net loss	$ (2,769)	$ (6,323)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on disposal of fixed assets	(6)	(1)
Depreciation and amortization	4	205
Stock-based compensation	925	1,220
Increase (decrease) in cash resulting from changes in:
Accounts receivable	27	(35)
Grants receivable	0	(44)
Inventory	0	(16)
Prepaid expenses and other assets	224	360
Accounts payable	(610)	(75)
Accrued expenses	(365)	(1,142)
Deferred revenue	0	7
Operating lease right-of-use assets and liabilities, net	0	(91)
Net cash used in operating activities	(2,570)	(5,935)
Cash Flows From Investing Activities
Proceeds from disposals of fixed assets	2	1
Net cash provided by investing activities	2	1
Cash Flows From Financing Activities
Proceeds from issuance of common stock and exercise of warrants, net	0	4,996
Employee taxes paid related to net share settlement of equity awards	(1)	(52)
Net cash provided by (used in) financing activities	(1)	4,944
Net decrease in cash, cash equivalents, and restricted cash	(2,569)	(990)
Cash, cash equivalents, and restricted cash at beginning of period	27,356	36,556
Cash, cash equivalents, and restricted cash at end of period	24,787	35,566
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	24,787	35,487
Restricted cash	0	79
Cash, cash equivalents, and restricted cash at end of period	24,787	35,566
Supplemental Disclosure of Cash Flow Information:
Receivable related to fixed asset sales	5	0
Assets held for sale	1	0
Income taxes paid	$ (2)	$ 0

XML 17 R7.htm IDEA: XBRL DOCUMENT

Description of Business

3 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of Business

Note 1. Description of Business

Nature of operations

Historical Operations and Strategic Alternatives Process

The Cooperation Agreement and Advisory Nominees Proposal

Following the Special Meeting and the termination of the Merger Agreement, the Company’s Board continued to solicit stockholder feedback regarding the Company’s strategic alternatives and how to maximize stockholder value. In response to feedback from its largest stockholder regarding its desire for the Board to consider opportunities in the 3D bioprinting field and suggestion that the Board should speak with Keith Murphy, the Company’s founder, stockholder and former Chief Executive Officer and Chairman, for potential business ideas, the Company’s Board initiated discussions with Mr. Murphy. Based on these discussions, the Company entered into a Cooperation Agreement with Mr. Murphy on July 14, 2020 (the “Cooperation Agreement”). Under the terms of the Cooperation Agreement, the Board appointed Mr. Murphy and Adam K. Stern to the Board as Class III directors, and two of the Company’s existing directors, Richard Maroun and David Shapiro, resigned from the Board and all Board committees. The Board also agreed to nominate, recommend, support and solicit proxies for the re-election of Messrs. Murphy and Stern at the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). The Board also agreed to nominate, recommend, support and solicit proxies for an advisory stockholder vote (the “Advisory Nominees Proposal”) at the 2020 Annual Meeting to appoint three individuals, Douglas Jay Cohen, David Gobel and Alison Tjosvold Milhous (collectively, the “Advisory Nominees”), to the Board. Mr. Murphy identified each of the Advisory Nominees. If the final vote tabulation for the Advisory Nominees Proposal receives more votes cast “FOR” than “AGAINST” its approval, the Board has approved the appointment of the Advisory Nominees, to be automatically effective immediately following the final adjournment of the 2020 Annual Meeting. In addition, immediately following the appointment of the Advisory Nominees, each of our existing directors (other than Messrs. Murphy and Stern) will resign from the Board, which will result in Messrs. Murphy and Stern and the Advisory Nominees constituting the full membership of the Board (collectively, the “New Director Slate”).

Proposed Drug Discovery Business

COVID-19

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of presentation and principles of consolidation

Liquidity

Use of estimates

Impairment of long-lived assets

Revenue recognition

Service revenues

Product sales, net

The Company’s former product-based business, Samsara Sciences, Inc., produced high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognized product revenue when the performance obligation was satisfied, which was at the point in time the customer obtained control of the Company’s product, typically upon delivery. Product revenues were recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration did not differ materially from its historical practices. Variable consideration was estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflected the Company’s best estimates of the amount of consideration to which it was entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may have differed from the Company’s estimates. If actual results varied materially from the Company’s estimates, the Company would have adjusted these estimates, which would have affected revenue from product sales and earnings in the period such estimates were adjusted.

The Company provided no right of return to its customers except in cases where a customer obtained authorization from the Company for the return. To date, there have been no product returns.

In March 2020, the Company dissolved Samsara.

Collaborative research, development, and licenses

Grant revenue

Cost of revenues

Net loss per share

Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 12.0 million at June 30, 2020 and 14.6 million at June 30, 2019.

Recent Accounting Pronouncements

Adoption of New Accounting Pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Jun. 30, 2020

Equity [Abstract]

Stockholders' Equity

Note 3. Stockholders’ Equity

Stock-based compensation expense and valuation information

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended
	June 30, 2020		June 30, 2019
Research and development	$	—	$	164
General and administrative	$	925	$	1,056
Total	$	925	$	1,220

As of June 30, 2020, there are no participants enrolled into the employee stock purchase plan for the current purchase period, beginning March 1, 2020.

	Three Months Ended			Three Months Ended
	June 30, 2020*			June 30, 2019
Dividend yield		—			—
Volatility		0.00	%		43.69	%
Risk-free interest rate		0.00	%	2.52
Expected term	0 months			6 months
Grant date fair value	$	-		$	0.29

*There are no participants in the ESPP for the current purchase period (beginning March 1, 2020).

Preferred stock

Common stock

Restricted stock units

The following table summarizes the Company’s restricted stock units (not including performance-based restricted stock units) activity from March 31, 2020 through June 30, 2020:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2020		480,256		$	1.95
Granted		—		$	—
Vested		(61,626	)	$	2.57
Cancelled / forfeited		—		$	—
Unvested at June 30, 2020		418,630		$	1.85

Performance-based restricted stock units

The following table summarizes the Company’s performance-based restricted stock unit activity from March 31, 2020 through June 30, 2020:

	Number of Shares		Weighted Average Price
Unvested at March 31, 2020		3,952,927	$	0.51
Granted		—	$	—
Vested		—	$	—
Cancelled / forfeited		—	$	—
Unvested at June 30, 2020		3,952,927	$	0.51

Stock options

The following table summarizes the Company’s stock option activity from March 31, 2020 to June 30, 2020:

	Options Outstanding		Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2020		7,638,076	$	2.08	$	37,440
Options granted		—	$	—	$	—
Options cancelled / forfeited		—	$	—	$	—
Options exercised		—	$	—	$	—
Outstanding at June 30, 2020		7,638,076	$	2.08	$	79,237
Vested and Exercisable at June 30, 2020		4,593,119	$	2.48	$	3,396

The weighted average remaining contractual term of options exercisable and outstanding at June 30, 2020 was approximately 7.13 years.

Employee Stock Purchase Plan

Common stock reserved for future issuance

Common stock reserved for future issuance consisted of the following at June 30, 2020:

Common stock options outstanding and reserved under the 2012 Plan			5,549,864
Common stock reserved under the 2012 Plan			14,158,654
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,188,718
Restricted stock units outstanding under the 2012 Plan			418,630
Performance-based restricted stock units outstanding under the 2012 Plan			3,794,221
Common stock options outstanding and reserved under the Incentive Award Agreement			2,088,212
Performance-based restricted stock units outstanding under the Incentive Award Agreement			158,706
Total at June 30, 2020			27,357,005

XML 20 R10.htm IDEA: XBRL DOCUMENT

Collaborative Research, Development, and License Agreements

3 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaborative Research, Development, and License Agreements

Note 4. Collaborative Research, Development, and License Agreements

XML 21 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Jun. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 5. Commitments and Contingencies

Legal matters

XML 22 R12.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

Note 6. Leases

Operating Leases

XML 23 R13.htm IDEA: XBRL DOCUMENT

Concentrations

3 Months Ended

Jun. 30, 2020

Risks And Uncertainties [Abstract]

Concentrations

Note 7. Concentrations

Credit risk

XML 24 R14.htm IDEA: XBRL DOCUMENT

Related Parties

3 Months Ended

Jun. 30, 2020

Related Parties

Note 8. Related Parties

XML 25 R15.htm IDEA: XBRL DOCUMENT

Restructuring

3 Months Ended

Jun. 30, 2020

Restructuring And Related Activities [Abstract]

Restructuring

Note 9. Restructuring

No restructuring charges were recorded during the three months ended June 30, 2020 and 2019.

The following table summarizes the activity and balances of the restructuring reserve (in thousands):

	Severance for Involuntary Employee Terminations
Balance at March 31, 2020	$	21
Reserve established		—
Increase to reserve		—
Utilization of reserve:
Payments		(21	)
Balance at June 30, 2020	$	—

XML 26 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

Note 10. Subsequent Events

XML 27 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2020 is derived from the Company’s audited consolidated balance sheet at that date. The unaudited condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2021 (see “Note 1. Description of Business”).
Liquidity	Liquidity As of June 30, 2020, the Company had cash and cash equivalents of approximately $24.8 million and an accumulated deficit of approximately $282.2 million. The Company also had negative cash flows from operations of approximately $2.6 million during the three months ended June 30, 2020. Through June 30, 2020, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the three months ended June 30, 2020, the Company issued no shares of its common stock through its ATM facility. Throughout the strategic alternatives assessment process, the Company has taken steps to manage its resources and extend its cash runway including selling various assets and reducing its workforce to the minimum level necessary to explore and support these strategic alternatives as well as to support the remainder of the Company’s on-going business activities and assets, including its intellectual property platform and collaborations with research institutions and universities. The Company believes its cash and cash equivalents on hand will be sufficient to meet its financial obligations for at least the next 12 months of operations. If the Advisory Proposal is approved, this will trigger a “Change of Control” under Organovo’s severance plan, as well as its Directors and Officers (“D&O”) liability insurance policies, requiring the following cash outlays: i) approximately $3.0 million for severance obligations and ii) approximately $2.0 million (or $1.7 million net of returned premium) for a six year D&O tail insurance policy. In addition, to the extent the New Director Slate recommences the Company’s operations and focus its efforts on drug discovery and development, the Company will need to raise additional capital to implement this new business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. If required, the Company may seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Company’s business, operating results, financial condition and ability to continue as a going concern.
Use of estimates	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the unaudited condensed consolidated financial statements include those assumed in the valuation of stock-based compensation expense, the valuation of impairment of long-lived assets, our assessment of contingent liabilities that would require the establishment of a reserve, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions. Though the impact of the COVID-19 pandemic to its business and operating results presents additional uncertainty, the Company continues to use the best information available to inform its critical accounting estimates.
Impairment of long-lived assets	Impairment of long-lived assets In accordance with ASC 360-10, the Company records an impairment loss on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets (i.e. not able to be recovered). The Company’s pursuit of strategic alternatives requires the reevaluation of the recoverability of the gross carrying value of its long-lived assets. The Company performed an asset impairment analysis on its long-lived asset group, consisting primarily of licensed intangible assets, computer equipment, and software following the completion of various asset sales prior to June 30, 2020, which concluded that the carrying amount is not recoverable. However, the Company’s analysis indicated that carrying amount of the asset group does not exceed its fair value. As such, no impairment loss is required to be recognized. Nonetheless, it is reasonably possible that the impairment analysis may change in the near term resulting in the need to write down those assets to fair value. The Company will continue to monitor assets for impairment.
Revenue recognition	Revenue recognition The Company has generated revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. The Company recognized revenue under Topic 606, Revenue from Contracts with Customers (“Topic 606”) when (or as) the promised services were transferred to customers in an amount that reflects the consideration to which it expected to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concluded were within the scope of ASC 606, the Company performed the following five steps: (i) identified the contract(s) with a customer; (ii) identified the performance obligation(s) in the contract; (iii) determined the transaction price; (iv) allocated the transaction price to the performance obligation(s) in the contract; and (v) recognized revenue when (or as) the performance obligation(s) were satisfied. At contract inception, the Company assessed the goods or services promised within each contract, assessed whether each promised good or service was distinct and identified those that were performance obligations. The Company recognized as revenue the amount of the transaction price that was allocated to the respective performance obligation when (or as) the performance obligation was satisfied. Billings to customers or payments received from customers were included in deferred revenue on the consolidated balance sheet until all revenue recognition criteria were met. As of June 30, 2020 and March 31, 2020, the Company had no deferred revenue. Service revenues The Company’s service-based business, Organovo, Inc., utilized its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contained multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which were satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer did not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service could be customized for each customer, it was not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilized point-in-time recognition under Topic 606. For service contracts, the Company allocated the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price was not observable through past transactions, the Company estimated the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts was a fixed consideration. In connection to the Company’s decision to pursue its strategic alternatives, the Company halted commercial activities related to its liver tissues. The Company is expected to continue to maintain its external research collaborations and its intellectual property portfolio. Product sales, net The Company’s former product-based business, Samsara Sciences, Inc., produced high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognized product revenue when the performance obligation was satisfied, which was at the point in time the customer obtained control of the Company’s product, typically upon delivery. Product revenues were recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration did not differ materially from its historical practices. Variable consideration was estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflected the Company’s best estimates of the amount of consideration to which it was entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may have differed from the Company’s estimates. If actual results varied materially from the Company’s estimates, the Company would have adjusted these estimates, which would have affected revenue from product sales and earnings in the period such estimates were adjusted. The Company provided no right of return to its customers except in cases where a customer obtained authorization from the Company for the return. To date, there have been no product returns. In March 2020, the Company dissolved Samsara. Collaborative research, development, and licenses The Company has entered into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzed whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”). The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements were distinct performance obligations, whether there were determinable stand-alone prices, and whether any licenses were functional or symbolic. The Company evaluated each performance obligation to determine if it could be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities were considered fixed, while milestone payments were identified as variable consideration which must be evaluated to determine if it was constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provided the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company determined that the intellectual property license was not distinct from the continued support promised under the agreement and was therefore a single combined performance obligation. The Company recognized revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation would not be fully satisfied until the end of the contract. As of September 30, 2019, the Company completed its obligations under the existing agreements with respect to receipts of revenue and does not anticipate recording any further revenue. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements. Grant revenue In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company concluded this government grant was not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company concluded this government grant did meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition did not apply, as the Company is a business entity and the grant was with a governmental agency. Revenues from this grant were based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue was recognized as the Company incurred expenses that were related to the grant. The Company believes this policy was consistent with the overarching premise in Topic 606, to ensure that it recognized revenues to reflect the transfer of promised goods or services to customers in an amount that reflected the consideration to which it expected to be entitled in exchange for those goods or services, even though there was no “exchange” as defined in the ASC. The Company believed the recognition of revenue as costs were incurred and amounts became earned/realizable was analogous to the concept of transfer of control of a service over time under Topic 606. In connection to the Company’s decision to pursue its strategic alternatives, specific to the NIH NASH grant, all internal research activities have been halted and transferred to the University of California, San Diego, leaving a remaining available balance of approximately $0.5 million that will not be utilized by the Company.
Cost of revenues	Cost of revenues The Company reported no cost of revenues for the three months ended June 30, 2020 and approximately $0.1 million in cost of revenues for the three months ended June 30, 2019. Cost of revenues consisted of costs related to manufacturing and delivering product and service revenue.
Net loss per share	Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three months ended June 30, 2020 or 2019, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 12.0 million at June 30, 2020 and 14.6 million at June 30, 2019.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. Adoption of New Accounting Pronouncements In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. The amendments in this update provide more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from this amendment are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance became effective for the Company on April 1, 2020 and did not have a significant impact on the Company’s unaudited condensed consolidated financial statements.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Jun. 30, 2020

Class Of Stock [Line Items]

Schedule of Stock-based Compensation Expense

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended
	June 30, 2020		June 30, 2019
Research and development	$	—	$	164
General and administrative	$	925	$	1,056
Total	$	925	$	1,220

Fair Value of Employee Stock Purchase Plan

The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:

	Three Months Ended			Three Months Ended
	June 30, 2020*			June 30, 2019
Dividend yield		—			—
Volatility		0.00	%		43.69	%
Risk-free interest rate		0.00	%	2.52
Expected term	0 months			6 months
Grant date fair value	$	-		$	0.29

*There are no participants in the ESPP for the current purchase period (beginning March 1, 2020).

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity from March 31, 2020 to June 30, 2020:

	Options Outstanding		Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2020		7,638,076	$	2.08	$	37,440
Options granted		—	$	—	$	—
Options cancelled / forfeited		—	$	—	$	—
Options exercised		—	$	—	$	—
Outstanding at June 30, 2020		7,638,076	$	2.08	$	79,237
Vested and Exercisable at June 30, 2020		4,593,119	$	2.48	$	3,396

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consisted of the following at June 30, 2020:

Common stock options outstanding and reserved under the 2012 Plan			5,549,864
Common stock reserved under the 2012 Plan			14,158,654
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,188,718
Restricted stock units outstanding under the 2012 Plan			418,630
Performance-based restricted stock units outstanding under the 2012 Plan			3,794,221
Common stock options outstanding and reserved under the Incentive Award Agreement			2,088,212
Performance-based restricted stock units outstanding under the Incentive Award Agreement			158,706
Total at June 30, 2020			27,357,005

Restricted stock units (RSUs) [Member]

Class Of Stock [Line Items]

Summary of Company's Restricted Stock Units Activity and Performance Based Restricted Stock Units Activity

The following table summarizes the Company’s restricted stock units (not including performance-based restricted stock units) activity from March 31, 2020 through June 30, 2020:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2020		480,256		$	1.95
Granted		—		$	—
Vested		(61,626	)	$	2.57
Cancelled / forfeited		—		$	—
Unvested at June 30, 2020		418,630		$	1.85

Performance-Based Restricted Stock Units [Member]

Class Of Stock [Line Items]

Summary of Company's Restricted Stock Units Activity and Performance Based Restricted Stock Units Activity

The following table summarizes the Company’s performance-based restricted stock unit activity from March 31, 2020 through June 30, 2020:

	Number of Shares		Weighted Average Price
Unvested at March 31, 2020		3,952,927	$	0.51
Granted		—	$	—
Vested		—	$	—
Cancelled / forfeited		—	$	—
Unvested at June 30, 2020		3,952,927	$	0.51

XML 29 R19.htm IDEA: XBRL DOCUMENT

Restructuring (Tables)

3 Months Ended

Jun. 30, 2020

Restructuring And Related Activities [Abstract]

Summary of Activity and Balances of Restructuring Reserve

The following table summarizes the activity and balances of the restructuring reserve (in thousands):

	Severance for Involuntary Employee Terminations
Balance at March 31, 2020	$	21
Reserve established		—
Increase to reserve		—
Utilization of reserve:
Payments		(21	)
Balance at June 30, 2020	$	—

XML 30 R20.htm IDEA: XBRL DOCUMENT

Description of Business - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2020 USD ($) sqft
Maximum [Member]
Description Of Business [Line Items]
Reimbursement of merger-related expenses \| $	$ 300,000
Space required for office and laboratory	7,000
Minimum [Member]
Description Of Business [Line Items]
Space required for office and laboratory	3,000

XML 31 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 31, 2017	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents		$ 24,787,000	$ 35,487,000	$ 27,356,000
Accumulated deficit		(282,234,000)		$ (279,465,000)
Cash flow from operations		$ 2,570,000	5,935,000
Issuance of common stock		130,618,203		130,558,098
Impairment of long-lived assets		$ 0
Deferred revenue		0		$ 0
Cost of revenues		0	100,000
Dilutive effect		$ 0	$ 0
Common stock equivalents excluded from computing diluted net loss per share		12,000,000	14,600,000
NIH Research Grants Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants	$ 1,657,000
Grant revenue funding period	3 years
Product [Member]
Summary Of Significant Accounting Policies [Line Items]
Product return revenue		$ 0
Grants [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue unutilized remaining available balance		500,000
Directors and Officers [Member]
Summary Of Significant Accounting Policies [Line Items]
Severance obligations		3,000,000
Directors and Officers [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Net of returned insurance premium		2,000,000
Directors and Officers [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Net of returned insurance premium		$ 1,700,000
At-The-Market Facility [Member]
Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock		0

XML 32 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 925	$ 1,220
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	0	164
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 925	$ 1,056

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2020 USD ($) Participant shares	Jun. 30, 2019 shares
Class Of Stock [Line Items]
Total unrecognized compensation cost related to unvested stock option grants	$ 2,651,000
Participants enrolled into the employee stock purchase plan \| Participant	0
Number of options granted \| shares	0	0
Stock options [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	1 year 6 months 29 days
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	1 year 5 months 23 days
Unrecognized stock-based compensation expense	$ 702,000
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	1 year 2 months 8 days
Unrecognized stock-based compensation expense	$ 1,038,000

XML 34 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) - 2016 Employee Stock Purchase Plan [Member] - $ / shares

3 Months Ended

Jun. 30, 2020

^[1]

Jun. 30, 2019

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Dividend yield

0.00%

Volatility

0.00%

43.69%

Risk-free interest rate

0.00%

2.52%

Expected term

0 days

6 months

Grant date fair value

$ 0

$ 0.29

[1]	There are no participants in the ESPP for the current purchase period (beginning March 1, 2020).

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Parenthetical) (Detail)	Jun. 30, 2020 Participant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Participants enrolled into the employee stock purchase plan	0
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Participants enrolled into the employee stock purchase plan	0

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Preferred Stock - Additional Information (Detail)	Jun. 30, 2020 shares
Equity [Abstract]
Preferred stock, shares authorized	25,000,000
Preferred stock, shares outstanding	0

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Common Stock - Additional Information (Detail) $ / shares in Units, U_xbrlipure in Millions		3 Months Ended		9 Months Ended
	Jun. 25, 2019 $ / shares	Jun. 30, 2020 USD ($) shares	Jun. 30, 2019 USD ($) shares	Dec. 31, 2019 USD ($)	Sep. 30, 2020 USD ($)	Mar. 31, 2020 shares	Mar. 16, 2018 USD ($)
Class Of Stock [Line Items]
Reverse stock split		20:1 to 40:1
Issuance of common stock \| shares		130,618,203				130,558,098
Minimum [Member]
Class Of Stock [Line Items]
Minimum closing bid price \| $ / shares	$ 1,000,000
Conversion ratio		20
Maximum [Member]
Class Of Stock [Line Items]
Conversion ratio		40
2018 Sales Agreement [Member]
Class Of Stock [Line Items]
Equity sales agreement expiration date		Feb. 22, 2021
Value of shares sold under equity distribution agreement				$ 18,700,000
Issuance of common stock \| shares		17,719,185
2018 Sales Agreement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance		$ 81,300,000
IPO [Member]
Class Of Stock [Line Items]
Securities authorized for offer and sale, amount					$ 100,000,000
At-The-Market Facility [Member]
Class Of Stock [Line Items]
Issuance of common stock \| shares		0
At-The-Market Facility [Member] \| 2018 Sales Agreement [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance		$ 31,300,000
Issuance of common stock from stock options exercises, net, Shares \| shares		0	6,087,382
Value of shares sold under equity distribution agreement		$ 0	$ 5,000,000
At-The-Market Facility [Member] \| 2018 Sales Agreement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance							$ 50,000,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Company's Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity (Detail)	3 Months Ended
	Jun. 30, 2020 $ / shares shares
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares \| shares	480,256
Granted, Number of Shares \| shares	0
Vested, Number of Shares \| shares	(61,626)
Canceled / forfeited, Number of Shares \| shares	0
Ending balance, Unvested, Number of Shares \| shares	418,630
Beginning balance, Unvested, Weighted Average Price \| $ / shares	$ 1.95
Granted, Weighted Average Price \| $ / shares	0
Vested, Weighted Average Price \| $ / shares	2.57
Canceled / forfeited, Weighted Average Price \| $ / shares	0
Ending balance, Unvested, Weighted Average Price \| $ / shares	$ 1.85
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares \| shares	3,952,927
Granted, Number of Shares \| shares	0
Vested, Number of Shares \| shares	0
Canceled / forfeited, Number of Shares \| shares	0
Ending balance, Unvested, Number of Shares \| shares	3,952,927
Beginning balance, Unvested, Weighted Average Price \| $ / shares	$ 0.51
Granted, Weighted Average Price \| $ / shares	0
Vested, Weighted Average Price \| $ / shares	0
Canceled / forfeited, Weighted Average Price \| $ / shares	0
Ending balance, Unvested, Weighted Average Price \| $ / shares	$ 0.51

XML 39 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail)				3 Months Ended
	Jul. 02, 2019 shares	Dec. 12, 2018 shares	Aug. 23, 2017 USD ($) Tranche shares	Jun. 30, 2020 Tranche shares	Apr. 24, 2017 shares
Inducement Award Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Number of tranches \| Tranche			5
Award vesting percentage		100.00%
Number of tranches expected to vest \| Tranche				0
Grant date fair values of tranches \| $			$ 165,000
Inducement Award Performance-Based Restricted Stock Units [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Number of shares allocated			208,822
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche One [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2018
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche One [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche One [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Two [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2019
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Two [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Two [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Three [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2020
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Three [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Three [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Four [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2021
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Four [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Four [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Five [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2020
Share based compensation arrangement, number of shares vested		41,764
Share based compensation arrangement, number of shares forfeited		8,352
Share based compensation arrangement, number of shares eligible to vest upon future performance				158,706
Share based compensation arrangement amendment description and terms				Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones.
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Five [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Five [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| CEO [Member]
Class Of Stock [Line Items]
Number of shares allocated					208,822
PBRSU Retention Awards [Member] \| Management Team [Member]
Class Of Stock [Line Items]
Number of shares allocated	6,027,899
Vesting period	24 months

XML 40 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Beginning balance	7,638,076
Granted, Options Outstanding	0	0
Cancelled / forfeited, Options Outstanding	0
Exercised, Options Outstanding	0
Options Outstanding, Ending balance	7,638,076
Vested and Exercisable, Options Outstanding	4,593,119
Weighted-Average Exercise Price, Options Beginning balance	$ 2.08
Options granted, Weighted-Average Exercise Price	0
Options cancelled / forfeited, Weighted-Average Exercise Price	0
Options exercised, Weighted-Average Exercise Price	0
Weighted-Average Exercise Price, Options Ending balance	2.08
Vested and Exercisable, Weighted-Average Exercise Price	$ 2.48
Aggregate Intrinsic Value, Options Beginning balance	$ 37,440
Options Exercised, Aggregate Intrinsic Value	0
Aggregate Intrinsic Value, Options Ending balance	79,237
Vested and Exercisable, Aggregate Intrinsic Value	$ 3,396

XML 41 R31.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2020 USD ($) shares
Class Of Stock [Line Items]
Weighted-average remaining contractual term of options exercisable	7 years 1 month 17 days
Weighted-average remaining contractual term of options outstanding	7 years 1 month 17 days
Number of common stock shares approved under ESPP	27,357,005
2016 Employee Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Number of common stock shares approved under ESPP	1,500,000
Employee subscription rate	15.00%
Compensation amount per employee \| $	$ 25,000
Number of shares per employee	10,000
Fair market value at discount	85.00%
Purchase period	6 months
Initial offering period	2016-09
Description of plan	Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period.
Shares available for purchase under ESPP	1,188,718

XML 42 R32.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail)	Jun. 30, 2020 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	27,357,005
Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	14,158,654
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,500,000
Stock options [Member] \| Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	5,549,864
Stock options [Member] \| 2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,188,718
Stock options [Member] \| Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	2,088,212
Restricted stock units (RSUs) [Member] \| Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	418,630
Performance-Based Restricted Stock Units [Member] \| Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	3,794,221
Performance-Based Restricted Stock Units [Member] \| Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	158,706

XML 43 R33.htm IDEA: XBRL DOCUMENT

Collaborative Research, Development, and License Agreements - Additional Information (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total Revenues	$ 0	$ 668,000
Non-exclusive patent license agreement annual fee	0	51,000
Collaborations and Licenses [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total Revenues	0	10,000
Collaborations and Licenses [Member] \| December 2016 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total Revenues	$ 0	$ 10,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
Leases - Additional Information (Details) - USD ($)	Oct. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Monthly rental payments	$ 4,000
Operating lease expense		$ 0	$ 262,000
Rent expense		12,000	0
Variable lease expense		0	107,000
Short term lease cost		$ 0	$ 15,000

XML 45 R35.htm IDEA: XBRL DOCUMENT

Related Parties - Additional Information (Detail) - USD ($)	1 Months Ended
	Aug. 10, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019
Related Party Transaction [Line Items]
Accounts receivable		$ 84,000	$ 111,000
Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Accounts receivable		84,000		$ 60,000
Viscient Biosciences [Member] \| Subsequent Event [Member]
Related Party Transaction [Line Items]
Amount received from related party	$ 84,000
On or Before June 17, 2020 [Member] \| Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Due from related party		28,000
On or Before July 24, 2020 [Member] \| Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Due from related party		28,000
On or Before August 23, 2020 [Member] \| Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Due from related party		19,000
On or Before September 22, 2020 [Member] \| Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Due from related party		19,000
On or Before October 22, 2020 [Member] \| Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Due from related party		$ 19,000

XML 46 R36.htm IDEA: XBRL DOCUMENT

Restructuring - Additional Information (Details)	3 Months Ended					12 Months Ended
Restructuring - Additional Information (Details)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2020 USD ($) Employee
Restructuring Cost And Reserve [Line Items]
Number of employees terminated \| Employee						52
Percentage of workforce terminated						90.00%
Restructuring charges	$ 0				$ 0
Employee Severance and Benefits Costs [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges						$ 2,700,000
Payments for restructuring		$ 100,000	$ 900,000	$ 1,700,000
Employee Severance and Benefits Costs [Member] \| Maximum [Member]
Restructuring Cost And Reserve [Line Items]
Payments for restructuring	$ 100,000

XML 47 R37.htm IDEA: XBRL DOCUMENT

Restructuring - Summary of Activity and Balances of Restructuring Reserve (Details) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Restructuring Cost And Reserve [Line Items]
Reserve established	$ 0	$ 0
Severance for Involuntary Employee Terminations [Member]
Restructuring Cost And Reserve [Line Items]
Balance at March 31, 2020	21,000
Reserve established	0
Increase to reserve	0
Utilization of reserve:
Payments	(21,000)
Balance at June 30, 2020	$ 0

XML 48 R38.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Details) - Directors and Officers [Member] - USD ($) $ in Millions		3 Months Ended
	Jul. 14, 2020	Jun. 30, 2020
Subsequent Event [Line Items]
Severance obligations		$ 3.0
Subsequent Event [Member]
Subsequent Event [Line Items]
Severance obligations	$ 3.0
Maximum [Member]
Subsequent Event [Line Items]
Net of returned insurance premium		2.0
Maximum [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Net of returned insurance premium	2.0
Minimum [Member]
Subsequent Event [Line Items]
Net of returned insurance premium		$ 1.7
Minimum [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Net of returned insurance premium	$ 1.7

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 118 272 1 true 41 0 false 8 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.organovo.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.organovo.com/20200630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.organovo.com/20200630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss Sheet http://www.organovo.com/20200630/taxonomy/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Unaudited Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.organovo.com/20200630/taxonomy/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity Unaudited Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.organovo.com/20200630/taxonomy/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows Unaudited Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Description of Business Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureDescriptionOfBusiness Description of Business Notes 7 false false R8.htm 100070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Stockholders' Equity Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 9 false false R10.htm 100090 - Disclosure - Collaborative Research, Development, and License Agreements Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements Collaborative Research, Development, and License Agreements Notes 10 false false R11.htm 100100 - Disclosure - Commitments and Contingencies Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 100110 - Disclosure - Leases Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureLeases Leases Notes 12 false false R13.htm 100120 - Disclosure - Concentrations Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureConcentrations Concentrations Notes 13 false false R14.htm 100130 - Disclosure - Related Parties Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureRelatedParties Related Parties Notes 14 false false R15.htm 100140 - Disclosure - Restructuring Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureRestructuring Restructuring Notes 15 false false R16.htm 100150 - Disclosure - Subsequent Events Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 16 false false R17.htm 100160 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.organovo.com/20200630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 100170 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquity 18 false false R19.htm 100180 - Disclosure - Restructuring (Tables) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureRestructuringTables Restructuring (Tables) Tables http://www.organovo.com/20200630/taxonomy/role/DisclosureRestructuring 19 false false R20.htm 100190 - Disclosure - Description of Business - Additional Information (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail Description of Business - Additional Information (Detail) Details 20 false false R21.htm 100200 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 21 false false R22.htm 100210 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) Details 22 false false R23.htm 100220 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) Details 23 false false R24.htm 100230 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityFairValueOfEmployeeStockPurchasePlanDetail Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) Details 24 false false R25.htm 100240 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Parenthetical) (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityFairValueOfEmployeeStockPurchasePlanParentheticalDetail Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Parenthetical) (Detail) Details 25 false false R26.htm 100250 - Disclosure - Stockholders' Equity - Preferred Stock - Additional Information (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityPreferredStockAdditionalInformationDetail Stockholders' Equity - Preferred Stock - Additional Information (Detail) Details 26 false false R27.htm 100260 - Disclosure - Stockholders' Equity - Common Stock - Additional Information (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityCommonStockAdditionalInformationDetail Stockholders' Equity - Common Stock - Additional Information (Detail) Details 27 false false R28.htm 100270 - Disclosure - Stockholders' Equity - Summary of Company's Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanySRestrictedStockUnitsActivityAndPerformanceBasedRestrictedStockUnitsActivityDetail Stockholders' Equity - Summary of Company's Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity (Detail) Details 28 false false R29.htm 100280 - Disclosure - Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityRestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsAdditionalInformationDetail Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail) Details 29 false false R30.htm 100290 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail Stockholders' Equity - Summary of Stock Option Activity (Detail) Details 30 false false R31.htm 100300 - Disclosure - Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Details 31 false false R32.htm 100310 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) Details 32 false false R33.htm 100320 - Disclosure - Collaborative Research, Development, and License Agreements - Additional Information (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail Collaborative Research, Development, and License Agreements - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Leases - Additional Information (Details) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 34 false false R35.htm 100340 - Disclosure - Related Parties - Additional Information (Detail) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail Related Parties - Additional Information (Detail) Details 35 false false R36.htm 100350 - Disclosure - Restructuring - Additional Information (Details) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails Restructuring - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Restructuring - Summary of Activity and Balances of Restructuring Reserve (Details) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureRestructuringSummaryOfActivityAndBalancesOfRestructuringReserveDetails Restructuring - Summary of Activity and Balances of Restructuring Reserve (Details) Details 37 false false R38.htm 100370 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.organovo.com/20200630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 38 false false All Reports Book All Reports onvo-20200630.xml onvo-20200630.xsd onvo-20200630_cal.xml onvo-20200630_def.xml onvo-20200630_lab.xml onvo-20200630_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 54 0001564590-20-038895-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-038895-xbrl.zip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end

Stockholders' Equity - Summary of Company's Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity (Detail)	3 Months Ended
	Jun. 30, 2020 $ / shares shares
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares \| shares	480,256
Granted, Number of Shares \| shares	0
Vested, Number of Shares \| shares	(61,626)
Canceled / forfeited, Number of Shares \| shares	0
Ending balance, Unvested, Number of Shares \| shares	418,630
Beginning balance, Unvested, Weighted Average Price \| $ / shares	$ 1.95
Granted, Weighted Average Price \| $ / shares	0
Vested, Weighted Average Price \| $ / shares	2.57
Canceled / forfeited, Weighted Average Price \| $ / shares	0
Ending balance, Unvested, Weighted Average Price \| $ / shares	$ 1.85
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares \| shares	3,952,927
Granted, Number of Shares \| shares	0
Vested, Number of Shares \| shares	0
Canceled / forfeited, Number of Shares \| shares	0
Ending balance, Unvested, Number of Shares \| shares	3,952,927
Beginning balance, Unvested, Weighted Average Price \| $ / shares	$ 0.51
Granted, Weighted Average Price \| $ / shares	0
Vested, Weighted Average Price \| $ / shares	0
Canceled / forfeited, Weighted Average Price \| $ / shares	0
Ending balance, Unvested, Weighted Average Price \| $ / shares	$ 0.51